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1 INTRODUCTION 
 
1.1 Cutaneous malignant melanoma 
 
Melanoma is a tumor arising from melanocytes, the neural crest-derived 
pigment-producing cells located in the skin, hair follicles, stria vascularis of the inner 
ear, and the uveal tract of the eye. Cutaneous malignant melanoma (CMM) 
represents roughly 5% of skin cancers and 1% of all malignant tumors. Its incidence 
has increased markedly over the past 40 years in white skinned populations (Micheli 
et al., 2002). Melanoma responds poorly to chemical and radiation therapy and the 
most effective treatment is surgical excision before the tumor is well advanced (for 
review see (Thompson et al., 2005)). 
Five major steps of tumor progression have been described for cutaneous 
melanoma (Hsu et al., 2002) (Figure 1). The common acquired nevus is postulated 
as earliest benign hyperplastic melanocytic lesion, whereas the candidate precursor 
for cutaneous melanoma is the dysplastic nevus, which shows an increased level of 
cytological and architectural atypia (Kraemer and Greene, 1985). The radial growth 
phase (RGP) primary melanoma is the first recognizable malignant stage, where 
tumor cells are either confined to the epidermis or locally invasive but do not show 
the capacity for rapid growth or metastasis. In vertical growth phase (VGP) primary 
melanoma lesions, melanoma cells infiltrate as an expanding mass into the dermis 
and the subcutaneous tissue with the associated risk of systemic dissemination. 
Finally, metastasis represents the most advanced step of tumor progression. 
It is important to recognize, that initial disruptions in the normal molecular 
dialogue between basal keratinocytes and melanocytes may indirectly incite 
phenotypic as well as genomic changes as is already evident in benign melanocytic 
lesions. Nevocytes comprising common acquired nevi differ already from normal 
melanocytes by their polygonal or epithelioid morphology and aberrant growth, 
leading to nest formation initially confined to the dermal-epidermal junction (junctional 
nevus) but eventually expanding to the underlying dermis (compound and dermal 
nevi) (Hsu et al., 2002). Interestingly, forced physical proximity of dermal nevocytes 
with undifferentiated keratinocytes renders a normal melanocytic phenotype (Shih et 
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al., 1994). This phenotypic plasticity suggests, that at least at the very early stage 
melanocytic transformation does not involve major genetic events but is rather a 
consequence of losing normal regulatory control exerted by basal keratinocytes. 
Nevertheless, once malignant transformation has occurred, melanoma cells become 
autonomous and no longer respond to keratinocytes.  
 
 
During melanoma progression, down-regulation of E-cadherin with upregulation 
of N-cadherin leads to a switch of communication partners from the surrounding 
keratinocytes to dermal fibroblasts and endothelial cells (Hsu et al., 1996). 
Expression of melanoma-associated antigens (MAAs), such as MelCAM and its 
ligand, further favor physical association of melanocytic cells with vascular 
endothelial (St Croix et al., 2000), smooth muscle (Shih et al., 1994), and activated T 
cells (Pickl et al., 1997). Thereby, the normal cells recruited to the melanoma 
microenvironment are integral parts of the tumorigenic process by producing a 
multitude of factors that affect the biological functions of melanoma cells in terms of 
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Figure 1 The five major stages of tumor progression postulated for cutaneous malignant melanoma. 
Normal dermal melanocytes (MC, colored in brown) reside at the basement membrane (BM), which 
separates the dermis from the epidermis, and are controlled in their proliferation by cell-cell 
interactions with the surrounding keratinocytes (KC, colored in beige). Nevi are characterized by 
aberrant cell growth, consisting of enlarged, coalescent nests of nevocytes, which display different 
degrees of cytologic dysplasia. Further progression results in malignant cells, which grow only within 
or in close proximity to the epidermis (RGP, radial growth phase). Eventually, cells acquire the ability 
to invade deeply into dermis (VGP, vertical growth phase) and then into lymphatic and blood vessels 
(BV), leading to systemic dissemination (metastatic melanoma). FB; fibroblast (colored in gray). 
Modified from (Hsu et al., 2002). 
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growth stimulation, motility, expression of adhesion molecules, and synthesis of 
proteolytic enzymes (Li and Herlyn, 2000). 
Apart from the microenvironment controlling melanocyte proliferation, several 
environmental factors can influence melanoma incidence such as geographical 
parameters (Armstrong and Kricker, 2001) and early exposure to ultraviolet light 
(Armstrong and Kricker, 1993). Other genetically determined host factors – fair 
complexion, red hair, and multiple benign or dysplastic nevi - have also been 
associated with increased melanoma risk (Bataille et al., 1996; Grange et al., 1995). 
In addition, several genes have been identified that play a substantial role in the 
development of cutaneous melanoma, such as those that confer a highly significant 
predisposition to melanoma if mutated in the germ line, or contribute to the 
development of melanoma if mutated somatically. Familial melanomas, which 
represent approximately 8-12% of all melanoma cases (Fountain et al., 1990), have 
shed light on the genetic lesions that govern the genesis of both familial and sporadic 
forms of the disease. Through linkage analysis studies and candidate gene searches 
in melanoma prone families, two melanoma susceptibility genes have been identified, 
namely CDKN2A (Hussussian et al., 1994) and CDK4 (Zuo et al., 1996). 
 
1.1.1 Germ line mutations in melanoma 
 
1.1.1.1 CDKN2A 
  
CDKN2A (cyclin-dependent kinase inhibitor 2A) is located on chromosome 
9p21 and encodes two unrelated proteins, p16INK4A (inhibitor of cyclin-dependent 
kinase) and p14ARF (alternative reading frame) by using different first exons (1α and 
1β) spliced to a common set of exons. Both proteins are tumor suppressors involved 
in cell cycle regulation. p16INK4A negatively regulates cell division by inhibition of 
CDK4 and CDK6, which phosphorylate proteins of the retinoblastoma family (pRb, 
p130, p107) (Schulze et al., 1994). Hypophosphorylated retinoblastoma family 
proteins act as repressors of E2F-mediated gene transcription and thereby prevent 
progression through the cell cycle. p14ARF on the other hand binds to HDM2, 
inhibiting its function of targeting p53 for degradation (Zhang et al., 1998). p53, 
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among many other targets, can upregulate p21, an inhibitor of CDK2, which also acts 
on cell cycle regulation. 
Overall, CDKN2A mutations have been found in 20-40% of melanoma prone 
families compared to only 0.2-2% of sporadic melanoma patients (Aitken et al., 1999; 
Tsao et al., 2000). Mutations in CDKN2A in melanoma frequently eliminate both 
p16INK4A and p14ARF (Ruas and Peters, 1998), with the majority of cases being 
missense mutations scattered throughout the coding sequences of exons 1α and 2. 
Recently, melanomas have also been associated with polymorphisms in the 5´ and 
3´ untranslated regions of CDKN2A, expanding the range of 9p21-associated familial 
melanoma alleles to those that alter translation or possibly regulate mRNA stability of 
p16INK4A (Kumar et al., 2001; Liu et al., 1999). Although CDKN2A is a definitive 
melanoma-susceptibility gene, a significant proportion of familial cases segregating 
with 9p21 markers do not possess germ line mutations targeting p16INK4A. 
Therefore, p14ARF has emerged as an additional candidate. Indeed, somatic 
mutations that exclusively affect the p14ARF-coding sequence in the shared exon 2 
have been described in human melanomas (Piccinin et al., 1997), and a p14ARF-
specific exon 1β deletion has been identified in two metastatic melanoma cell lines 
(Kumar et al., 1998). 
To further study the role of the CDKN2A locus in the development and 
progression of malignant melanoma, several mouse models were established. The 
first reported Cdkn2a knockout mice, with inactivation of both Ink4a and Arf 
transcripts, did not develop melanoma, although they were susceptible to the 
development of fibrosarcomas and lymphomas (Serrano et al., 1996). When these 
mice were crossed with Tyr-Hras transgenic mice, which harbored an activated Hras 
mutation in their melanocytes, the resulting progeny spontaneously developed 
cutaneous malignant melanoma with short latency (Chin et al., 1997). However, the 
melanomas were only locally invasive and did not metastasize. These data indicate, 
that inactivation of Cdkn2a is insufficient for the development of melanoma and 
further genetic changes are necessary for late stage melanoma progression in mice. 
Recently, the contribution of Ink4a versus Arf to melanoma suppression has 
been compared more directly using specific knockout mice for the two proteins. 
Animals that are specifically deficient for Ink4a show a low frequency of melanoma 
spontaneously or after carcinogen treatment (Krimpenfort et al., 2001; Sharpless et 
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al., 2002). However, melanoma susceptibility imparted by Ink4a deficiency could be 
significantly enhanced when the mice were crossed with Arf hemizygotes 
(Krimpenfort et al., 2001), suggesting a cooperation between the Ink4a and Arf 
pathways in melanoma development. When crossed onto the melanoma-prone Tyr-
Hras transgenic allele, either Ink4a or Arf loss facilitated melanoma formation 
(Sharpless et al., 2003). Interestingly, in melanomas from Tyr-Hras/Arf-/- mice Rb-
pathway lesions were encountered, whereas in Tyr-Hras/Ink4a-/- mice p53-pathway 
lesions were detected. These results provide direct evidence, that both products of 
the Cdkn2a locus have prominent roles in melanoma suppression in vivo. 
 
1.1.1.2 CDK4 
 
CDK4 (cyclin-dependent kinase 4) is located on chromosome 12q14 and 
mutations in this gene have been found in seven families worldwide (Soufir et al., 
1998; Zuo et al., 1996). These mutations affect a single site in the CDK4 coding 
sequence that renders the molecule resistant to p16INK4A binding and inhibition. 
The identical lesion has also been observed as a somatic mutation in a sporadic 
melanoma case (Wolfel et al., 1995). By abrogating the interaction between 
p16INK4A and CDK4, phosphorylation of retinoblastoma family proteins is not 
inhibited, thereby driving the cell through the cell cycle. The CDK4 mutations are 
epistatic to p16INK4A inactivation in melanoma, further supporting the view that the 
important function of p16INK4A in melanoma suppression is the regulation of 
CDK4/6 activity. This hypothesis is in accordance with the indistinguishable clinical 
impact of germ line CDKN2A (p16INK4A) and CDK4 mutations, manifesting with a 
similar mean age of melanoma diagnosis, mean number of melanomas and number 
of nevi (Goldstein et al., 2000). 
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1.1.2 Pigmentary traits 
 
Pigmentary traits such as red hair, a fair complexion, the inability to tan and a 
tendency to freckle (“red hair color” or RHC phenotype) have been shown to act as 
independent risk factors for all skin cancers, including melanoma (Valverde et al., 
1995). Therefore, it is logical to suspect that allelic variants of genes encoding 
proteins involved in melanin synthesis or transport play a role in melanoma 
susceptibility. Key determinants of the pigmentary process are MC1R (melanocortin 1 
receptor) and α-MSH (melanocyte-stimulating hormone), which is produced by the 
intermediate lobe of the pituitary gland. The human MC1R is a G-protein coupled 
receptor that is expressed on epidermal melanocytes. Upon stimulation of MC1R with 
its ligand α-MSH, the cyclic AMP (cAMP) pathway is upregulated (Busca and Ballotti, 
2000). This in turn leads to activation of MITF (Microphthalmia-associated 
transcription factor), a critical basic helix-loop-helix (bHLH) transcription factor of the 
melanocyte lineage, which potently transactivates pigmentary genes such as TRP-1 
(tyrosinase-related protein-1) and DCT (dopachrome tautomerase) (Widlund and 
Fisher, 2003). Recently, two groups reported that MITF can transcriptionally activate 
key regulators of the cell cycle, but the results are contradictory. Du et al. showed 
that CDK2 is regulated in a tissue specific manner by MITF leading to melanoma 
growth and proliferation (Du et al., 2004). On the other hand, Carreira et al. reported 
that MITF can act as anti-proliferative transcription factor by activating p21CIP1 and 
thereby inducing a G1 cell cycle arrest (Carreira et al., 2005). This ability to activate 
transcription can be potentiated by cooperation between MITF and Rb1. 
MC1R is highly polymorphic in human populations and three common variants 
of MC1R have been associated with the RHC phenotype (Box et al., 2001; Palmer et 
al., 2000). Carrying a single RHC MC1R variant has been shown to significantly 
diminish the ability of the epidermis to respond to damage by UV light, presumably 
leading to increased melanoma risk (Healy et al., 2000; Palmer et al., 2000). 
However, several studies have shown that the impact of MC1R variants on 
melanoma risk can not be entirely attributed to its effect on skin type alone and that 
MC1R variants markedly modify the penetrance of mutations at the CDKN2A locus 
(Box et al., 2001; van der Velden et al., 2001). 
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1.1.3 Somatic mutations in melanoma 
 
1.1.3.1 Mitogen-activated protein kinase signaling pathway 
 
The MAPK (mitogen-activated protein kinase) signaling cascade is activated 
via sequential phosphorylation of a number of kinases to rapidly alter cellular 
behavior, for example gene expression, mitosis, movement, metabolism, and 
programmed cell death in response to diverse environmental stimuli like growth 
factors or UV light (Johnson and Lapadat, 2002). Such stimuli activate the RAS 
family of proto-oncoproteins (NRAS, HRAS, and KRAS), which in turn activate the 
RAF family of serine/threonine kinases (c-RAF1, BRAF, and ARAF). RAF then 
phosphorylates the MAPK kinase MEK, which subsequently phosphorylates and 
activates ERK1 and ERK2 (Busca et al., 2000). Activated ERKs translocate to the 
nucleus, where they phosphorylate specific substrates that are involved in the 
regulation of various cellular responses. 
In sporadic melanoma, activating mutations of RAS have been identified with 
an incidence of 10-15%. For example, activating NRAS point mutations have been 
correlated with nodular lesions and sun exposure (Jafari et al., 1995; van Elsas et al., 
1996) and occur in as many as 33% of primary melanomas and 26% of metastatic 
melanoma samples (Demunter et al., 2001). On the other hand, NRAS mutations are 
rarely found in dysplastic nevi (Albino et al., 1989; Papp et al., 2003). Also, HRAS is 
occasionally involved in melanoma and has been shown to be amplified in acral 
melanoma (Bastian et al., 2000). 
Activating BRAF mutations have been identified in up to 60% of human 
melanoma samples and cell lines (Davies et al., 2002). Importantly, these point 
mutations are clustered in specific regions of biochemical importance, and 80% of 
them resulted in a single amino acid substitution (V600E) in the kinase-activating 
domain, which is known to constitutively activate BRAF (Wellbrock et al., 2004). 
BRAF mutations have also been shown to be common in benign and dysplastic nevi 
(Pollock et al., 2003), supporting the hypothesis that activation of ERKs is an early 
event in melanoma progression (Cohen et al., 2002). In addition, recent findings 
show, that oncogenic BRAF signaling initially stimulates moderate melanocyte 
INTRODUCTION 
 
 8
proliferation but subsequently leads to a growth-inhibitory response, which is 
associated with classical hallmarks of senescence (Michaloglou et al., 2005). These 
findings point to a potential initiating role of BRAF in transformation and to the need 
for additional cooperating genetic events to achieve full malignancy. It is interesting 
to note, that activating mutations in BRAF and NRAS are mutually exclusive on the 
genetic level, suggesting that these mutants are functionally equivalent in 
transformation. 
 
1.1.3.2 HGF/SF-MET signaling pathway 
 
HGF/SF (hepatocyte growth factor/scatter factor) acts as ligand for its 
tyrosine-kinase receptor c-MET, which is present on epithelial cells and melanocytes 
(Bottaro et al., 1991). Although HGF normally acts in a paracrine manner, autocrine 
activation of HGF/SF-MET has been shown in various transformed cells and tumors, 
including melanoma (Li et al., 2001). HGF/SF can stimulate proliferation and motility 
of human melanocytes in culture (Halaban et al., 1992) and disrupts adhesion 
between melanocytes and keratinocytes via down-regulation of E-cadherin and 
desmoglein-1 (Li et al., 2001). The resultant decoupling of melanocytes from 
keratinocytes is thought to be permissive for deregulated proliferation and scattering 
(Li et al., 2001). In addition, HGF/SF-MET activation has also been implicated in 
melanoma progression. Increased c-MET expression has been observed in 
metastatic melanoma (Natali et al., 1993), and gain of 7q33-qter, where c-MET 
resides, seems to be a late event in melanoma progression (Bastian et al., 1998). 
 
1.1.3.3 PTEN-AKT signaling pathway 
 
PTEN (phosphatase and tensin homolog) is located on chromosome 10q23.3 
and the protein functions as a dual-specificity phosphatase with lipid and protein 
phosphatase activity (Simpson and Parsons, 2001). As lipid phosphatase PTEN 
negatively regulates the phosphatidylinositol 3-kinase (PI3K)-AKT pathway, which 
plays an important role in cell survival, protecting cells from apoptosis (Stambolic et 
al., 1998). On the other hand, PTEN also inhibits MAPK signaling through its protein 
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phosphatase activity (Wu et al., 2003). In melanoma, allelic loss or mutations of 
PTEN have been described in 5-15% of uncultured melanoma specimens and 
metastases, as well as in 30-40% of established melanoma cell lines (Guldberg et 
al., 1997; Teng et al., 1997). In addition, ectopic expression of PTEN in PTEN-
deficient melanoma cell lines was able to suppress growth, tumorigenicity and 
metastasis (Hwang et al., 2001; Robertson et al., 1998).  Although PTEN is a bona 
fide tumor suppressor of 10q23.3, the existence of additional melanoma suppressors 
has been inferred by the fact, that in the 30-50% of human melanomas with LOH 
(loss of heterozygosity) of the 10q region reintroduction of PTEN seems to have no 
growth-suppressive effect (Robertson et al., 1998). A strong candidate for another 
melanoma suppressor gene on 10q is the MYC antagonist MXI1, although its role in 
melanoma genesis has not been rigorously evaluated (Schreiber-Agus et al., 1998).  
 
1.2 Methods for cytogenetic and whole-genome analyses 
 
Carcinogenesis requires several genetic alterations that convey a selective 
growth advantage. Most cancers accumulate numerous genetic changes at the level 
of the nucleotide, gene and chromosome (Lengauer et al., 1998). Many cancers also 
acquire epigenetic changes, which can alter gene expression (Jones and Baylin, 
2002). These findings have led to the suggestion, that the acquisition of some form of 
inherent genomic instability is a hallmark of tumorigenesis (Hanahan and Weinberg, 
2000). 
The most important genetic changes involve alterations in oncogenes, tumor-
suppressor genes, and stability genes. Oncogenes are mutated in ways that render 
the gene constitutively active or active under conditions in which the wild-type gene is 
not. This activation can result from chromosomal translocations, gene amplifications, 
or subtle intragenic mutations. Tumor-suppressor genes on the other hand are 
targeted through inactivation of the gene product. Such inactivations arise from 
missense mutations, mutations that truncate the resulting protein, deletions or 
insertions, or from epigenetic silencing. Mutations in oncogenes and tumor-
suppressor genes drive the neoplastic process by increasing tumor cell number 
through the stimulation of cell division or the inhibition of apoptosis or cell-cycle 
arrest. 
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Stability genes or caretakers promote tumorigenesis in a different way when 
mutated (Hoeijmakers, 2001; Markowitz, 2000). These genes are responsible for 
repairing mistakes made during normal DNA replication or upon exposure to 
mutagens and control mitotic recombination and chromosomal segregation. Stability 
genes keep genetic alterations to a minimum, and thus when they are inactivated, 
mutations in other genes occur at a higher rate (Friedberg, 2003). 
To detect chromosomal aberrations in tumors, numerous cytogenetic and 
molecular methods have been developed. Some of these methods, namely M-FISH, 
CGH, and digital karyotyping, have been used in this work to analyze malignant 
melanoma cell lines and are described in detail in the following sections. 
 
1.2.1 Fluorescence in situ hybridization 
 
For several decades chromosomes were analyzed by traditional karyotyping, 
which depends on the analysis of characteristic banding patterns along the length of 
each chromosome (Caspersson et al., 1968; Caspersson et al., 1970). However, the 
major disadvantage of conventional cytogenetic banding methods is their limited 
resolution, which depends on the number of chromosomal bands that can be 
visualized after staining with a certain dye. This drawback was overcome by the 
development of the fluorescence in situ hybridization (FISH) technique, allowing the 
direct visualization and localization of selected DNA regions within a genome 
(Cremer et al., 1988; Lichter et al., 1988; Pinkel et al., 1988). Thereby, a small DNA 
fragment of known origin (a painting probe) is fluorescently labeled and hybridized to 
metaphase chromosome spreads or interphase nuclei. The probe binds to 
homologous sequences within the chromosomes, which can be visualized by 
fluorescence microscopy. 
Initially, painting probes were often used to verify a chromosomal 
rearrangement, which was obvious or suspected in banding analysis. However, the 
deciphering of complex rearrangements with involvement of unidentifiable 
chromosomal material is inefficient if only one or two chromosome paints per 
hybridization are used. Therefore, technologies were developed which allow the 
simultaneous hybridization of multiple chromosome painting probes in different 
colors. With the introduction of 24-color FISH, namely M-FISH and SKY, all 22 
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autosomes and the two sex chromosomes can be visualized simultaneously. 
Multiplex fluorescence in situ hybridization (M-FISH) uses combinatorial labeling with 
a total of seven fluors to uniquely identify each of the 24 chromosomes based on 
different optical filters (Speicher et al., 1996). Spectral karyotyping (SKY) on the other 
hand is a technique, that also employs the combinatorial labeling strategy for probe 
discrimination (Schrock et al., 1996) but the detection is interferometer-based. 
The 24-color karyotyping technologies have proven to be useful tools in 
clinical diagnostics (Uhrig et al., 1999) and in deciphering complexly rearranged 
tumor karyotypes (Veldman et al., 1997). For example, it is possible to rapidly identify 
numerical and structural aberrations, as well as translocations, duplications and 
deletions. However, these technologies also have some limitations, which for 
example are difficulties in the determination of the exact band of origin of a marker or 
the evaluation of breakpoints of intrachromosomal rearrangements. Furthermore, the 
detection sensitivity for small (< 3 Mbp) intrachromosomal rearrangements, deletions 
or duplications is poor. Nevertheless, these problems have already been addressed 
and solutions have been proposed by increasing the number of fluorochromes for 
probe labeling (Azofeifa et al., 2000), by replacing painting probes with region-
specific probes (Fauth et al., 2001), or by developing so called “bar coding” strategies 
(Lengauer et al., 1993).  
 
1.2.2 Comparative genomic hybridization 
 
Comparative genomic hybridization (CGH) was developed for genome-wide 
analysis of DNA sequence copy number in a single experiment (du Manoir et al., 
1993; Kallioniemi et al., 1992). Thereby, total genomic DNA from a “test” (tumor) and 
a “reference” (normal) cell population are differentially labeled with green and red 
fluorochromes and co-hybridized to normal metaphase chromosomes, where the 
green and red labeled DNA fragments compete for hybridization to their locus of 
origin. The resulting ratio of the fluorescence intensities is measured along the 
chromosome axis and is approximately proportional to the ratio of the copy numbers 
of the corresponding DNA sequences in the test and reference genomes at that 
specific location on the chromosomes. 
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CGH has been widely applied in cancer research including the screening of 
tumors for genetic aberrations (Monni et al., 1998; Riopel et al., 1998), the search for 
genes involved in the carcinogenesis of particular subsets of cancers (Simon et al., 
1998), the analysis of tumors in experimental models to obtain an insight into tumor 
progression (Tienari et al., 1998), diagnostic classification (Simon et al., 1998), and 
prognosis assessment (Isola et al., 1995). 
Although useful in cancer research, CGH has also some drawbacks, for 
example it cannot detect structural chromosomal aberrations without copy number 
changes, such as balanced chromosomal translocations, inversions, or ring 
chromosomes, and it does not yield information in the context of tissue architecture. 
The sensitivity of CGH can be hampered by contamination of tumor material with 
normal cells and also depends on the level and size of the copy number changes. 
The use of metaphase chromosomes limits the detection of events involving small 
regions of the genome, the resolution of closely spaced aberrations and hampers the 
linking of ratio changes to genomic/genetic markers. Based on CGH experiments, the 
resolution was estimated to be in the range of 10-20 Mbp (Bentz et al., 1995; Bentz 
et al., 1998). Much higher resolutions can be achieved with newly developed 
techniques such as array-CGH (Pinkel et al., 1998) or matrix-CGH (Solinas-Toldo et 
al., 1997). For example, whole genome arrays or single chromosome tiling path 
arrays achieve resolutions of ~10 Mbp or ~100 kbp, respectively. 
 
1.2.3 Digital karyotyping 
 
The digital karyotyping (DK) technique has been developed to examine genome-wide 
DNA copy number changes with so far unprecedented resolution (Wang et al., 2002). 
Digital karyotyping quantitatively analyses short sequence fragments of 21 bp (tags), 
which are obtained from specific locations in the genome and which contain sufficient 
information to uniquely identify the genomic loci from which they were derived (Figure 
2). 
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Figure 2 Scheme of the digital karyotyping approach. Colored boxes represent genomic tags, gray 
and dotted boxes represent linkers. Small black circles denote biotin modifications and large brown 
circles denote streptavidin magnetic beads. Cleavage sites of restriction enzymes are labeled with S 
(for SacI), N (for NlaIII), or * (for MmeI). Modified from (Parrett and Yan, 2005; Wang et al., 2002) 
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To obtain these tags, genomic DNA of a cell population, for example a tumor 
cell line, is fragmented by a mapping restriction endonuclease into representative 
fragments of a certain size. For example, fragments of approximately 4 kbp can be 
obtained after cleavage with SacI. After ligation of biotinylated linkers, the DNA 
molecules are isolated with streptavidin magnetic beads and further digested with a 
second fragmenting restriction endonuclease, cutting on average 16 times inside the 
already obtained fragments (for example NlaIII). Linkers containing a recognition site 
for a type IIS restriction endonuclease (for example MmeI) are ligated to the DNA 
molecules, which are still captured by the streptavidin magnetic beads. 
Subsequently, the DNA fragments are cleaved by MmeI, releasing 21 bp genomic 
tags. Isolated tags are self-ligated to form ditags, which are PCR amplified, 
concatenated, cloned, and sequenced. After sequencing, tags can be extracted with 
the SAGE2000 software, which identifies the fragmenting enzyme site between 
ditags and are then matched to a virtual tag library extracted from the human 
genome sequence, which contains only tags obtained from unique loci. Experimental 
tags with the same sequence as virtual tags are used for subsequent analysis with 
the digital karyotyping software. Thereby, tags are matched to their genomic position 
along each chromosome and tag densities are calculated. Regions with over- or 
underrepresentation of tags contain possible sites of copy number changes in the 
analyzed genome. 
Digital karyotyping is assumed to be highly reliable from the standpoint of 
comparing genetic dosage signals from different areas of the genome, as tag counts 
are directly proportional to the amount of genetic material present and do not depend 
upon quantitating and comparing a non-linear hybridization signal across 
heterogeneous nucleotide probes. The theoretical resolution of digital karyotyping is 
also the highest of the current high-resolution whole-genome screens (for review see 
(Parrett and Yan, 2005; Shih Ie and Wang, 2005)). At present, however, the 
resolution for the detection of gene dosage alterations is limited by the number of 
experimentally derived tags that can be sequenced economically, which is 
approximately 100,000-200,000. For example, the analysis of 100,000 tags is 
expected to reliably detect a 10-fold amplification ≥100 kbp, homozygous deletions 
≥600 kbp, or a single gain or loss of regions ≥4 Mbp in a diploid genome (Wang et 
al., 2002). 
INTRODUCTION 
 
 15
1.3 Dystrophin 
 
1.3.1 DMD gene and isoforms 
 
Dystrophin (DMD) is the second largest gene in humans and located on 
chromosome Xp21.2. It spans about 2.5 Mbp of genomic sequence with a full-length 
messenger RNA of 14 kbp (for review see (Blake et al., 2002; Muntoni et al., 2003)). 
Three independently regulated promoters (for brain, muscle and Purkinje cells) 
control expression of the full-length DMD transcript with a unique first exon spliced to 
a common set of 78 exons (Figure 3 and Table 1). The brain promoter drives 
expression primarily in cortical neurons and the hippocampus of the brain (Gorecki et 
al., 1992; Nudel et al., 1989). The transcript from the Purkinje promoter is expressed 
in the cerebellar Purkinje cells and at a very low level in skeletal muscle (Bies et al., 
1992; Bies et al., 1992). The muscle transcript is mainly expressed in skeletal muscle 
and cardiomyocytes in addition to the expression at a low level in some glial cells in 
the brain (Yaffe et al., 1992). An additional full-length lymphocyte isoform has been 
described (Nishio et al., 1994), although recent findings suggest that it might 
represent an artifact, making its functional role uncertain (Wheway and Roberts, 
2003). 
The DMD gene has at least four internal promoters that give rise to shorter 
dystrophin transcripts that encode truncated COOH-terminal isoforms (Figure 3 and 
Table 1). Each of these internal promoters uses a unique first exon that is spliced to 
exons 30, 45, 56, and 63 to generate proteins of 260 kD (Dp260) (Pillers et al., 
1993), 140 kD (Dp140) (Lidov et al., 1995), 116 kD (Dp116) (Byers et al., 1993), and 
71 kD (Dp71) (Bar et al., 1990). Dp71 is detected in most non-muscle tissues 
including brain, kidney, liver, and lung (Hugnot et al., 1992; Lederfein et al., 1992), 
while the remaining short isoforms are primarily expressed in the central and 
peripheral nervous system (Byers et al., 1993; D'Souza et al., 1995; Lidov et al., 
1995; Schofield et al., 1994). In addition, Dp140 has also been implicated in the 
development of the kidney (Durbeej et al., 1997). The COOH-terminal isoforms 
contain the necessary binding sites for a number of dystrophin-associated proteins 
(see chapter 1.3.5), and although the molecular and cellular function of these 
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isoforms has not been elucidated, they are thought to be involved in the stabilization 
and function of non-muscle dystrophin-like protein complexes. 
 
 
In addition to these shorter isoforms, the dystrophin gene produces many 
isoforms generated through alternative splicing events in a tissue-specific way (Bies 
et al., 1992; Feener et al., 1989). These splice variants not only affect full-length 
dystrophin but are also found in the shorter isoforms such as Dp71. They are formed 
both through the exclusion of some exons from the primary transcript (exon skipping) 
and by subversion of the reciprocal order of exons (exon scrambling) (Sadoulet-
Puccio and Kunkel, 1996; Surono et al., 1999). It has been suggested, that this 
differential splicing may regulate the binding of dystrophin to dystrophin-associated 
proteins at the membrane (Crawford et al., 2000). 
C
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Xp21
Dp427p
Dp427m
Dp427c Dp260 Dp140 Dp116 Dp71
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Figure 3 Structure of the dystrophin (DMD) gene. DMD is located on Xp21 and spans about 2.5 Mbp 
of genomic sequence as indicated underneath the chromosome ideogram. The vertical black lines 
represent the 79 exons of the DMD gene. The arrows indicate the different promoters, which 
correspond to the different protein isoforms; namely the cortical (C; Dp427c), the muscle (M; 
Dp427m), the Purkinje (P; Dp427p), the retinal (R; Dp260), the kidney (K; Dp140), the Schwann cell 
(S; Dp116), and the ubiquitously (U; Dp71) expressed transcript. Modified from (Muntoni et al., 2003). 
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Table 1 Expression pattern and position of the transcription start site of the different dystrophin 
isoforms. 
Name Isoform Promoter and first exon Pattern of protein expression 
Dp427c cortical 
(brain) 
5´ of the muscle promoter cortical neurons, skeletal and cardiac 
muscle 
Dp427m muscle between the cortical promoter 
and intron 1 
skeletal and cardiac muscle, glial cells 
Dp427p Purkinje between intron 1 and 2 Purkinje cerebellar neurons 
Dp260 retinal intron 29 retina 
Dp140 kidney intron 44 CNS, kidney 
Dp116 S-dystrophin intron 55 Schwann cells 
Dp71 G-dystrophin intron 62 ubiquitously expressed in most tissues 
except for skeletal muscle 
Modified from (Muntoni et al., 2003). Abbreviations: CNS; central nervous system. 
 
1.3.2 Dystrophin protein 
 
Dystrophin is a 427 kD cytoskeletal protein that is a member of the β-
spectrin/α-actinin protein family (Koenig et al., 1988). Dystrophin can be organized 
into four separate domains based on sequence homologies and protein-binding 
capabilities – the actin-binding domain at the NH2 terminus, the central rod domain, 
the cysteine-rich domain, and the COOH-terminal domain (Figure 4). The NH2 
terminus is homologous to α-actinin and binds directly to but does not cross-link 
cytoskeletal actin (F-actin) (Rybakova et al., 1996). The central rod domain is formed 
by 24 spectrin-like triple-helical elements. These repeats are interrupted by four 
proline-rich non-repeat segments, the so-called hinge regions. The central domain 
accounts for the majority of the dystrophin protein and is thought to give the molecule 
a flexible rod-like structure (Koenig and Kunkel, 1990). The central rod domain is 
followed by a WW domain, which is a protein-binding module found in several 
signaling and regulatory molecules. The WW domain binds to proline-rich substrates 
and mediates interaction with the cytoplasmic domain of β-dystroglycan (Rosa et al., 
1996). The cysteine-rich domain shows similarity to α-actinin and contains a ZZ 
domain and two potential EF-hand motifs that could bind intracellular Ca2+ (Koenig et 
al., 1988). The ZZ domain comprises a number of conserved cysteine residues and 
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is similar to many types of zinc fingers. In addition, it can bind to calmodulin in a 
Ca2+-dependent manner (Anderson et al., 1996). The COOH terminus of dystrophin 
contains two polypeptide stretches that are predicted to form coiled coils and 
therefore has been named the CC domain. The CC region forms the binding site for 
dystrobrevin and can modulate the interaction between syntrophin and other 
dystrophin-associated proteins (Blake et al., 1995). 
 
 
1.3.3 Duchenne and Becker Muscular Dystrophies 
 
Duchenne and Becker muscular dystrophies (DMD/BMD) are X-linked 
recessive disorders that are caused by defects in the DMD gene (Emery, 1993). 
These gene mutations lead to a deficiency of the dystrophin protein in skeletal 
muscle as well as in other tissues in which isoforms of dystrophin are normally 
expressed, such as brain, retina, and smooth muscle (see chapter 1.3.1). Typically, 
DMD patients are clinically normal at birth with 1 in 3500 males being affected. The 
first symptoms of DMD are generally observed between the ages of 2 and 5 years 
with a delay in the achievement of motor milestones, including a delay in walking, 
unsteadiness, and difficulty in running (Jennekens et al., 1991). Eventually, 
decreased lower-limb muscle strength and joint contractures result in wheel-chair 
dependence, usually by the age of 12. Most patients die in their early twenties as a 
result of respiratory complications. Death can also be the result of cardiac 
dysfunction caused by cardiomyopathy (Emery, 1993). 
ABD CCCYSH1 H2 H3 H41 2 3 4 5 6 7 8 9 10 11121314 15161718 19 20 2122 2324 WW
NH2-terminal domain COOH-terminal domainCentral rod domain
 
Figure 4 Structure of the dystrophin protein. The NH2-terminus of dystrophin contains the actin-
binding domain (ABD), which is followed by the central rod domain consisting of 24 spectrin-like 
repeats (1-24) that are interrupted by four proline-rich hinge regions (H1-H4). Adjacent to the rod 
domain follows the WW domain and the cysteine-rich domain (CYS). The COOH-terminus forms a 
coiled coil structure (CC). 
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In individuals affected by BMD, the clinical course is similar to that of DMD, 
although the onset of symptoms and the rate of progression are delayed. More than 
90% of patients are still alive in their twenties (Comi et al., 1994). There is a 
continuous clinical spectrum between a mildly affected BMD patient and a severely 
affected DMD patient. In addition, some BMD and DMD patients are affected by mild 
cognitive impairment, indicating that nerve cell function is also abnormal in these 
disorders (Mehler, 2000). 
 
1.3.4 Mutations in DMD 
 
The most common changes in DMD are intragenic deletions, which account 
for 65% of DMD mutations (Koenig et al., 1989; Monaco et al., 1985). The frequency 
of duplications may range from 5% to 15%, whereas the remaining cases are caused 
by small mutations, pure intronic deletions, or exonic insertions of repetitive 
sequences (Roberts et al., 1994). The vast majority of large deletions detected in 
BMD and DMD cluster around two mutation “hot spots” (Koenig et al., 1989). The first 
region is located at the 3´-end of DMD and involves exons 45-53 (Beggs et al., 
1990), whereas the other hotspot includes exons 2-20 at the 5´-end of DMD (Liechti-
Gallati et al., 1989). One-third of DMD cases are caused by very small deletions and 
point mutations, most of which introduce premature stop codons and appear to be 
evenly distributed throughout the gene (Gardner et al., 1995; Prior et al., 1995). 
Mutations that maintain the reading frame (in-frame) generally result in abnormal but 
partially functional dystrophin and are associated with BMD (Monaco et al., 1988). In 
patients with DMD, deletions, duplications or mutations disrupt the reading frame 
(frame-shift), resulting in unstable RNA that eventually leads to the production of 
nearly undetectable concentrations of truncated proteins (Kerr et al., 2001). 
Exceptions to this reading-frame hypothesis do exist and these include patients with 
BMD who carry frame-shift deletions or duplications and patients with DMD with in-
frame deletions or duplications (Love et al., 1990; Nevo et al., 2003). 
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1.3.5 Dystrophin-glycoprotein complex 
 
The identification of the dystrophin protein and its localization to the muscle 
cell membrane led to the biochemical co-purification of a group of sarcolemmal and 
sub-sarcolemmal proteins, that form the dystrophin-glycoprotein complex (DGC) 
(Campbell and Kahl, 1989; Yoshida and Ozawa, 1990) (Figure 5). In skeletal muscle, 
the NH2 terminus of dystrophin binds to cytoskeletal actin (Rybakova et al., 1996), 
whereas the COOH terminus binds the intracellular domain of β-dystroglycan (Jung 
et al., 1995). β-dystroglycan is a transmembrane protein with its extracellular domain 
binding to α-dystroglycan (Ibraghimov-Beskrovnaya et al., 1993). α-dystroglycan acts 
as a receptor for a number of extracellular matrix components, including laminin 
(Ibraghimov-Beskrovnaya et al., 1992), agrin (Gee et al., 1994), and perlecan in 
muscle, and neurexin in brain (Sugita et al., 2001). Thus, the dystrophin-dystroglycan 
complex serves as a transmembrane link between the extracellular matrix and the 
cytoskeleton, and this structural role may protect the muscle from the shearing forces 
of contraction (Petrof et al., 1993). 
In skeletal muscle several other proteins are associated with dystrophin and 
dystroglycan, namely the dystrobrevins and syntrophins, and the sarcoglycan-
sarcospan complex. In non-muscle tissues intracellular binding partners for β-
dystroglycan include the Dp260, Dp140, Dp116 and Dp71 isoforms of dystrophin 
(Jung et al., 1995; Saito et al., 1999) and utrophin, the autosomal homolog of 
dystrophin (Chung and Campanelli, 1999). Other proteins that bind to the DGC are 
calmodulin (Madhavan et al., 1992), Grb2 (Yang et al., 1995), and NOS1 (Brenman 
et al., 1996) suggesting a role for the DGC in cellular signaling. 
Many of the dystrophin/dystroglycan-associated proteins found in skeletal and 
cardiac muscle are also expressed in other tissues. Thus, different dystroglycan 
complexes may form in different tissues playing roles in epithelial cell development 
(Durbeej et al., 1995), basement membrane formation (Henry and Campbell, 1998; 
Williamson et al., 1997), and synaptogenesis (Montanaro et al., 1998).  
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Figure 5 The dystrophin-glycoprotein complex (DGC) at the muscle cell membrane. The 
dystroglycans (α-DG and β-DG) anchor the DGC at the muscle cell membrane. α-DG can bind to 
several ligands (e.g. laminin-2) present in the extracellular matrix, whereas β-DG binds to dystrophin, 
which is linked to F-actin facilitating a connection with the intracellular cytoskeleton. Associated with 
the dystroglycans is the sarcoglycan complex, which also binds to sarcospan. Intracellular binding 
partner for the sarcoglycan complex is α-dystrobrevin, which at the same time can bind to dystrophin. 
Several signaling molecules are associated intracellularly with the DGC, namely Grb2, NOS1, the 
syntrophins α1 and β1 as well as calmodulin. In addition, both dystrophin and α-dystrobrevin can be 
modified by multiple phosphorylations. 
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2 AIM OF THE STUDY 
 
The present study had the following aims: 
 
I. Characterization of chromosomal aberrations in a panel of newly established 
melanoma cell lines by M-FISH and CGH analysis 
 
II. Detection of genome-wide genetic alterations employing the digital karyotyping 
technique in malignant melanoma cell lines in order to identify single gene copy 
number changes, which might indicate the presence of tumor-suppressor genes 
or oncogenes 
 
III. Functional analysis of candidate tumor-suppressor genes or oncogenes 
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3 MATERIALS 
 
3.1 Chemicals 
 
Chemical Supplier 
1,4-diazabicyclo(2,2,2)octane (DAPCO) Sigma, Taufkirchen, Germany 
3-(N-morpholine)propanesulphonic acid (MOPS) ICN Biomedicals, Shelton, USA 
4,6-diamidino-2-phenylindole (DAPI) Sigma, Taufkirchen, Germany 
5-bromo-4-chloro-3-indolyl β-D-galacto-
pyranoside (X-gal) 
Sigma, Taufkirchen, Germany 
Acrylamide Serva, Heidelberg, Germany 
Agarose Peqlab, Erlangen, Germany 
Ammonium peroxodisulfate (APS) Bio-Rad, München, Germany 
Ampicillin Sigma, Taufkirchen, Germany 
β-mercaptoethanol Merck, Darmstadt, Germany 
Biotin-16-dUTP Boehringer, Ingelheim, Germany 
Bisacrylamide Roth, Karlsruhe, Germany 
Bovine serum albumin (BSA) NEB, Frankfurt/Main, Germany 
Bromphenol blue Sigma, Taufkirchen, Germany 
Coomassie G250 Serva, Heidelberg, Germany 
Cot-1 DNA Roche, Mannheim, Germany 
Cy3 (cyanine-dye) Amersham, Piscataway, USA 
Cy5.5 (cyanine-dye) Amersham, Piscataway, USA 
Cy7 (cyanine-dye) Amersham, Piscataway, USA 
Deionized formamide pH 7.0 Sigma, Taufkirchen, Germany 
Demecolcine (colcemid) Sigma, Taufkirchen, Germany 
Deoxynucleotides (dATP/dCTP/dGTP/dTTP) ABgene, Hamburg, Germany 
Dextransulfate Sigma, Taufkirchen, Germany 
Diethylaminocoumarine (DEAC) Amersham, Piscataway, USA 
Digoxigenin-11-dUTP Boehringer, Ingelheim, Germany 
Dimethyl sulfoxide (DMSO) Sigma, Taufkirchen, Germany 
Dithiothreitol (DTT) Sigma, Taufkirchen, Germany 
Ethidium bromide Sigma, Taufkirchen, Germany 
Ficoll® 400 Sigma, Taufkirchen, Germany 
Fluoresceinisothiocyanate (FITC) Amersham, Piscataway, USA 
Geneticin® (G418, neomycin) Invitrogen, Karlsruhe, Germany 
Glutaraldehyde Serva, Heidelberg, Germany 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) Roth, Karlsruhe, Germany 
Kanamycin Sigma, Taufkirchen, Germany 
Matrigel basement membrane matrix Becton Dickinson, Heidelberg 
Germany 
Mitomycin C Sigma, Taufkirchen, Germany 
N,N,N',N'-tetramethylethylenediamine (TEMED) Serva, Heidelberg, Germany 
Paraformaldehyde Sigma, Taufkirchen, Germany 
Phenol/chloroform/isoamylalcohol (25:24:1) Roth, Karlsruhe, Germany 
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Chemical Supplier 
Phenylmethylsulfonylfluoride (PMSF)  Sigma, Taufkirchen, Germany 
Propidium iodide Sigma, Taufkirchen, Germany 
Protease inhibitor cocktail complete mini Roche, Mannheim, Germany 
Puromycin dihydrochloride Sigma, Taufkirchen, Germany 
Salmon-sperm DNA Sigma, Taufkirchen, Germany 
Sodium fluoride Sigma, Taufkirchen, Germany 
Sodium orthovanadate Aldrich, Steinheim, Germany 
TexasRed Invitrogen, Karlsruhe, Germany 
Triton X-100 Roth, Karlsruhe, Germany 
Tween® 20 Sigma, Taufkirchen, Germany 
 
3.2 Enzymes 
 
Enzyme Supplier 
Alkaline phosphatase calf intestine (CIP) NEB, Frankfurt/Main, Germany 
DNA polymerase I Boehringer, Ingelheim, Germany 
DNase I Sigma, Taufkirchen, Germany 
FIREPol® DNA polymerase Solis BioDyne, Tartu, Estonia 
Pepsin  Sigma, Taufkirchen, Germany 
Platinum® Taq DNA polymerase Invitrogen, Karlsruhe, Germany 
Proteinase K Sigma, Taufkirchen, Germany 
Restriction endonucleases NEB, Frankfurt/Main, Germany 
MBI Fermentas, St. Leon-Rot, 
Germany 
T4-DNA ligase Roche, Mannheim, Germany 
Trypsin Invitrogen, Karlsruhe, Germany 
 
3.3 Commercial kits and other materials 
 
Product Supplier 
3MM Whatman® filter paper Whatman, Dassel, Germany 
BigDye® Terminator v3.1 Sequencing Kit Applera, Darmstadt, Germany 
Cell culture plastics Corning, Schiphol, Netherlands 
Nunc, Wiesbaden, Germany 
BD Falcon, Bedford, USA 
DNA ladder, 1 kbp Invitrogen, Karlsruhe, Germany 
DNA ladder, 100 bp Roth, Karlsruhe, Germany 
Dynabeads® M-280 Streptavidin Dynal Biotech, Swestad, Norway 
FastStart-DNA Master SYBR Green 1 Roche, Mannheim, Germany 
FuGENE6™ Roche, Mannheim, Germany 
Immobilon-P PVDF membrane Millipore, Schwalbach, Germany 
Oligonucleotides Metabion, Martinsried, Germany 
PageRuler™ Prestained Protein Ladder MBI Fermentas, St. Leon-Rot, 
Germany 
QIAGEN Plasmid Maxi Kit Qiagen, Hilden, Germany 
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Product Supplier 
QIAprep Miniprep Kit Qiagen, Hilden, Germany 
QIAquick Gel Extraction Kit Qiagen, Hilden, Germany 
RNAgents total RNA isolation system Promega, Mannheim, Germany 
Siliconized microcentrifuge tubes Fisher Scientific, Schwerte, 
Germany 
Spin-X tubes Costar, Schiphol, Netherlands 
SuperScriptTM III first-strand synthesis system Invitrogen, Karlsruhe, Germany 
SuperSignal® West Dura Pierce, Rockford, USA 
Western Lightning Chemiluminescence  
Reagent Plus 
Perkin Elmer, Boston, USA 
 
3.4 Buffers and stock solutions 
 
All buffers and solutions were prepared with bidistilled water unless stated otherwise. 
 
Solution Recipe 
  
Bradford solution (5x) 50% (w/v) Coomassie G250 
23.75% (v/v) ethanol 
42.5% (v/v) phosphoric acid 
  
Coomassie G250 staining solution 0.25% (w/v) Coomassie G250 
45% (v/v) methanol 
10% (v/v) acetic acid 
  
Crystal violet solution 5 mg/ml crystal violet 
20% (v/v) methanol 
  
DAPCO antifade 23.3 mg/ml DAPCO 
20 mM Tris/HCl pH 8.0 
90% (v/v) glycerol 
  
Destaining solution 50% (v/v) methanol 
15% (v/v) acetic acid 
  
DNA loading buffer (10x) 20% (w/v) Ficoll® 400  
1 mM EDTA pH 8.0 
0.05% (w/v) bromphenol blue 
  
Gel drying solution 2% (v/v) glycerol 
20% (v/v) ethanol 
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Solution Recipe 
  
Laemmli buffer (2x) 
 
100 mM Tris/HCl pH 6.8 
10% (w/v) SDS 
50% (v/v) glycerol 
0.05% (w/v) bromphenol blue 
10% (v/v) β-mercaptoethanol 
  
LB agar 1.5% (w/v) agar 
in LB medium 
  
LB medium 1% (w/v) tryptone 
0.5% (w/v) yeast extract 
1% (w/v) NaCl 
pH 7.2 
  
Low TBST 20 mM Tris/HCl pH 7.5 
100 mM NaCl 
0.05% (v/v) Tween® 20 
  
Lower Tris buffer (4x) 1.5 M Tris base 
0.4% (w/v) SDS 
pH 8.8 (HCl) 
  
MOPS buffer  (10x) 200 mM MOPS 
50 mM sodium acetate 
10 mM EDTA 
pH 7.0 (NaOH) 
  
PBS 13.7 mM NaCl 
2.7 mM KCl 
80.9 mM Na2HPO4 
1.5 mM KH2PO4 
pH 7.4 (HCl) 
  
PCR buffer (10x) 166 mM (NH4)2SO4 
670 mM Tris/HCl pH 8.8 
67 mM MgCl2 
100 mM β-mercaptoethanol 
  
Proteinase K buffer 10 mM Tris/HCl pH 8.0 
100 mM NaCl 
25 mM EDTA pH 8.0 
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Solution Recipe 
  
RIPA lysis buffer 50 mM Tris/HCl pH 7.5 
150 mM NaCl 
1 mM EDTA 
1% (v/v) NP-40 
0.1% (w/v) SDS 
0.25% (w/v) sodium deoxycholate 
1 mM PMSF 
1 mM NaF 
1 mM Na3VO4 
  
RNA loading buffer (4x) 6.47% (v/v) formaldehyde 
50% (v/v) formamide 
10% (v/v) glycerol 
1.5 µg/ml ethidium bromide 
0.2% (w/v) bromphenol blue 
0.2% (w/v) xylene cyanol 
in MOPS buffer 
  
SDS/proteinase K solution 0.1 mg/ml proteinase K 
0.1% (w/v) SDS 
in proteinase K buffer 
  
SSC buffer (20x) 3 M NaCl 
342 mM sodium citrate 
pH 7.0 (HCl) 
  
TAE buffer (10x) 400 mM Tris/acetate 
10 mM EDTA 
pH 8.0 (acetic acid) 
  
TBS 100 mM Tris/HCl pH 7.5 
150 mM NaCl 
  
TBST 100 mM Tris/HCl pH 7.5 
150 mM NaCl 
0.05% (v/v) Tween® 20 
  
TE 10 mM Tris/HCl pH 8.0 
0.1 mM EDTA pH 8.0 
  
LoTE 3 mM Tris/HCl pH 7.5 
0.2 mM EDTA pH 7.5 
  
Transfer buffer (25x) 300 mM Tris base 
2.4 M glycine 
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Solution Recipe 
  
Tris-Glycine-SDS buffer (10x) 248 mM Tris/HCl pH 7.5 
1918 mM glycine 
1% (w/v) SDS 
  
Triton X-100 lysis buffer 
 
50 mM HEPES pH 7.5 
150 mM NaCl 
1 mM EGTA 
10% (v/v) glycerol 
1% (v/v) Triton X-100 
100 mM NaF  
10 mM Na4P2O7 * 10 H20 
1 mM PMSF 
1 mM Na3VO4 
  
Upper Tris buffer (4x) 500 mM Tris base 
0.4% (w/v) SDS 
pH 6.8 (HCl) 
  
X-gal stain (pH 6.0) 3 mM K3Fe(CN)6 
3 mM K4Fe(CN)6 
1 mM MgCl2 
1 mg/ml X-gal 
in PBS pH 6.0 
 
3.5 Antibodies 
 
3.5.1 Primary antibodies 
 
Antibody Supplier/Reference 
mouse monoclonal anti-dystrophin Ab-1 (clone 
1808) 
Dunn Labortechnik, Asbach, 
Germany 
mouse monoclonal anti-dystrophin NCL-Dys1 Novocastra, Newcastle, UK 
mouse monoclonal anti-dystrophin NCL-Dys2 Novocastra, Newcastle, UK 
mouse monoclonal anti-VSV (clone p5d4) Department of Molecular Biology, 
MPI of Biochemistry 
mouse monoclonal anti-α-dystroglycan IIH6 gift from Dr. K. P. Campbell 
(Ervasti and Campbell, 1991) 
rabbit polyclonal anti-β-actin Sigma, Taufkirchen, Germany 
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3.5.2 Secondary antibodies 
 
Antibody Supplier/Reference 
avidin-Cy3.5-conjugate Amersham, Piscataway, USA 
donkey anti-mouse IgG Cy3-conjugate Jackson ImmunoResearch, West 
Grove, USA 
goat anti-mouse IgG HRP-conjugate Promega, Mannheim, Germany 
goat anti-rabbit IgG HRP-conjugate Sigma, Taufkirchen, Germany 
sheep anti-Dig FITC-conjugate Roche, Mannheim, Germany 
 
3.6 DNA constructs 
 
Table 2 Description of DNA constructs. 
Vector Description Origin 
attb-pDysE pCR3.1 backbone with CMV promoter, 
attb site and expression of dystrophin N-
terminally tagged with EGFP 
gift from Dr. J. P. Tremblay 
(Chapdelaine et al., 2000) 
  
 
attb-pEGFP EGFP from pEGFP-C1 cloned into the 
backbone of attb-pDysE 
this work 
   
pCMV-DAG1-VSV pECFP-C1 backbone with expression of 
dystroglycan (cloned from pDAG1) 
C-terminally tagged with VSV 
this work 
   
pDAG1 pcDNA3.1 backbone with expression of 
dystroglycan 
gift from Dr. C. Herzog (Herzog et 
al., 2004) 
   
pECFP-C1 mammalian expression plasmid with CMV 
promoter and enhanced cyan fluorescent 
protein (ECFP) 
BD Clontech, Heidelberg, Germany 
   
pEGFP-C1 mammalian expression plasmid with CMV 
promoter and enhanced green fluorescent 
protein (EGFP) 
BD Clontech, Heidelberg, Germany 
   
pRetroSuper self-inactivating retroviral vector for short 
hairpin RNA expression 
Dr. T. R. Brummelkamp 
(Brummelkamp et al., 2002) 
   
pRetroSuper 
shDMD 
pRetroSuper backbone with expression of 
short hairpin RNA targeting DMD 
this work 
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3.7 Oligonucleotides 
 
Table 3 Sequence and description of oligonucleotides. 
Name Sequence 5´-3´ Product length Reference 
DMD LC Fw CCCATTTCCTTCACAGCATTT 187 bp Alex Epanchintsev 
DMD LC Rv GTCTTTCACCACTTCCACATCA   
Dp427c Fw CGTATCAGATAGTCAGAGTGGTTAC 561 bp NM_000109 
Dp427m Fw CCTGGCATCAGTTACTGTGTTGAC 548 bp NM_004006 
Dp427p Fw CCTATGAAGGTGTGTAGCCAGCC 331 bp NM_004009 
Dp427 Rv CCATCTACGATGTCAGTACTTCC  NM_004006 
Dp260 Fw AGGAACATTCGACCTGAGAAAG 214 bp NM_004011 
Dp260 Rv TCCACCTTGTCTGCAATATAAGC   
Dp140 Fw ATTGCTGGCTGCTCTGAACTAA 161 bp NM_004013 
Dp140 Rv CATCTGTTTTTGAGGATTGCTG   
Dp116 Fw GGGTTTTCTCAGGATTGCTATG 364 bp NM_004014 
Dp116 Rv CCGGCTTAATTCATCATCTTTC   
Dp71 Fw GAAGCTCACTCCTCCACTCGTA 393 bp NM_004015 
Dp71 Rv AGCCAGTTCAGACACATATCCAC   
shDMD TTAACTGGCTGGAGTATCA - Alex Epanchintsev 
DMD1b CTCTCCATCAATAGAACTGCC - (Roberts et al., 1991) 
UTRN Fo1 GCTCACCACATACCTGACTGAC 180 bp NM_007124 
UTRN Re1 ACATCCATCTGACTTCCTCCTCT   
DAG1 Fo1 TGCCGCTGATACCTTGATGATAT 60 bp 
DAG1 Re1 TGACCATTCCAACAGATTTGATTG  
(Arning et al., 2004) 
SNTB2 Fo1 GCTGGCAGAACAGGCAAAAC 65 bp 
SNTB2 Re1 TCACAGCCATGAGGACAGGTC  
(Arning et al., 2004) 
SGCB Fo1 CAGCAAAGTTCCAATGGTCCTG 67 bp 
SGCB Re1 TGACACTCCTTCTCTCAACAGCCT  
(Arning et al., 2004) 
SGCE Fo1 GCGCCTGAACGCCATAAAC 95 bp 
SGCE Re1 CCATGACATAAACGCCCTCCT  
(Arning et al., 2004) 
LAMA2 Fo1 CTGTTGCTGATAACCTCCTCTTT 185 bp NM_000426 
LAMA2 Re1 CCCAGTTCTTGATGCTACGATAC   
SSPN Fo1 GGCTTGTTTATGCTTTGTGTCTC 157 bp NM_005086 
SSPN Re1 ACTGTGTGAGCTGCGAATAGTG   
NOS1 Fo1 GTGATGTCTTCTGTGTGGGAGAT 211 bp NM_000620 
NOS1 Re1 GTTGACCGACTGGATTTAGGG   
DTNA Fo1 CCAAGGACAGTGAAGTAGAGCAG 137 bp NM_001390 
DTNA Re1 GACATACAACCCGATGAGAACAT   
LAMA2 Fo2 ACACTCTGCTGGTCTCCTCTTTA 547 bp NC_000006 
LAMA2 Re2 GTGCTCTTATGCTTTGGCTTGTA   
16q22/+6000 Fo CTACTCACTTATCCATCCAGGCTAC 209 bp NC_000016 
16q22/+6000 Re ATTTCACACACTCAGACATCACAG   
C-MYC Int2 Fo CTTCTCAGCCTATTTTGAACACTG 164 bp NC_000008 
C-MYC Int2 Re TGGTATGACTTTAGCAACTCCCTAT   
AKT3 Fo CTGCTACTTCACTGTCATCTTCAAT 162 bp NC_000001 
AKT3 Re TGCGTGTATGTGTGTTTTCA   
RaTERT Fo TCCGAGGTGTCCCTGAGTATGG 193 bp Dr. Dmitri Lodygin 
RaTERT Re AGGTGCGCTCACCTGGAGTAGT   
ACTB Fo2 TGACATTAAGGAGAAGCTGTGCTAC 213 bp NM_001101 
ACTB Re2 GAGTTGAAGGTAGTTTCGTGGATG   
p16Int1 Fo CTTTCTGTGTTTGGCTTATTTCATT 312 bp NC_000009 
p16Int1 Re TTCTCTCTGACTGTGACCCTCTAAT   
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Table 3 continued. 
Name Sequence 5´-3´ Product length Reference 
LEZ500_9a Fo7 GCACAATCACAGAAATGGAAAC 449 bp NC_000009 
LEZ500_9a Re7 CAGTATGGAGGGGAGTAAAAAGAGT  21.546 Mbp 
LEZ500_9a Fo4 
LEZ500_9a Re4 
TGATGAGACTGAATAACTGAAGGAG 
AAAATGGGACTTGGAGGTAGTGA 
272 bp NC_000009 
21.615 Mbp 
LEZ500_9a Fo1 
LEZ500_9a Re1 
CTCCATTTCTTCCTCCTCCTCATA 
CTCAAAGTCAAAGTCTCCAATCTG 
493 bp NC_000009 
21.843 Mbp 
LEZ500_9a Fo2 
LEZ500_9a Re2 
GCCCCTTCTGTCTTTTCCTTAG 
CACTTCCCTGCTGTCTTTCTTT 
499 bp NC_000009 
22.105 Mbp 
LEZ500_9a Fo3 
LEZ500_9a Re3 
TACTTGCCTTAGTCTTTGGTTGTG 
CTGCCTTTTTCATCTGGAGTCT 
452 bp NC_000009 
22.996 Mbp 
LEZ500_9a Fo5 
LEZ500_9a Re5 
TGAGTGTTATGGTTGTTAGAGGAC 
CTATGGAGGATGAAGCAGGAGA 
282 bp NC_000009 
23.312 Mbp 
LEZ500_9a Fo8 
LEZ500_9a Re8 
AGAGATGTAGAAAGAACTGGAGCAA 
GAGACCTGAAACTGGGTGTAAATAA 
241 bp NC_000009 
23.463 Mbp 
LEZ500_9a Fo9 
LEZ500_9a Re9 
TTTAGTTACAGGTCTCTGGGTCATC 
CTATTTGTTCCTCTCTGCTTTCTCT 
200 bp NC_000009 
23.473 Mbp 
LEZ300_1b Fo1 
LEZ300_1b Re1 
GGTCTTTCCTTTCTTTGTGCTTAG 
GTTCAGTTCCACCAGTATCTATCA 
240 bp 1p22.1 
LEZ300_10c Fo1 
LEZ300_10c Re1 
CCCATCTTCCTATTTGAGTCCTTT 
CTAAGTTTGAGCATCCCTCCATT 
475 bp 10q25 
SU7100_1b Fo 
SU7100_1b Re 
GAGATGAGGACAGGATGAAGAAA 
ACAGACCAACAAGCAAATGAAC 
300 bp 1p36.2 
SU7200_4b Fo 
SU7200_4b Re 
GTAGACCAGCAAGACTCGGAAAA 
GAAGGAAGGTGAAGGCAAACTC 
294 bp 4q31-q32 
SU7200_6c Fo 
SU7200_6c Re 
CCACCCCAGGTTATTAGGATTA 
AAGGAAACGAGTGAGGAAGAAA 
288 bp 6q25 
SacI linker A 
SacI linker B 
biotin-TTTGCAGAGGTTCGTAATCGAGTTGGGTGAGCT 
phosphate-CACCCAACTCGATTACGAACCTCTGC 
(Wang et al., 2002) 
LS linker 1A 
 
LS linker 1B 
TTTGGATTTGCTGGTGCAGTACAACTAGGCTTAATATC
CGACATG 
phosphate-TCGGATATTAAGCCTAGTTGTACTGCACCA 
GCAAATCC-amino-modified C7 
(Wang et al., 2002) 
LS linker 2A 
 
LS linker 2B 
TTTCTGCTCGAATTCAAGCTTCTAACGATGTACGTCC
GACATG 
phosphate-TCGGACGTACATCGTTAGAAGCTTGAATTC 
GAGCAG-amino-modified C7 
(Wang et al., 2002) 
LS primer 1 
LS primer 2 
biotin-TTTTTTTTTGGATTTGCTGGTGCAGTACA 
biotin-TTTTTTTTTCTGCTCGAATTCAAGCTTCT 
(Wang et al., 2002) 
M13F 
M13R 
GTAAAACGACGGCCAGT 
GGAAACAGCTATGACCATG 
- (Wang et al., 2002) 
 
3.8 Bacteria strains 
 
Table 4 Description of bacteria strains. 
Strain Description Origin 
XL1-Blue recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac 
[F’ proAB lacIqZ∆M15 Tn10(Tetr)] 
Stratagene, La Jolla, USA 
  
 
XL10-Gold Tetr ∆(mcrA)183 ∆(mcrCB-hsdSMR-mrr)173 endA1 
supE44 thi-1 recA1 gyrA96 relA1 lac Hte [F´proAB 
lacIqZ∆M15 Tn10(Tetr) Amy Camr] 
Stratagene, La Jolla, USA 
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3.9 Cell lines and cell culture media 
 
All cell lines, their origin and culturing conditions are listed in Supplementary 
Table 1. The following media and supplements were obtained from Invitrogen 
(Karlsruhe, Germany): Hanks' Balanced Salt Solutions (HBSS), Dulbecco's Modified 
Eagle Medium (DMEM) with high or low glucose, McCoy’s 5A medium, RPMI 1640 
medium, Minimal Essential Medium (MEM), Leibovitz's L15 medium, penicillin-
streptomycin solution, non-essential amino acid solution, and sodium pyruvate 
solution. MCDB 153 medium powder and bovine insulin were from Sigma 
(Taufkirchen, Germany), and fetal bovine serum (FBS) from Perbio Science (Bonn, 
Germany). 
 
3.10 Equipment 
 
Equipment Supplier 
Axioplan II Imaging epifluorescence 
microscope 
Karl Zeiss, Oberkochen, Germany 
 
Axiovert 200M fluorescence microscope 
with a CoolSNAP-HQ CCD camera 
and Metamorph software 
Karl Zeiss, Oberkochen, Germany 
Photometrics, Tucson, USA 
Universal Imaging, Downingtown, USA 
Axiovert 25 microscope 
with a HyperHad CCD camera 
and ImageBase software 
Karl Zeiss, Oberkochen, Germany 
Sony, Köln, Germany 
Kappa Optoelectronics, Gleichen, 
Germany 
Capillary sequencer 3700 Applera, Norwalk, USA 
Digital karyotyping software gift from Dr. K. Kinzler 
DMRXA-RF8 epifluorescence 
microscope 
Leica Microsystems, Wetzlar, Germany 
DryEase® Mini-Gel Drying System Invitrogen, Karlsruhe, Germany 
FACScan unit BD Biosciences, Mountain View, USA 
Kodak Imager (440CF imaging system) Kodak, Stuttgart, Germany 
Leica QFISH software Leica Microsystems, Wetzlar, Germany 
LightCyclerTM real-time PCR system  Roche, Mannheim, Germany 
Metafer/Isis software MetaSystems, Altlussheim, Germany 
Mini Trans-Blot® Cell system Bio-Rad, Hercules, USA 
Mini-PROTEAN® 3 Electrophoresis 
System 
Bio-Rad, Hercules, USA 
PCR thermocycler Perkin Elmer 9700 Applied Biosystems, Foster City, USA 
SAGE2000 software gift from Dr. V. Velculescu 
Ultra Evolution 384-well plate reader Tecan, Crailsheim, Germany 
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4 METHODS 
 
4.1 Chromosome metaphase spreads 
 
Cells were treated with 0.1 µg/ml colcemid at 37°C for 3 hours, trypsinized and 
pelleted. The cell pellet was resuspended in 10 ml of 0.8% sodium citrate and 
incubated for 25-40 minutes at 37°C. Cells were pel leted again, fixed with ice-cold 
methanol/glacial acetic acid (3:1) and incubated on ice for 5 minutes. Afterwards, 
cells were washed four times in fixative, resuspended in 1-2 ml of fixative and stored 
at -20°C. For chromosome metaphase spreads fixed ce lls were dropped onto glass 
slides and air-dried. 
 
4.2 Comparative genomic hybridization 
 
All CGH experiments were performed in the laboratory of Dr. M. R. Speicher. 
1 µg of genomic DNA from melanoma cell lines and normal placenta was nick-
translated with 1x NT-buffer (0.5 M Tris/HCl pH 8.0; 50 mM MgCl2; 0.5 mg/ml BSA), 
10 mM β-mercaptoethanol, 0.05 mM ACG-mix (dATP; dCTP; dGTP), 1 mM labeled 
dUTP (digoxigenin-11-dUTP for normal DNA and biotin-16-dUTP for tumor DNA), 
4.5 ng DNase I and 5 U DNA polymerase I in a total of 50 µl for 2 hours at 15°C. The 
labeled fragments of tumor and normal DNA were combined and ethanol precipitated 
together with 70 µg Cot-1 DNA and 182 µg salmon-sperm DNA. The pellet was 
resuspended in 4 µl of deionized formamide for 10 minutes at 42°C and mixed with 
4 µl of 30% dextransulfate. Chromosome metaphase spreads from normal males on 
glass slides were used for hybridization. First, metaphase chromosomes were 
incubated in a pepsin solution (0.03 mg/ml in 0.01N HCl, pH 2.3) for 1-3 minutes at 
37°C. Then, slides were washed briefly in PBS and d ehydrated in 70%, 90%, and 
100% ethanol for 3 minutes each. The chromosomes on the slides were denatured in 
70% formamide/SSC for 1 minute and 45 seconds at 72°C. Afterwards, the slides 
were dehydrated in a cold (-20°C) ethanol series (7 0%, 90%, 100%) for 5 minutes 
each. At the same time, the hybridization mixture was denatured for 7 minutes at 
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78°C and pre-hybridized for 20 minutes at 42°C. The  hybridization mixture was then 
applied onto the slides with the denatured chromosomes, covered with a coverslip, 
sealed and hybridized in a water bath for 72 hours. After hybridization, slides were 
washed three times 5 minutes in 4x SSC/0.2% Tween® 20 at 42°C, three times 5 
minutes in 1x SSC at 60°C and blocked with 3% BSA/4 xSSC/0.2% Tween® 20 for 30 
minutes at 37°C. The slides were washed briefly in 4xSSC/0.2% Tween® 20 and 
incubated with the primary antibodies sheep anti-Dig-FITC (dilution 1:100) and 
avidin-Cy3.5 (dilution 1:300) in 1% BSA/4xSSC/0.2% Tween® 20 for 45 minutes at 
37°C. Finally, slides were washed three times 5 min utes in 4xSSC/0.2% Tween® 20 
at 42°C, briefly incubated in DAPI solution (0.2 µg /ml) and covered with a coverslip. 
CGH analysis was done as described previously (du Manoir et al., 1993; Kallioniemi 
et al., 1992). 
 
4.3 7-Fluor M-FISH 
 
All M-FISH experiments were performed in the laboratory of Dr. M. R. Speicher. 
For FISH analysis, labeling of DNA with seven fluorochromes (24-color FISH) was 
done as described (Azofeifa et al., 2000). The labeling pattern of chromosomes with 
the seven different fluorophores is shown in Table 5. 
 
Table 5 Labeling of single chromosomes with seven different fluorophores. 
Chromosome 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 X Y ps 
DEAC X         X       X     X     X             X   X 
FITC X     X X   X                     X X   X         
Cy3     X     X   X     X       X     X   X           
TexasRed     X X         X X             X         X   X X 
Cy5   X                   X X   X   X       X         
Cy5.5         X     X       X   X               X X   X 
Cy7   X         X   X   X     X   X                   
 
Treatment of chromosomes and hybridization of labeled probes was done as 
described in section 4.2. 
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4.4 Digital karyotyping 
 
Digital karyotyping was performed according to the protocol provided by Wang 
et al. (Wang et al., 2002). Genomic DNA from the melanoma cell lines M2 and M3 
was extracted as described in section 4.5. First, 4 µg of genomic DNA were 
incubated with 120 U of the mapping enzyme SacI for 1.5 hours at 37°C. The 
digested DNA was extracted with phenol/chloroform, ethanol precipitated and 
resuspended in 5 µl LoTE. For ligation of biotinylated linkers both primers (SacI 
Linker A and SacI Linker B) were first annealed to form linkers. Therefore, 1.8 µg of 
both primers were mixed, heated to 95°C for 2 minut es, placed at 65°C and 37°C for 
10 minutes each, and cooled down at room temperature for 20 minutes. Then, 56 ng 
of annealed SacI linker were mixed with 1 µg of digested DNA in ligation buffer, 
heated to 50°C for 2 minutes and cooled down at roo m temperature for 10 minutes. 
Afterwards, 5 U of T4 DNA ligase were added and the ligation reaction was carried 
out at 16°C for 3 hours. DNA fragments were extract ed with phenol/chloroform, 
ethanol precipitated, and resuspended in 20 µl LoTE. 
Cleavage with the fragmenting enzyme was carried out with 80 U of NlaIII at 
37°C for 1 hour. The DNA was extracted with phenol/ chloroform, ethanol 
precipitated, and resuspended in 10 µl LoTE. DNA fragments ligated to biotinylated 
linkers were isolated with streptavidin-linked magnetic beads. First, 200 µl Dynabead 
M-280 streptavidin slurry were washed with 400 µl washing buffer D (5 mM Tris/HCl 
pH 7.5, 0.5 mM EDTA, 1 M NaCl, 200 µg/µl BSA), mixed with 300 µl washing 
buffer D containing the 10 µl DNA solution, and incubated for 20 minutes at room 
temperature with intermittent shaking. The beads were washed three times with 
400 µl washing buffer D, once with 300 µl 1x ligation buffer, and resuspended in 
300 µl of 1x ligation buffer. The beads were divided equally into two tubes and LS 
linkers were ligated to the bound genomic DNA. Annealing of LS primer 1A/1B and 
LS primer 2A/2B to form linkers was carried out as described for SacI linkers. The 1x 
ligation buffer was removed from both tubes containing the DNA fragments bound to 
Dynabeads® and 23.5 µl LoTE and 7 µl 5x ligation buffer were added. In addition, 2 
µl annealed LS linker 1A/B were added to tube 1 and 2 µl annealed LS linker 2A/B 
were added to tube 2. Both tubes were heated for 2 minutes at 50°C and cooled 
down at room temperature for 10 minutes. 12.5 U T4 ligase were added to each tube 
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and the ligation was carried out for 2 hours at 16°C with gentle mixing every 15 
minutes. After ligation, each tube was washed four times with 600 µl washing buffer 
D. The beads were transferred to two new tubes, washed once with washing buffer D 
and twice with 200 µl 1x buffer 4 (NEB), and resuspended in 200 µl 1x buffer 4. 
For the release of genomic tags, buffer 4 was removed from both tubes and 
118 µl LoTE, 15 µl 10x buffer 4, 15 µl 10x S-adenosylmethionine, and 70 U MmeI 
were added to each tube and incubated for 1 hour at 37°C with intermittent mixing. 
Afterwards, 100 µl supernatant were collected from each tube and combined for 
subsequent use as ligation reaction (tube 1) and 50 µl supernatant from each tube 
were combined as no ligation control reaction (tube 2). The DNA in both tubes was 
extracted with phenol/chloroform, ethanol precipitated, and resuspended in 1.5 µl 
LoTE. 
In the following reaction blunt-ended tags were ligated to form ditags. A 2x 
ligase mix (5 µl 3 mM Tris/HCl pH 7.5, 6 µl 5x ligase buffer, 4 µl T4 ligase (5 U/µl)) 
and a 2x no ligase mix (9 µl 3 mM Tris/HCl pH 7.5, 6 µl 5x ligase buffer) were 
prepared. 1.5 µl of the ligase mix were added to tube 1 and 1.5 µl of the no ligase mix 
were added to tube 2 which served as negative control in the following PCR reaction. 
The ligation reaction was carried out overnight at 16°C. Afterwards, 14 µl LoTE were 
added to tube 1 containing the ligase mixture. 
In the next step, ditags were amplified by PCR in a volume of 50 µl containing 
1x PCR buffer, 3 µl DMSO, 75 mmol dNTPs, 175 ng LS PCR primer 1, 175 ng LS 
PCR primer 2, 2.5 U Platinum® Taq DNA polymerase, and 1 µl ligation product. PCR 
was carried out at 94°C for 1 minute, then 26-30 cy cles at 94°C for 30 seconds, 55°C 
for 1 minute, and 70°C for 1 minute, with a final e xtension of 5 minutes at 70°C. First, 
PCR conditions were optimized by testing different dilutions of the template of 1/20, 
1/40, and 1/80. Likewise, the PCR reaction was carried out for 26, 28, and 30 cycles. 
The starting amount of template and cycle number is critical for isolating an adequate 
amount of DNA for subsequent steps. The aim was to obtain a high yield of ditags 
with only minor amounts of incorrect byproducts. For the amplification of ditags from 
the cell line M2 a dilution of 1/20 with 26 cycles and for the cell line M3 a dilution of 
1/40 with 28 cycles were chosen. Template from the no ligase control reaction was 
not diluted and amplified with 35 cycles. It did not contain any product of the size of  
the ditags. After optimization of the PCR conditions, large-scale amplification of 
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ditags was performed with 250 reactions (50 µl each) aliquoted into three 96-well 
plates. Afterwards, PCR products were pooled, ethanol precipitated, resuspended in 
144 µl LoTE, and heated at 37°C for 5 minutes. Afte r addition of 36 µl 5x loading 
buffer, ditags were loaded onto two 16% polyacrylamide gels and run at 40 V 
overnight. Amplified ditags of 134 bp were excised and the gel pieces were placed 
into 0.5 ml tubes pierced at the bottom with a 21-gauge needle. The 0.5 ml tubes 
were placed in 2.0 ml siliconized microcentrifuge tubes and centrifuged at 13,000 
rpm for 2 minutes. Thereby, the gel pieces were broken up into smaller fragments, 
which remained at the bottom of the 2.0 ml tube. The 0.5 ml tubes were discarded 
and 250 µl LoTE and 50 µl 7.5 M ammonium acetate were added to the gel 
fragments in each tube in order to extract the ditags. The tubes were vortexed and 
placed at 65°C for 15 minutes with intermittent mix ing. Afterwards, the supernatant 
from each tube was transferred to a SpinX microcentrifuge tube and centrifuged at 
13,000 rpm for 5 minutes. This procedure separated the supernatant from any 
remaining gel pieces. The cleared eluates were extracted with phenol/chloroform, 
ethanol precipitated, and resuspended in 80 µl LoTE. 
Before concatenation of the isolated ditags, biotinylated linkers were removed 
by cleavage with the restriction endonuclease NlaIII. Therefore, the 80 µl of ditags 
were divided equally into two tubes and incubated each with 200 U of NlaIII in a total 
volume of 200 µl for 1 hour at 37°C. Afterwards, bi otinylated linker fragments were 
removed from ditags by incubation with streptavidin-linked magnetic beads. First, 
1600 µl of beads were prewashed three times with the same volume of washing 
buffer D and divided equally into eight tubes. Then, 400 µl 2x B&W buffer (10 mM 
Tris/HCl pH 7.5, 1 mM EDTA, 2 M NaCl) and 4 µl 100x BSA were added to a total 
volume of 400 µl of restriction digest solution, mixed and divided into the first two 
tubes containing magnetic beads. Both tubes were mixed end over end for 15 
minutes at room temperature. The supernatant was removed and applied to the next 
set of tubes with beads and mixed end over end for 15 minutes at room temperature. 
At the same time, the first set of tubes with beads was washed with 200 µl of 1x B&W 
buffer and 1x BSA and mixed end over end for 15 minutes at room temperature. This 
procedure was continued; the supernatant from the second set of tubes was 
collected and applied to the third and fourth set. Likewise, the B&W solution from the 
first set was applied sequentially to the remaining sets of tubes. After washing of the 
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last set of tubes all supernatants were consolidated and in order to prevent 
disassembly of the ditags all subsequent steps were performed on ice. First, the 
ditags were extracted with phenol/chloroform, ethanol precipitated, and resuspended 
in 7 µl TE. After addition of sample buffer, ditags were loaded onto a 16% 
polyacrylamide gel and run at 40 V overnight. A 36 bp band corresponding to the 
ditags was excised and the gel pieces were placed into 0.5 ml tubes pierced at the 
bottom with a 21-gauge needle. The 0.5 ml tubes were placed in 2.0 ml siliconized 
microcentrifuge tubes and centrifuged at 13,000 rpm for 2 minutes. The 0.5 ml tubes 
were discarded and 250 µl TE and 50 µl 7.5 M ammonium acetate were added to the 
gel fragments in each tube in order to extract the ditags. The tubes were vortexed 
and placed at 37°C for 20 minutes with intermittent  mixing. Afterwards, the 
supernatant from each tube was transferred to a SpinX microcentrifuge tube and 
centrifuged at 13,000 rpm for 5 minutes. The cleared eluates were ethanol 
precipitated and resuspended in 10.5 µl cold LoTE. 
After purification, ditags were ligated to form concatemers, which were then 
cloned and sequenced. For the ligation reaction, 5x ligation buffer and 7.5 U T4 DNA 
ligase were added to the purified ditags and incubated for 2 hours at 16°C. 
Afterwards, sample buffer was added and the sample was heated at 65°C for 5 
minutes. The concatemers were applied to a 1.5% agarose gel, which was run at 
60V for 2.5 hours. The concatemers formed a smear on the gel, which ranged from 
100 bp to about 8 kbp. Concatemers in the range of 600 – 1100 bp were excised, 
purified with the QIAquick gel extraction kit, extracted with phenol/chloroform, ethanol 
precipitated, and resuspended in 10 µl LoTE. 
For cloning of concatemers, 1 µg of the pZERO vector was cleaved with the 
restriction endonuclease SphI, phenol/chloroform extracted, ethanol precipitated and 
resuspended in LoTE. The ligation was performed with 3 µl purified concatemers, 
25 ng linearized pZERO vector, and 1 U T4 DNA ligase at 16°C overnight. 
Afterwards, the ligation reaction was extracted with phenol/chloroform, ethanol 
precipitated, and resuspended in 30 µl LoTE. 1 µl of the ligated concatemers was 
transfected into ElectroMAX DH10B electrocompetent bacteria by electroporation. 
1/10 of the transfected bacteria was then plated onto 10 agar plates containing 
zeocin for selection of positive transformants. Between 200 – 300 colonies were 
counted on each plate and at least 60 colonies were subsequently analyzed by PCR 
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to assess the size of the inserted fragment. PCR was carried out in a total volume of 
25 µl containing 1x PCR buffer, 1.25 µl DMSO, 12.5 mmol dNTPs, 175 ng M13F 
primer, 175 ng M13R primer, 1 U FIREPol® DNA polymerase, and a small amount of 
bacteria from a single colony. PCR was performed with an initial denaturation of 94°C 
for 5 minutes, then 30 cycles with 94°C for 45 seco nds, 54°C for 30 seconds, 72°C 
for 1 minute, and a final elongation at 72°C for 5 minutes. PCR products were 
evaluated on 1% agarose gels and usually more than 95% of colonies contained 
inserts between 800 bp and 1100 bp in size. After verification of sufficient amounts of 
positive transformants and the correct size of the inserted concatemers, the purified 
ligation reaction was sent to the Agencourt Biosciences company (Beverly, USA) for 
contract sequencing. 
About 7000 clones corresponding to approximately 200,000 tags were 
sequenced for each library. Afterwards, extraction of 21 bp tags was carried out with 
the SAGE2000 software. Repetitive sequences were removed by aligning tags to a 
virtual tag library generated from the June 28, 2002 human genome assembly 
containing only tags obtained from unique loci. Tag densities were calculated by 
matching tags to their genomic position along each chromosome. Sites with over- or 
underrepresentation of genomic tags, representing potential sites of genomic 
amplifications and deletions, were visualized with the map viewer of the digital 
karyotyping software using a sliding window size of 100 to 1000, which corresponds 
to a resolution of 200 kbp to 4 Mbp. The position and size of potential genomic 
alterations was determined by blasting the 21 bp tags located at the borders of the 
alteration against the human genome assembly. Then, primers were designed to 
confirm potential sites of deletion or amplification by conventional PCR or qPCR, 
respectively. SAGE 2000 and digital karyotyping software were a kind gift from Dr. V. 
Velculescu and Dr. K. Kinzler. 
 
METHODS 
 
 40
4.5 Isolation of genomic DNA from cell lines and paraffin-embedded tissue 
sections 
 
Tissue sections were de-paraffinized using xylol and briefly stained with 
hematoxylin and eosin. Tissue material was scratched off from designated areas and 
subjected to extraction of genomic DNA. For extraction of genomic DNA from cell 
lines, cells were trypsinized, washed, and pelleted. Genomic DNA was isolated by 
overnight incubation with 100 µg/ml proteinase K and 0.1% (w/v) SDS in proteinase 
K buffer at 55°C. Subsequently, a phenol/chloroform  extraction was performed and 
genomic DNA was precipitated using isopropanol. 
 
4.6 RNA isolation and RT reaction 
 
RNA was isolated using the RNAgents total RNA isolation system according to 
the manufacturer’s protocol. For RT, 2-3 µg of total RNA were reverse transcribed 
using an oligo(dT)20 primer or the DMD-specific primer DMD1b and SuperScriptTM III 
first-strand synthesis system. The RT reaction was performed at 50°C or 55°C for 60 
min in a total volume of 20 µl. 
 
4.7 RT-PCR analysis 
 
For PCR analysis, all cDNAs were diluted twofold. If necessary, the amount of 
cDNA was normalized on a LightCycler with β-actin as standard. For analysis of 
expression of the full-length DMD isoforms (Dp427c, Dp427m, Dp427p, Dp427l), 
cDNA transcribed with the DMD-specific primer DMD1b was used, whereas for 
analysis of Dp260, Dp140, Dp116, Dp71, and the components of the DGC cDNA 
transcribed with the oligo(dT)20 primer was used. The PCR reaction contained 1 µl of 
cDNA, 5 µl 10 x PCR buffer, 1 µl dNTP mix (10 mM dATP, 10 mM dCTP, 10 mM 
dGTP, 10 mM dTTP), 20 pmol of gene-specific primer (see Table 3, chapter 3.7), and 
2.5 U of Platinum® Taq DNA polymerase in a total volume of 50 µl. PCR was carried 
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out for 40 cycles with an annealing temperature of 58°C to 60°C. The total reaction 
was analyzed by agarose gel electrophoresis. 
 
4.8 qPCR analysis 
 
Quantification of DMD, hTERT, C-MYC, and AKT3 was performed by real-time 
PCR with gene-specific primers (see Table 3, chapter 3.7) using FastStart-DNA 
Master SYBR Green 1 on a LightCycler. The generation of specific products was 
confirmed by melting-curve analysis and gel electrophoresis. Each primer pair was 
tested with a logarithmic dilution of cDNA to generate a linear standard curve 
(crossing point [CP] plotted vs. log of template concentration), which was used to 
calculate the primer pair efficiency (E = 10(-1/slope)). cDNAs were normalized using β-
actin primers, whereas genomic DNA was normalized with the 16q22/+6000 primer. 
For data analysis, the second-derivative maximum method was applied, and 
induction of a cDNA or amplification of a locus on genomic DNA (geneX) was 
calculated according to Pfaffl (Pfaffl, 2001) as follows: 
 
( ) ( )
( ) ( ) inductionfoldE
E
cDNAtumorcDNAnormalCP
actin
cDNAtumorcDNAnormalCP
geneX
=
−∆
−
−∆
β
 
 
4.9 PCR analysis of genomic DNA 
 
For deletion analysis of p16INK4A in melanoma cell lines, primers LEZ500, 
LEZ300, SU7100, and p16Int1 were used (see Table 3, chapter 3.7). PCR reactions 
were performed in a total volume of 50 µl containing 50 ng of genomic DNA, 5 µl 10x 
PCR buffer, 2.5 µl DMSO, 1 µl dNTP mix (10 mM dATP, 10 mM dCTP, 10 mM dGTP, 
10 mM dTTP), 20 pmol of each primer, and 1-2 U of Platinum® Taq DNA polymerase. 
PCR amplification was performed with an initial denaturation of 4 minutes at 94°C, 28 
to 40 cycles of denaturation for 30 seconds at 94°C , annealing for 30 seconds at 
50°C to 60°C, elongation at 72°C with 1 minute/kbp of product, and a final elongation 
for 2 minutes at 72°C. 
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4.10 DNA sequencing 
 
300 ng of template DNA were used in each sequencing reaction together with 
5 pmol primer, 1.5 µl BigDye® Terminator v3.1 sequencing mix, and 1 µl 5x BigDye® 
sequencing buffer in a total volume of 10 µl. PCR amplification was performed with 
30 cycles of denaturation for 20 seconds at 96°C, a nnealing for 10 seconds at 50°C, 
and elongation at 60°C for 4 minutes. Purification and sequencing of the PCR 
products was carried out by the sequencing service of the Max-Planck Institute of 
Biochemistry. 
 
4.11 Western blot analysis 
 
Exponentially growing cells were lysed in Triton X-100 or RIPA lysis buffer. 
Protein concentration was measured with the Bradford assay. 30-150 µg of protein 
lysate were diluted in 2x Laemmli buffer, separated on 6% or 10% 
SDS/polyacrylamide gels, and transferred to Immobilon-P PVDF membranes. 
Membranes were blocked with 5% nonfat dry milk and incubated with primary 
antibody diluted in TBST or low TBST. Dystrophin (Dp427m isoform) was detected 
with the NCL-Dys1 antibody diluted 1:100, the NCL-Dys2 (Dp116 isoform) antibody 
1:25, or the Dystrophin Ab-1 (Dp71 isoform) antibody 1:200.  α-dystroglycan was 
detected with the IIH6 antibody (1:200) diluted in low TBST. Signals were visualized 
in combination with HRP-conjugated secondary antibody diluted 1:10,000. Equal 
loading was confirmed using β-actin antibody (dilution 1:1000). For the description of 
antibodies see chapter 3.5. 
 
4.12 Generation of stable cell lines 
 
For the expression of short hairpin RNAs mediating down-regulation of DMD 
mRNA, three different 19 bp sequences (shDMD) targeting the full-length Dp427 
isoforms were cloned into pSUPER based constructs (Brummelkamp et al., 2002) by 
Alex Epanchintsev and were tested by transient transfection in HEK293T cells. The 
ability to down-regulate expression of ectopic dystrophin was assessed by Western 
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blot analysis and the most efficient construct was chosen for further experiments. 
The entire H1-promoter-shDMD cassette was released from pSUPER after restriction 
digest with EcoRI and BamHI and inserted into the same sites of the self-inactivating 
retroviral vector pRetroSuper. The resulting construct or empty vector as control were 
transfected into the Phoenix A packaging cell line, which produced the respective 
retroviruses. Afterwards, the melanoma cell lines C-32 and M7 were infected with the 
retrovirus containing pRetroSuper empty vector or pRetroSuper shDMD. Resistant 
pools were selected with puromycin for seven days and single cell clones were 
generated by limiting dilution. 
For ectopic expression of dystrophin, the attb-pDysE vector expressing full-
length dystrophin N-terminally fused to eGFP was used. The melanoma cell lines 
WM-793 and RPMI-7951 were transfected with attb-pDysE or attb-pEGFP control 
vector. Resistant pools were obtained by selection for two weeks in the presence of 
neomycin (G418). 
 
4.13 Cell growth in matrigel 
 
Matrigel basement membrane matrix was diluted with growth medium (without 
FBS) to a concentration of 3 mg/ml and stored at –20°C. For each assay an aliquot of 
matrigel was thawed on ice overnight and mixed carefully. 60 µl of matrigel were 
transferred to a Costar 96-well plate and allowed to gel for three hours or overnight at 
37°C. For the analysis of branching morphology, cel ls were trypsinized and 
resuspended in normal growth medium. 1x104 cells were seeded in each well on top 
of the matrigel layer. Cells were incubated at 37°C  and morphology was assessed 
over a period of ten days. Every seven days the growth medium was carefully 
exchanged without disturbing the cells in the matrigel matrix. Pictures of three 
different areas in each well were taken every day with an Axiovert 25 microscope 
equipped with a HyperHAD CCD camera and ImageBase software. 
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4.14 Cell migration assays 
 
To assess cell migration in the scratch assay, confluent monolayers of cells 
were treated with 10 µg/ml mitomycin C for 2 hours to inhibit cell proliferation. 
Subsequently, the cell monolayer was scratched with the sealed tip of a Pasteur 
pipette. Cells were washed and fresh medium was added. Cell migration was 
monitored for 24-31 hours using an Axiovert 200M microscope integrated into a 
CO2/37°C incubator, equipped  with a CCD camera. Pictures of at least four different 
areas in each well were taken at different time points using a motorized XY precision 
stage. Metamorph software was used to quantitate migration by measuring the cell-
free area in each picture. 
Migration was also studied using transwell chambers containing membranes 
with 8 µm pores. Cells were trypsinized and resuspended in normal growth medium 
with 0.5% FBS. 1x105 cells in medium supplemented with 0.5% FBS were added to 
the upper compartment of the transwell chamber, the lower compartment was filled 
with growth medium containing 10% FBS. Cells were incubated at 37°C and allowed 
to migrate to the underside of the membrane for 18-24 hours. Subsequently, cells 
were fixed with 70% ethanol for 20 minutes and stained with crystal violet for 30 
minutes. Cells on top of the filter were removed with a cotton swab and membranes 
were rinsed with tap water to remove excess dye. Pictures of representative areas of 
the membranes were taken with an Axiovert 25 microscope. Finally, the dye was 
released from the cells on the membranes and the cell number was quantitated by 
measuring absorbance at 570 nm with an Ultra Evolution 384-well plate reader. 
 
4.15 Cell proliferation assay 
 
Cells were trypsinized and resuspended in normal growth medium without 
phenol red. 3x103 cells were seeded per well in 24-well plates in triplicates. For each 
time point 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl tetrazolium bromide was added to 
the respective wells for 4 hours at 37°C to stain l iving cells. Then, triplex solution 
(10% (v/v) SDS, 5% (v/v) isobutanol, 0.012 M HCl) was added and plates were 
incubated at 37°C in the dark to release the dye fr om the cells. Cell number was 
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analyzed 20 hours later by measuring absorbance at 570 nm with an Ultra Evolution 
384-well plate reader. 
 
4.16 Analysis of apoptosis by flow cytometry 
 
For analysis of apoptosis by flow cytometry the supernatant with floating cells 
as well as the adherent cells were collected and washed once with PBS. Cells were 
fixed with ice-cold 70% ethanol for more than 2 hours or overnight at 4°C. 
Afterwards, cells were pelleted, washed with PBS and incubated in staining solution 
containing 50 µg/ml propidium iodide, 0.2 mg/ml RNase A, and 0.1% (v/v) Triton 
X-100 for 30 minutes at room temperature. For each sample 1x104 cells were 
analyzed with a FACScan unit. The amount of apoptotic cells was determined by 
comparing the percentage of cells in the sub-G1 fraction between samples. 
 
4.17 Senescence-associated β-galactosidase staining 
 
Cells were washed once with PBS (pH 7.5) and fixed by incubation with 0.5% 
(v/v) glutaraldehyde in PBS for 5 minutes at room temperature. Cells were washed 
three times with PBS (pH 6.0) containing 1 mM MgCl2 and stained with X-gal solution 
(pH 6.0) at 37°C for 5 hours or overnight protected  from light. Afterwards, cells 
expressing senescence-associated β-galactosidase (SA-β-gal) were distinguished by 
their blue color (Dimri et al., 1995). Pictures of different areas were taken with an 
Axiovert 25 microscope equipped with a HyperHAD CCD camera and ImageBase 
software, and the percentage of senescent cells was evaluated by determining the 
amount of blue cells compared to the amount of total cells.  
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4.18 Immunofluorescence staining and confocal microscopy 
 
For localization of dystrophin and β-dystroglycan, cells were grown on glass 
coverslips. Cells were transfected with either attb-pDysE or pCMV-DAG1-VSV 
vectors for ectopic expression of both proteins, because it was not possible to detect 
endogenous protein in immunofluorescence. As control, vectors containing only 
eGFP (attb-pEGFP) or a VSV-tag (pCMV-VSV) were transfected. 24 hours after 
transfection cells were washed once with PBS and fixed with 4% paraformaldehyde 
for 20 minutes at room temperature. Cells were washed three times with PBS and 
coverslips with cells transfected with attb-pDysE or attb-pEGFP were mounted onto 
glass slides with DAPCO antifade. Cells transfected with pCMV-DAG1-VSV or 
pCMV-VSV were permeabilized with 0.2% (v/v) Triton X-100 in PBS for 15 minutes at 
room temperature. After washing with PBS unspecific binding sites were blocked with 
100% FBS for 30 minutes at room temperature. Cells were washed again with 
washing buffer (PBS containing 10% FBS and 0.05% (v/v) Tween® 20) and incubated 
for 1.5 hours at room temperature with the mouse anti-VSV antibody diluted 1:100 in 
washing buffer. After washing, cells were incubated with donkey anti-mouse Cy3 
antibody diluted 1:400 in washing buffer for 45 minutes at room temperature. Finally, 
cells were washed with PBS/0.05% (v/v) Tween® 20, then PBS, briefly rinsed in water 
and mounted on glass slides with DAPCO antifade. Pictures of single cells were 
taken with a Leica TCS SP2 confocal laser scanning microscope. 
 
4.19 Statistical analysis 
 
Statistical significance was determined either with the chi square test or the 
student’s t-test. The chi square test is a non-parametric test for bivariate tabular 
analysis and was used for independent and mutually exclusive variables that were 
generated as raw frequencies. First, a four square table was generated as drawn 
below (Table 6), with M1 and M2 describing independent biological variables, each of 
them occurring in two different states (denoted as + and -). 
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Table 6 Four square table showing the setup of variables for a chi square test. Two independent 
biological variables M1 and M2, each occurring in two different states (+ and -), were measured. 
            M2 
M1       
-           + Σ 
- 
+ 
a           b 
c           d 
a+b=n1 
c+d=n2 
Σ a+c        b+d a+b+c+d=n 
 
Using the four square table the chi square value (Χ2) was calculated with the 
following equation.  
( ) ( )
( ) ( ) ( ) ( )dbcadcba
bcadn
++++
−−
=Χ
2
2 1
 
 
For each Χ2-value a corresponding P-value was derived, and P < 0.05 was 
considered statistically significant. 
The student’s t-test was applied to two normally distributed populations. Each 
of the two data sets was characterized by a number of data points. t was calculated 
for an unpaired t-test assuming equal variances as shown below with 21 , µµ  as the 
averages, 2221 ,δδ  as the variances, and 21 ,nn  as the number of trials of the first and 
second experiment, respectively. The equation represents a one-tailed comparison of 
t and a level of significance of α = 221 −+ nn  degrees of freedom. t (or P) < 0.05 was 
considered statistically significant. 
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5 RESULTS 
 
5.1 Characterization of malignant melanoma cell lines 
 
5.1.1 General characteristics 
 
An initial panel of nine melanoma cell lines (M1-M9) was derived from 
metastases of malignant melanoma with cells being cultured for a few passages only. 
The cell lines were established in the Department of Dermatology at the University 
Hospital of Erlangen and were a kind gift from Dr. Beatrice Schuler-Thurner. The 
clinicopathologic characteristics are listed in Table 7. In addition, CRL-1974 was 
obtained from ATCC and has been described previously (Trevor et al., 2004). 
 
Table 7 Clinicopathologic characteristics of nine melanoma cases. 
Cell line/ 
patient 
Age/sex Primary tumor / 
Breslow thickness 
Clark level Site of metastasis 
M1 68/f SSM, 9 mm IV lymph node, groin 
M2 47/f n. c. melanoma, 0.5 mm III abdomen 
M3 49/m SSM, 1.4 mm n. a. adrenal gland 
M4 43/m SSM, 2 mm IV thorax 
M5 31/f NM, 4.5 mm n. a. lymph node, groin 
M6 74/f NM, 1.9 mm n. a. upper arm 
M7 n. a./f n. a. n. a. lymph node, groin 
M8 65/f SSM, n. a. IV labium majus 
M9 60/f SSM, 3.5 mm IV gluteal 
Abbreviations: f, female; m, male; SSM, superficial spreading melanoma; NM, nodular melanoma; 
n. c., not classifiable; n. a., not available. 
 
Chromosome metaphase spreads were prepared of eight melanoma cell lines 
and chromosome number and ploidy level were determined (Table 8). For the cell 
lines M8 and M9 it was not possible to establish suitable conditions to obtain 
chromosome metaphase spreads. 
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Table 8 Chromosome number and ploidy level of eight melanoma cell lines. 
Cell line Mean chromosome 
number 
Ploidy levela 
M1 57 hyperdiploid 
M2 80 hypertriploid 
M3 65 hypotriploid 
M4 75 hypertriploid 
M5 51 hyperdiploid 
M6 42 hypodiploid 
M7 70 hypertriploid 
CRL-1974 62 hypotriploid 
aThe ploidy level was determined according to the ISCN 1995 guidelines. 
 
5.1.2 M-FISH analysis of malignant melanoma cell lines 
 
The melanoma cell lines M1, M2, M3, and M7 were analyzed by 7-Fluor M-
FISH (Speicher et al., 1996) in the laboratory of Dr. M. R. Speicher. Chromosome 
metaphase spreads were prepared and hybridized with painting probes for all 24 
human chromosomes. The hybridization mixture contained pools that were 
differentially labeled with DEAC, FITC, Cy3, Texas Red, Cy5, Cy5.5, and Cy7. All 
chromosomes were counterstained with DAPI. The chromosomes were identified by 
their specific and unique color combination and visualized by false color images 
(Figure 6). 
For each tumor cell line at least 9 metaphases were analyzed for 
chromosomal aberrations. Thereby, the melanoma cell line M1 displayed a 
hyperdiploid karyotype with 56-59 chromosomes in each cell. Although this cell line 
possessed the lowest mean chromosomes number of the four cell lines analyzed the 
karyotype proved to be the most complex (Table 9). 52 chromosomes with 
translocations were found with only nine of these chromosomes (A5, A12, A14, A16, 
A19, A22, A25, A27, A29) present in at least 70% of the cells. Underrepresentation 
was observed for chromosomes 14 and 18 and overrepresentation for chromosomes 
6, 7, and 20. 
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Figure 6 7-Fluor M-FISH analysis of four melanoma cell lines. Representative examples of single 
metaphases from the melanoma cell lines M1 (A), M2 (B), M3 (C), and M7 (D) hybridized with the 7-
Fluor M-FISH painting probe mix are shown. Depicted are false color images for each chromosome, 
which is indicated by the respective number. Translocated fragments were assigned by the color 
corresponding to their chromosomal origin. 
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The melanoma cell line M2 showed a hypertriploid karyotype with the 
chromosome number varying between 75 and 84. A more homogeneous karyotype 
was observed in M2 with eight chromosomes containing translocations with six of 
them (A1, A2, A5 - A8) present in at least 70% of cells (Table 10). Chromosome 6 
showed underrepresentation, whereas chromosomes 7, 15, 19, 21, and 22 were 
overrepresented. 
In the melanoma cell line M3 a hypotriploid karyotype with 64-68 
chromosomes was observed. M3 presented the least number of structural 
aberrations with only five chromosomes showing translocations, three of them (A1, 
A3, A4) present in 100% of cells (Table 11). Underrepresentation was detected for 
chromosomes 4 and 18 and overrepresentation for chromosomes 1, 3, 7, 15, and 22. 
The melanoma cell line M7 displayed a hypertriploid karyotype with 64-75 
chromosomes per cell. This cell line showed the second most complex karyotype of 
the four melanomas with translocations observed in 21 chromosomes with only 
seven of them (A5 - A7, A13, A15, A16, A20) present in at least 70% of cells (Table 
12). Chromosomes 10, 13, 15, 21, and 22 displayed underrepresentation and 
chromosome 3 overrepresentation. 
Taken together, the karyotypes of M1 and M7 showed a higher percentage of 
cells with non-clonal structural rearrangements. However, no distinct subpopulations 
of cells were detected in any of the four melanoma cell lines analyzed. Chromosome 
18 was underrepresented and chromosomes 3 and 7 were overrepresented in at 
least two of four cell lines. In addition, chromosomes 1 and 8 were affected by 
translocations in three of four cell lines. 
 
 
RESULTS 
 
 53
Table 9 Numerical and structural aberrations observed with M-FISH in the cell line M1. In the upper 
part of the table the number of the individual chromosomes per metaphase is listed, whereas the lower 
part describes the different translocations observed in each metaphase. 
Numerical abnormalities Metaphases 1-9 
1  2 2 3 2 2 2 2 2 2 
2  2 2 2 2 3 2 3 3 2 
3  3 3 2 3 3 3 3 3 3 
5  3 3 3 3 3 3 3 3 3 
6  4 4 3 3 4 4 3 3 4 
7  4 4 4 5 3 5 4 5 4 
9  2 3 3 2 3 3 2 2 2 
10  2 2 3 2 2 2 2 2 3 
11  3 3 3 3 3 3 3 3 3 
12  3 2 2 3 3 2 3 3 3 
13  3 3 3 2 3 3 3 2 3 
14  1 2 2 1 2 2 2 2 1 
15  2 2 2 2 1 1 1 3 2 
18  2 1 1 3 1 1 1 2 2 
19  3 2 3 3 3 3 4 3 4 
20  4 4 3 4 3 4 5 3 3 
21  3 3 3 2 1 3 2 2 3 
22  2 1 3 2 3 3 3 2 2 
X  2 2 2 2 2 2 2 1 1 
Structural rearrangements       
A1 der(1)t(1;8 ;14)     1x      
A2 der(1)t(1;12)          1x 
A3 der(1)t(1;20)    1x  1x  1x   
A4 der(1)t(2;1)      1x     
A5 der(1)t(2;6)        1x 1x  
A5 del(1)  1x 1x 1x 1x 1x 1x 1x 1x 1x 
A7 der(2)t(2;12;17)   1x        
A8 der(3)t(3;12)    1x       
A9 del(3)      1x     
A10 der(4)t(4;12)       1x    
A11 der(5)t(5;12;22)  1x         
A12 del(5)   1x 1x 1x 1x 1x 1x 1x 1x 
A13 der(6)t(6;2)  1x 1x 1x  1x 1x   1x 
A14 del(6)  1x 1x  1x 1x 1x 1x 1x 1x 
A15 der(7)t(7;13)         1x  
A16 der(7)t(7;17)  2x 2x 2x 2x 1x 2x 2x 2x 2x 
RESULTS 
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Table 9 continued. 
Structural rearrangements      Metaphases 1-9 
A17 dic(7)t(7;18)      1x     
A18 del(7)      1x     
A19 der(8)t(8;1)  1x 1x  1x 1x 1x 1x 1x 1x 
A20 der(8)t(8;3)    1x       
A21 der(9)t(9;10)  1x         
A22 der(9)t(9;18)   1x 1x  1x 1x 1x 1x 1x 
A23 del(9)  1x 1x 1x 1x 1x 1x    
A24 del(10)          1x 
A25 der(11)t(11;1)  1x 1x 1x 1x 1x  1x 1x 1x 
A26 der(11)t(11;1;15)       1x    
A27 der(12)t(12;1)  2x 2x 2x 2x 2x 2x 2x 2x 2x 
A28 del(12)  1x   1x 1x  1x 1x 1x 
A29 der(13)t(13;13)  1x 1x 1x 1x 1x 1x  1x 1x 
A30 der(13)t(13;14)          1x 
A31 der(13)t(13;15)        1x   
A32 der(13)t(13;21)      1x     
A33 der(13)t(13;22)    1x       
A34 der(14)t(14;8)   1x 1x    1x 1x  
A35 der(14)t(14;8;X)  1x         
A36 der(14)t(14;9)        1x   
A37 der(14)t(14;18)       1x    
A38 der(14)t(14;21)     1x      
A39 der(14)t(14;22)         1x  
A40 der(15)t(15;9)         1x  
A41 der(15)t(15;14)  1x         
A42 der(15)t(15;15)         1x  
A43 der(15)t(15;19;22)   1x        
A44 der(17)t(17;11)       1x 1x  1x 
A45 der(17)t(17;20)  1x 1x 1x 1x 1x     
A46 der(17)t(17;21)  1x    1x   1x  
A47 der(18)t(18;9)  1x   1x      
A48 der(19)t(19;7)    1x 1x 1x  1x  1x 
A49 der(19)t(19;16)  1x         
A50 der(X)t(X;7)   1x        
A51 der(X)t(X;13)     1x      
A52 der(X)t(X;15)      1x     
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Table 10 Numerical and structural aberrations observed with M-FISH in the cell line M2. In the upper 
part of the table the number of the individual chromosomes per metaphase is listed, whereas the lower 
part describes the different translocations observed in each metaphase. 
Numerical abnormalities Metaphases 1-10 
1 3 3 2 3 3 3 3 3 3 3 
2 4 4 4 3 3 3 3 3 4 3 
3 4 4 4 4 4 4 4 4 3 4 
4 2 3 3 3 2 3 3 2 3 3 
5 4 4 4 4 4 4 4 3 4 4 
7 6 6 6 6 6 6 6 5 6 6 
8 4 4 4 4 4 4 4 3 4 4 
9 2 2 4 4 4 4 4 5 4 4 
10 2 4 3 4 4 4 4 4 4 4 
11 4 4 2 2 2 2 2 2 1 2 
12 4 4 3 4 4 4 4 4 4 4 
13 3 3 3 3 3 3 3 3 3 3 
14 2 3 3 3 3 3 3 3 3 3 
15 3 4 4 4 4 4 4 3 2 4 
16 4 4 4 4 4 4 4 4 4 4 
17 3 3 3 3 3 3 3 3 3 3 
18 4 3 3 2 4 3 3 3 3 3 
19 4 4 3 4 4 4 4 3 4 4 
20 3 4 4 4 4 4 4 4 4 4 
21 4 5 4 6 4 4 2 5 3 4 
22 4 3 4 2 4 4 6 2 4 4 
X 3 4 3 3 3 3 3 2 2 3 
Structural rearrangements 
A1 der(9)t(9;11)   2x 2x 2x 2x 2x 3x 2x 2x 
A2 del(10)  2x 2x 2x 2x 2x 2x 2x 2x 2x 
A3 der(11)t(11;9)  1x 2x        
A4 del(12)        1x   
A5 der(13)t(13;6) 1x 1x 1x 1x 1x 1x 1x 2x 1x 1x 
A6 der(14)t(14;6) 1x 2x 2x 2x 2x 2x 2x 1x 2x 2x 
A7 der(21)t(21;22) 2x 3x 2x 4x 2x 2x  3x 2x 2x 
A8 der(22)t(22;21) 2x 1x 2x  2x 2x 4x 1x 2x 2x 
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Table 11 Numerical and structural aberrations observed with M-FISH in the cell line M3. In the upper 
part of the table the number of the individual chromosomes per metaphase is listed, whereas the lower 
part describes the different translocations observed in each metaphase. 
Numerical abnormalities Metaphases 1-10 
1 4 4 4 4 4 3 4 4 4 4 
2 3 3 4 3 4 3 3 3 4 4 
3 4 4 3 4 4 4 4 4 4 4 
4 2 2 2 1 2 2 2 2 2 2 
6 3 3 3 3 3 3 3 3 3 3 
7 4 4 4 3 4 4 4 4 4 3 
10 2 2 1 2 2 2 2 2 2 2 
11 2 2 3 2 2 2 2 2 2 2 
13 3 3 4 4 4 3 3 3 3 4 
14 3 3 2 3 3 3 3 3 3 3 
15 4 4 3 4 4 4 4 4 4 4 
16 3 3 3 3 3 3 3 3 3 3 
17 3 3 3 3 3 3 3 3 3 3 
18 2 2 2 2 2 2 2 2 2 1 
19 3 3 3 3 3 3 3 3 3 3 
20 3 3 3 3 3 3 3 3 3 3 
21 3 2 3 3 3 2 2 2 2 3 
22 2 4 4 4 4 4 4 4 4 4 
X 2 2 2 2 2 2 2 2 2 2 
Structural rearrangements 
A1 der(1)t(1;12) 2x 2x 2x 2x 2x 1x 2x 2x 2x 2x 
A2 der(1)t(1;16)   1x        
A3 der(10)t(10;8) 1x 1x 1x 1x 1x 1x 1x 1x 1x 1x 
A4 der(12)t(12;10) 2x 2x 2x 2x 2x 2x 2x 2x 2x 2x 
A5 der(22)t(22;21)      1x     
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Table 12 Numerical and structural aberrations observed with M-FISH in the cell line M7. In the upper 
part of the table the number of the individual chromosomes per metaphase is listed, whereas the lower 
part describes the different translocations observed in each metaphase. 
Numerical abnormalities Metaphases 1-10 
1 4 3 3 4 4 3 4 3 3 3 
2 4 4 3 3 4 4 4 3 3 4 
3 5 4 5 5 4 5 5 3 5 4 
4 4 3 4 3 4 4 4 3 4 4 
5 4 4 5 2 3 3 5 3 3 4 
6 3 4 3 2 4 3 3 3 3 4 
7 4 5 4 4 5 4 3 3 4 3 
8 3 3 3 3 3 3 3 3 3 3 
9 3 3 3 3 3 3 2 3 3 3 
11 2 5 5 3 3 3 3 2 2 5 
12 4 3 4 4 3 4 4 3 4 3 
13 2 2 1 2 2 2 2 2 2 2 
14 3 3 3 3 3 3 3 3 3 3 
15 2 3 2 2 2 2 2 2 2 2 
16 3 4 3 3 4 3 3 3 3 3 
17 3 3 3 2 3 3 2 3 3 3 
18 3 3 3 3 3 3 3 3 3 2 
19 4 4 4 4 4 4 4 4 4 4 
20 4 4 2 3 4 4 4 4 5 3 
21 0 0 0 0 0 0 0 1 0 0 
22 2 2 2 2 2 2 2 0 2 3 
X 3 4 3 3 5 3 2 5 3 5 
Structural rearrangements 
A1 der(1)t(1;3)  1x  1x 1x   1x  1x 
A2 der(1)t(1;5)      1x   1x  
A3 der(1)t(1;11) 1x          
A4 der(1)t(1;15)   1x        
A5 der(3)t(3;1) 1x 1x 1x  1x 1x 1x 1x  1x 
A6 der(3)t(3;17) 2x  2x 2x  2x 2x  2x  
A7 der(3)t(3;22) 2x 3x 2x 2x 3x 2x 2x 2x 2x 3x 
A8 der(3)t(3;1;8)    1x       
A9 der(3)t(3;1;2)         1x  
A10 del(4)       1x    
A11 der(5)t(5;3) 1x      1x    
A12 del(6) 1x      1x    
A13 der(8)t(8;1;3) 1x 1x 1x 1x 1x 1x 1x 1x 1x 1x 
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Table 12 continued. 
Structural rearrangements    Metaphases 1-10 
A14 del(11)  2x 2x  2x      
A15 der(14)t(14;21) 1x 1x 1x 1x 1x 1x 1x 1x 1x 1x 
A16 del(17)  1x 1x  1x 1x  1x 1x 1x 
A17 der(20)t(20;6)       1x    
A18 der(20)t(20;11) 1x          
A19 der(21)t(21;22)       1x    
A20 der(22)t(22;21) 2x 2x   2x 2x 2x  2x 3x 
A21 del(X)     1x      
 
5.1.3 CGH analysis of malignant melanoma cell lines 
 
The melanoma cell lines M1-M7, M9, and CRL-1974 were analyzed by 
conventional metaphase CGH for regions with over- or underrepresentation of 
genomic material. The experiments were performed in the laboratory of Dr. M. R. 
Speicher. Genomic DNA of all nine cell lines was prepared and labeled, and together 
with normal placental DNA hybridized to normal metaphase chromosomes (46, XY). 
Thereby, several genomic aberrations were detected, which are listed in Table 13. In 
addition, Figure 7 shows a graphical summary of the CGH results of all melanoma 
cell lines. Taken together, the most frequently overrepresented chromosomal regions 
were 1q, 6p, 7p/q, 20p/q, 22p/q, and Xp/q, whereas the most frequently 
underrepresented chromosomal regions were 6q, 9p, and 10q. In total, more 
chromosomal gains (8.6 gains per tumor) than losses (4.7 losses per tumor) were 
observed. 
In some of the melanoma cell lines high level gains or losses of specific 
chromosomal regions were detected (examples are shown in Figure 8). For example, 
in the cell line M4 the distal end of chromosomes 1q, 5p, and 8q were locally 
amplified, and in the cell line M7 two regions on chromosome 3 (3p13-p14 and 3q21-
q25) showed distinct amplicons (Figure 8). On chromosomes 5p15.33 and 8q24 two 
genes frequently amplified in tumors are located, namely hTERT (Pirker et al., 2003) 
and C-MYC (Morrison et al., 2005). In addition, frequent losses were observed at the 
distal end of chromosome 9, especially in the cell line M2. This region harbors the 
tumor-suppressor gene p16INK4A (9p21) (Castellano et al., 1997). 
RESULTS 
 
 59
Table 13 Chromosomal alterations detected by CGH in nine melanoma cell line. For each cell line the 
gains and losses of genomic material are listed. 
Cell line Gains  Losses 
M1 1p31-33, 6p21, 13q13-q14, 13q31-q34, 
17q21-q23, 20p, 20q 
 6q14-q21, 9p23-p24 
M2 21q, 22q, Xp11.22-22.2, Xq12-q21, 
Xq22-q28 
 1p, 1q21.2-q32, 2p, 2q22-q37, 4p, 4q, 6q, 
9p13-p24, 10q21-q26, 11q12.3-q25, 13q21-
q34, 14q11.1-q32 
M3 1q, 2p, 2q, 3p, 3q, 6p, 7p, 7q, 10q23-
q25, 12p, 13q, 15q, 17q11-q21, 22q, Xp, 
Xq 
  
M4 1q21.2-q32, 1q41-q44, 5p14-15.3, 
6p21.1-p22, 6p23-p25, 8q22-q24.3, 17q, 
22q11.2-q13 
 4p13-p16, 10p12-p14, 10q21-q26, 11p11.2-
p15, 11q13-q24 
M5 1q31-q41, 2q23-qter, 6p21.3-pter, 7p, 
7q, 8q, 12p, 12q12-q21, 17p, 20p, 20q, 
Xp, Xq 
  
M6 3p25-p26, 5q34-q35, 17q24-q25, 22q13  6q22-q24 
M7 1q24-q32.1, 3p13-p14, 3q21-q25, Xp, Xq  1q41-q42, 3p21-p26, 6q, 8p21-p23, 8q23-
q24.3, 9p21-p24, 10p, 10q, 11p12-p14, 
11q14-q25, 13q, 17p, 18p 
M9 1p13.1-p21, 1q, 2q22-q33, 6p21.3-p25, 
7p, 7q, 13q, 20p, 20q, 22q 
 6q14-q27, 9p21-p23 
CRL-1974 1q21-q44, 4q12-q28, 4q32-q35, 6p, 7p, 
7q, 20p, 20q, 22q 
 1p13-p22, 5p12-p15.3, 5q12-q35, 9p21-p24, 
10q21-q26, 15q13-q24, 16q11.2-q24 
 
 
At this time, no specific candidate genes had been described in melanoma for 
the regions amplified on chromosomes 1, 3, and 12. Nevertheless, for the amplicon 
on chromosome 1 in the cell line M4 a region containing the AKT3 gene (1q43-q44) 
was chosen for further analysis. As AKT activity can be negatively regulated by 
PTEN (for review see (Robertson, 2005)), which itself often displays decreased 
activity in melanoma, this seemed to be a likely target for amplification. 
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Figure 7 Summary of copy number aberrations found by CGH analysis of nine malignant melanoma cell lines. The vertical red lines on 
the left side of each chromosome ideogram show regions of reduced copy number, and the green lines on the right side show regions  
of increased copy number. Each line is labeled with the tumor in which the alteration occurred. For each tumor between 22 and 30  
metaphases were evaluated. 
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Figure 8 Examples of single chromosome CGH profiles of different malignant melanoma cell lines. 
The name of the cell line is indicated above each ideogram and the chromosome number is given 
below. For M2 and M7 gains are indicated in red on the left side of the chromosome ideogram and 
losses in green on the right side. For M4, M5, and M9 gains are indicated in green on the right side of 
the chromosome ideogram and losses in red on the left side. 
 
To validate some of the CGH results, C-MYC, hTERT, and AKT3 were 
analyzed for copy number changes by quantitative PCR (qPCR) with primers specific 
for each gene. Genomic DNA isolated from the melanoma cell lines M1-M7, M9, and 
CRL-1974 was normalized utilizing a primer in a region with low gene density on 
chromosome 16q22, which has not been described to be affected by chromosomal 
aberrations in melanoma. Copy number changes were evaluated by comparison with 
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genomic DNA isolated from early passage human diploid fibroblasts (HDF), and the 
results are listed in Table 14. 
 
Table 14 Copy number values determined in nine malignant melanoma cell lines by qPCR analysis 
and deletion status of the p16INK4A gene. Copy number values were calculated per haploid genome. 
Copy numbers ≥2.0 are marked in bold. Abbreviations: n. d., not determined; P, present; HD, 
homozygous deletion. 
Cell line C-MYC hTERT AKT3 p16INK4A 
M1 1.1 3.2 2.2 P 
M2 1.1 2.4 1.7 HD 
M3 1.2 1.9 1.6 HD 
M4 5.9 11.2 4.3 HD 
M5 1.4 1.8 1.6 HD 
M6 1.4 2.9 n. d. P 
M7 1.0 2.7 2.6 P 
M9 0.8 0.8 1.3 HD 
CRL-1974 2.0 2.4 3.3 P 
 
 
The p16INK4A gene was analyzed for homozygous deletion by conventional 
PCR. Absence of a PCR product with a primer located inside the p16INK4A gene 
together with presence of a PCR product from the primer located at 16q22 was 
scored as homozygous deletion. Again, genomic DNA from HDF was used as 
positive control. The results are listed in Table 14. 
Overall, the PCR analyses showed a good correlation with the results from 
CGH. The analyzed genes (C-MYC, hTERT, AKT3) proved to be amplified in the 
regions with high-level gains in the respective cell lines. Also, homozygous deletion 
of p16INK4A was frequently observed in the underrepresented chromosomal region 
on 9p. In addition, these amplifications and homozygous deletions were also 
observed by PCR in other melanoma cell lines without being detected by CGH. 
Nevertheless, other genes located inside the regions with high level gains or losses, 
which are likewise affected by copy number alterations could also contribute to the 
pathogenesis of malignant melanoma. 
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5.2 Digital karyotyping analysis of malignant melanoma cell lines 
 
With the cytogenetic characterization of melanoma cell lines by M-FISH and 
CGH analysis, a general overview of genomic alterations was gained. Based on 
these findings, a technique with higher resolution was utilized in order to search for 
small genomic regions with amplifications or deletions, which may indicate the 
presence of so far unknown oncogenes or tumor-suppressor genes. Therefore, 
digital karyotyping was applied, as this newly developed technique allows for a much 
higher resolution than conventional karyotyping techniques (Figure 2, chapter 1.2.3) 
(Wang et al., 2002). In total, four digital karyotyping experiments were performed with 
the cell lines M1, M2, M3, and CRL-1974, which were chosen because no high level 
gains or losses were detected in chromosomal regions containing known tumor-
suppressor genes or oncogenes. 
The digital karyotypings of M1 and CRL-1974 were carried out by Alex 
Epanchintsev. About 210,000 tags were sequenced for each library so that after the 
removal of repetitive sequences about 100,000 tags could be used for analysis (for 
details see Table 15). 
 
Table 15 Size of the digital karyotyping libraries obtained from four malignant melanoma cell lines. 
The column tags describes the total number of tags sequenced, whereas filtered tags denotes tags 
without repetitive sequences, which can be used for analysis. 
Cell line Tags Filtered tags 
M1 210,004 101,428 
M2 204,768 103,301 
M3 206,465 111,245 
CRL-1974 207,543 104,071 
 
5.2.1 Validation of the digital karyotyping results 
 
First, tag densities were dynamically analyzed along each chromosome by 
using sliding windows containing ≥1,000 virtual tags. The term “virtual tags” refers to 
those tags that were computationally extracted from the human genome assembly 
and represent unique loci. The aforementioned resolution of ≥1,000 virtual tags was 
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predicted to reliably detect subchromosomal changes ≥4Mbp, for example gains and 
losses of chromosomal arms. The tag density maps for each chromosome generated 
by the digital karyotyping software for the cell lines M2 and M3 revealed several 
changes, which were compared with the CGH single chromosome profiles of these 
cell lines. Thereby, the overall changes detected for each chromosome were largely 
consistent with the CGH analysis. As example, a comparison between digital 
karyotyping and CGH for the chromosomes 1 and 6 in the cell line M3 is shown in 
Figure 9. 
 
 
For the detailed analysis of amplifications in the digital karyotyping libraries of 
the cell lines M2 and M3, sliding window sizes of 50 virtual tags were used. This 
window size was expected to reliably detect amplifications with 10-fold copy numbers 
of at least 200 kbp in size. With the digital karyotyping software only very few 
regions, which displayed amplifications of three to six fold per haploid genome, were 
detected in both libraries. To validate these amplifications, primers were designed for 
every region and qPCR was performed. Thereby, the only amplification which could 
be validated was located on chromosome 20q13.3 with a 2.3-fold change in the 
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Figure 9 Examples of subchromosomal changes of chromosomes 1 and 6 in the cell line M3 revealed 
by low-resolution tag density maps. The upper set in each graph corresponds to the digital karyotype 
(DK), while the lower graph represents the CGH profile. Values on the x-axis indicate position along 
the chromosome and values on the y-axis represent copies per haploid genome. 
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melanoma cell line M2. Two genes were located in the amplified region – STMN3 
(stathmin-like 3) and C20orf41 (now called RTEL1, regulator of telomere elongation 
helicase 1). STMN3 belongs to the stathmin/oncoprotein 18 family of microtubule-
destabilizing phosphoproteins (Gavet et al., 1998), whereas RTEL1, also a member 
of the stathmin family, may contribute to cell growth and tumor progression through 
amplification or overexpression (Bai et al., 2000; Ding et al., 2004). Both proteins are 
located in a gene-rich cluster on chromosome 20 with other potentially tumor-related 
genes. Therefore, genomic DNA from other melanoma cell lines was analyzed by 
qPCR and increases of 2-fold could be shown for 20q13.3 in the cell lines M1 and 
M8. As no high level amplifications for 20q13.3 were detected in any of the 
melanoma cell lines, this region was not further analyzed. 
Deletions in the digital karyotyping libraries were analyzed with a sliding 
window size of 150 virtual tags, which corresponds to a resolution of around 600 kbp 
when analyzing a total of 100,000 tags. The detection of homozygous deletions was 
expected to be more difficult than the detection of amplifications, because the copy 
number difference for homozygous deletions (two copies in normal cells compared to 
zero copies in deleted regions) is far less than that observed for amplifications (about 
10-200 copies in amplified regions). In both libraries evidence was found for several 
regions with apparent deletions. The most prominent region was located in the cell 
line M2 on chromosome 9p21 with an estimated size of 1.9 Mbp. This deletion was 
verified by PCR and spanned the CDKN2A locus, which encodes p16INK4A and 
p14ARF (Figure 10A). Homozygous deletion of p16INK4A had already been 
observed in the cell line M2 when validating the results from CGH analysis (Table 
14). 
All other deletions predicted by the digital karyotyping software in the libraries 
of M2 and M3 could not be confirmed by PCR. Nevertheless, in some of the regions 
analyzed a substantial reduction in genomic content was observed. Examples of 
PCR analysis of potentially deleted regions in both cell lines are shown in Figure 11. 
Not detected by digital karyotyping was the homozygous deletion of p16INK4A in the 
cell line M3 (Table 14). By PCR analysis this deletion was shown to span only 250 
kbp (data not shown), which is below the resolution achieved by digital karyotyping 
when analyzing a total of 100,000 tags. 
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Analysis of the library generated from the cell line M1, which was derived from 
a female patient, revealed a homozygous deletion on the X chromosome inside the 
DMD gene. The deletion was confirmed by PCR with genomic DNA by Alex 
Epanchintsev and spanned 570 kbp. This resulted in an in-frame removal of exons 3-
29 of the DMD gene.  
So far, deletions in DMD had only been associated with the muscle-wasting 
diseases Duchenne or Becker Muscular Dystrophy but not with cancer. Therefore, it 
was of interest to elucidate whether the loss of dystrophin might play a role in 
pathologic states such as malignant melanoma. 
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Figure 10 Homozygous deletion of the CDKN2A locus in the cell line M2. (A) Graphical representation 
of the homozygous deletion on chromosome 9p21 in the cell line M2 with the digital karyotyping 
software. Tag density values were calculated in sliding windows of 200 virtual tags. Values on the x-
axis represent position along the chromosome, values on the y-axis show copies per haploid genome. 
(B) PCR analysis of the homozygous deletion of the CDKN2A locus detected by digital karyotyping in 
the cell line M2. DNA from HDF (human diploid fibroblast) was used as positive control. Numbers on 
the right indicate chromosome position. 
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5.3 Analysis of DMD in malignant melanoma 
 
5.3.1 Deletion of DMD in malignant melanoma cell lines 
 
All PCR reactions analyzing the deletion status of DMD in melanoma cell lines 
were performed by Alex Epanchintsev. First, to confirm whether the deletion in the 
DMD gene in the cell line M1 was a tumor specific event, genomic DNA isolated from 
paraffin-embedded non-tumor cells of the same patient was evaluated. By PCR 
analysis no deletion of exons 3-29 could be detected, demonstrating that the DMD 
deletion in M1 represents a somatic event not present in other cells of the patient. 
Next, different regions of the DMD gene using genomic DNA from a panel of 49 
melanoma cell lines (including M2-M9 and CRL-1974) were examined by PCR. 
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Figure 11 PCR analysis of regions potentially deleted in the melanoma cell lines M2 and M3. (A) PCR 
analysis of two regions on chromosomes 1 and 10 in the cell line M2. Expected sizes of PCR 
products: 16q22 (209 bp), 1p22.1 (240 bp), 10q25 (475 bp). (B) PCR analysis of three regions on 
chromosomes 1, 4, and 6 in the cell line M3. Expected sizes of PCR products: 16q22 (209 bp), 1p36.2 
(300 bp), 4q31-q32 (294 bp), 6q25 (288 bp). DNA from HDFs (human diploid fibroblasts) was used as 
standard diploid genome. The primer 16q22 served as control for equal amounts of DNA. The PCR 
reaction had been optimized in order to compare the amount of product before plateau phase was 
reached. 
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Thereby, an additional homozygous deletion spanning exons 17-30 of the DMD gene 
was identified in the cell line RPMI-7951 (derived from a female patient), resulting in 
an in-frame truncation of the dystrophin protein. No matching non-tumor material was 
available for the cell line RPMI-7951 to evaluate tumor-specificity of the deletion. 
Another deletion of exons 42-43 resulting in the termination of the dystrophin protein 
in exon 44 was identified in the cell line WM-793 (derived from a male patient). This 
deletion was absent in genomic DNA derived from immortalized B-cells from the 
same patient and consequently represents a tumor-specific event.  
 
5.3.2 Expression of DMD isoforms in primary melanocytes 
 
So far, expression of the full-length 427 kD dystrophin protein had only been 
observed in muscle cells and nerve cells, together with a differential expression of 
shorter isoforms in different tissues (for details see chapter 1.3.1). In order to 
evaluate if deletions in DMD could be of functional consequence in melanoma cells, 
the expression of dystrophin isoforms was analyzed in primary melanocytes. Early 
passage cultures of primary melanocytes were kindly provided by Dr. Carola Berking 
(Department of Dermatology, LMU Munich). RNA was isolated from three different 
cultures of melanocytes and reverse transcribed with either the DMD-specific primer 
DMD1b, which binds in the 5´-end of DMD, or an oligo(dT)20 primer. 
To analyze expression of the full-length Dp427 isoforms, cDNA from three 
different donors transcribed with the DMD1b primer was used for PCR with primers 
specific for each of the isoforms. In all cases only the muscle-specific Dp427m 
isoform could be detected, but not Dp427c, Dp427p, or Dp427l (Figure 12A). To 
complete the picture, Dp427l was included in the analysis, although recent findings 
suggest that this isoform might represent an artifact, making its functional role 
uncertain (Wheway and Roberts, 2003). 
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cDNA from two different donors transcribed with the oligo(dT)20 primer was 
used to examine expression of the shorter DMD isoforms, and PCR was carried out 
with primers specific for each isoform. Thereby, specific PCR products for Dp71 and 
Dp116, but not Dp140 and Dp260 were detected in primary melanocytes (Figure 
12B). 
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Figure 12 RT-PCR analysis of DMD isoforms in primary melanocytes. (A) Analysis of differential 
Dp427 isoform expression. RT-PCR was performed with RNA from three different cultures of primary 
human melanocytes (HM) using primer pairs specific for the indicated DMD isoforms. Expected sizes 
of PCR products: Dp427c (561 bp), Dp427m (548 bp), Dp427p (331 bp), Dp427I (319 bp). (B) RT-
PCR analysis of the DMD isoforms Dp260, Dp140, Dp116, and Dp71. Total RNA was obtained from 
primary human melanocytes (HM) from two donors. RT-PCR was carried out using primer pairs 
specific for the indicated isoforms. Expected sizes of PCR products: Dp260 (214 bp), Dp140 (161 bp), 
Dp116 (364 bp), Dp71 (393 bp). 
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5.3.3 Expression of dystrophin isoforms in melanoma cell lines 
 
Protein expression of the Dp427 full-length isoform in melanoma cell lines was 
assessed by Western blot analysis (Figure 13). Protein lysates from a panel of 55 
melanoma cell lines and primary melanocytes were examined with the dystrophin 
antibody NCL-Dys1, which recognizes an epitope in the central rod domain of the 
protein. In untransformed primary melanocytes the expression of the Dp427m protein 
was high. In contrast, in 38 of 55 (69%) melanoma cell lines the dystrophin protein 
was absent and in 10 of 55 (18%) only present at very low levels. Only the cell line 
WM-115 displayed a higher amount of dystrophin than primary melanocytes. 
In addition, expression of the shorter dystrophin isoforms was analyzed in 
melanoma cell lines (Figure 14). By Western blot analysis expression of the Dp116 
and Dp71 isoforms could be detected with the dystrophin antibodies NCL-Dys2, 
which recognizes the C-terminus of dystrophin and Ab-1 (epitope not determined). 
Dp116 was present in 5 of 7 (71%) cell lines positive for the expression of the full-
length dystrophin protein and in 1 of 5 (20%) that were negative for Dp427 protein 
(Figure 14A, upper panel). On the other hand, all of eight melanoma cell lines 
analyzed showed expression of Dp71 (Figure 14A, lower panel). Of those eight cell 
lines two showed expression of the full-length dystrophin protein, whereas in the six 
other cell lines the full-length dystrophin protein was absent. Therefore, expression of 
the Dp71 isoform seems to be retained in melanoma cell lines independent of the 
expression of the Dp427 isoform, whereas the Dp116 isoform seems to be 
preferentially expressed in a subset of melanoma cell lines, which still express full-
length dystrophin. 
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As confirmation of the Western blot analysis, RNA was prepared from the cell 
line WM-115, which showed expression of Dp116 and Dp71 protein and reverse 
transcribed with an oligo(dT)20 primer. By PCR with primer pairs specific for the 
shorter isoforms, expression of Dp116 and Dp71 could be confirmed (Figure 14B).  
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Figure 14 Expression of shorter dystrophin isoforms in melanoma cell lines. (A) Western blot analysis 
of the expression of Dp116 and Dp71 in melanoma cell lines. Dp116 was detected with the NCL-Dys2 
antibody and Dp71 with the Ab-1 antibody. β-actin was used as control. (+) and (-) indicate presence 
or absence of full-length dystrophin protein expression. (B) RT-PCR analysis of the expression of the 
DMD isoforms Dp260, Dp140, Dp116, and Dp71 in the melanoma cell line WM-115. Expected sizes of 
PCR products: Dp260 (214 bp), Dp140 (161 bp), Dp116 (364 bp), Dp71 (393 bp). 
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In addition to the analysis of the level of dystrophin protein in melanoma cell 
lines, expression of DMD mRNA was quantitated. RNA was prepared from a subset 
of 37 melanoma cell lines, including 16 cell lines with and 21 without full-length 
dystrophin protein expression, and reverse transcribed with an oligo(dT)20 primer. 
mRNA expression was analyzed by quantitative real-time PCR (qPCR) with the DMD 
LC primer, which is specific for the Dp427 isoforms. Figure 15 shows an example of 
an agarose gel with the products from qPCR after 40 cycles. The amount of DMD 
mRNA was calculated based on crossing point differences between the individual 
samples normalized to the β-actin control with the DMD expression in primary 
melanocytes set to 100% (for details see chapter 4.8). Only five melanoma cell lines 
(MRI-H 221, M7, Hs-294T, Sk-Mel 31, WM-98) showed expression levels of DMD 
mRNA similar to primary melanocytes, whereas in all other cell lines a diminished 
DMD expression was detected (Figure 16). 
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Figure 15 Representative examples of DMD mRNA expression. cDNA from different melanoma cell 
lines and primary melanocytes (HM40p7) was analyzed by qPCR for expression of DMD. 
Quantification was done using crossing point differences between primary melanocytes and 
melanoma samples normalized to β-actin. Afterwards, LightCycler PCR products were visualized on a 
2% agarose gel. Expected sizes of PCR products: DMD (187 bp), β-actin (213 bp). 
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A good correlation was observed when comparing the amount of DMD mRNA 
with the protein level in each cell line. For cell lines with 50-100% of DMD expression 
compared to primary melanocytes, dystrophin protein could also be detected in 
Western blot analysis, whereas in most cell lines with low DMD expression no 
dystrophin protein was observed. General information about all cell lines together 
with expression levels of DMD mRNA and protein is listed in Supplementary Table 2. 
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Figure 16 Correlation of DMD mRNA and protein expression. DMD mRNA expression was 
determined by quantitative PCR and compared to dystrophin protein expression assessed by 
Western blot analysis. Expression of DMD in each cell line is indicated by its ratio to that of the mean 
expression of primary melanocytes from three different donors. Protein levels were determined by 
Western blot analysis and classified as high to moderate expression (black bars), low expression 
(gray bars) and no expression (white bars). 
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5.3.4 Functional analysis of dystrophin 
 
5.3.4.1  Analysis of the components of the dystrophin-glycoprotein complex 
 
In muscle cells, dystrophin acts as a linker between the muscle basement 
membrane and the inner cytoskeleton through binding to cytoskeletal F-actin and β-
dystroglycan, which together with α-dystroglycan forms a complex at the muscle cell 
membrane (for details see chapter 1.3.5). In addition, the sarcoglycan complex and 
several other proteins are associated with the dystrophin-glycoprotein complex 
(DGC) in muscle tissue. In most non-muscle cells the full-length dystrophin isoform is 
not expressed and replaced by its homolog utrophin or shorter dystrophin isoforms. 
The association of other proteins with the dystroglycan complex can vary greatly in 
different tissues (Durbeej and Campbell, 1999; Imamura et al., 2000). 
As nothing was known about the dystrophin-glycoprotein complex in primary 
melanocytes, the expression of several components of the DGC was analyzed. 
cDNA from primary melanocytes was examined by PCR with primers specific for 
different components of the complex. Thereby, specific products for dystroglycan 
(DAG1), utrophin (UTRN), syntrophin-β2 (SNTB2), β-sarcoglycan (SGCB), ε-
sarcoglycan (SGCE), laminin-α2 (LAMA2), sarcospan (SSPN), and nitric oxide 
synthase 1 (neuronal) (NOS1) but not α-dystrobrevin (DTNA) were detected (Figure 
17). These results show, that all the necessary components are expressed to form a 
functional dystrophin-dystroglycan complex in melanocytes, although no conclusions 
can be drawn as to the exact composition of the DGC. 
It has been shown, that dystrophin deficiency in muscle leads to a secondary 
deficiency of all the components of the DGC either through down-regulation or 
mislocalization of the respective proteins (Ohlendieck and Campbell, 1991). 
Therefore, melanoma cell lines with and without the expression of dystrophin protein 
were analyzed by qPCR for down-regulation of some of the components of the DGC. 
The expression of UTRN, DAG1, SGCB, SGCE, SNTB2, and LAMA2 was evaluated 
in the cell lines WM-115 (with normal dystrophin expression), RPMI-7951, WM-793, 
and M1, (all three with deletions in DMD) and compared to the expression of the 
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respective mRNA in the primary melanocyte sample HM40p7. For UTRN, DAG1, 
SGCB, SGCE, and SNTB2 no significant changes in expression level could be 
detected, whereas expression of LAMA2 was down-regulated in the cell lines M1 and 
RPMI-7951, and absent in WM-793. Expression of LAMA2 was normal in WM-115. 
Because no specific product for LAMA2 could be detected in WM-793, genomic DNA 
was analyzed but no deletion of the gene locus was observed with PCR. 
 
Next, mRNA of 37 melanoma cell lines and two primary melanocyte samples was 
examined for down-regulation of LAMA2. Conventional PCR was employed and PCR 
products were evaluated on an agarose gel with β-actin as standard to ensure equal 
amounts of template. In 23 of 37 (62%) melanoma cell lines expression of laminin-α2 
was diminished or absent (Table 16). 
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Figure 17 Expression of DGC components in primary melanocytes. cDNA from primary melanocytes 
(HM40p7) was analyzed by PCR for the expression of utrophin (UTRN; 180 bp), laminin-α2 (LAMA2; 
185 bp), sarcospan (SSPN; 157 bp), nitric oxide synthase 1 (NOS1; 211 bp), α-dystrobrevin (DTNA; 
137 bp), dystroglycan (DAG1; 60 bp), syntrophin-β2 (SNTB2; 65 bp), β-sarcoglycan (SGCB; 67 bp), 
and ε-sarcoglycan (SGCE; 95 bp). Except for DTNA, specific products were observed for all 
transcripts analyzed. 
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Table 16 PCR analysis of LAMA2 expression. cDNA of two primary melanocyte samples (HM40p7 
and HM37p7) and 37 melanoma cell lines was analyzed for expression of LAMA2 and compared to 
dystrophin protein expression. ++ strong expression; + low expression; - no expression. 
Cell line LAMA2 cDNA 
expression 
dystrophin protein 
expression 
HM40p7 ++ ++ 
HM34p7 ++ ++ 
Sk-Mel 31 ++ ++ 
M7 ++ ++ 
WM-115 ++ ++ 
WM-98 ++ + 
Hs-294T ++ + 
WM-852 ++ + 
MM-195 ++ + 
M4 ++ + 
Sk-Mel 24 ++ + 
WM-266-4 ++ + 
Sk-Mel 2 ++ - 
WM-239A ++ - 
WM-902B ++ - 
MRI-H 221 + ++ 
C-32 + ++ 
WM-3456 + + 
WM-3453 + + 
WM-35 + + 
CRL-1974 + - 
M5 + - 
F-01 + - 
Sk-Mel 5 + - 
M2 + - 
M1 + - 
RPMI-7951 + - 
WM-1341D - + 
Bow-G - - 
WM-793 - - 
KAII - - 
M6 - - 
WM-1205LU - - 
Malme3M - - 
MeWO3 - - 
MM-194 - - 
M3 - - 
Mel Juso - - 
Hs-695T - - 
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In the subset of melanoma without dystrophin protein 11 of 21 (52%) cell lines 
were negative for LAMA2 expression, whereas in the 16 cell lines with dystrophin 
protein only one cell line (6%) was negative for LAMA2 expression. Statistical 
analysis with a Χ² test proved this finding to be significant with P < 0.0036, which 
indicates a correlation between the loss of expression of the dystrophin protein and 
absence of LAMA2 mRNA.  
In addition, DAG1 expression was evaluated on protein level, because for a 
number of cancers decreased expression of α-dystroglycan (α-DG) has been 
described and analysis of the mRNA suggested that this is likely regulated at a post-
transcriptional level (Henry et al., 2001; Sgambato et al., 2003). Therefore, α-
dystroglycan expression was evaluated by Western blot analysis with the IIH6 
antibody in a panel of melanoma cell lines with and without expression of dystrophin 
protein (Figure 18). As this antibody recognizes a glycosylated epitope of α-
dystroglycan, the protein is detected with several bands indicating a varying number 
of added sugar moieties. Although differences in the expression level of α-DG were 
detected, there was no correlation to the expression level of dystrophin protein. 
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Figure 18 Western blot analysis of α-dystroglycan (α-DG) expression in primary melanocytes and 
melanoma cell lines. (A) Expression of α-DG in primary melanocytes (HM46p5) detected with the IIH6 
antibody. Protein lysate from C2C12 mouse myotubes was used as positive control for the expression 
of α-DG. (B) Expression of α-DG in melanoma cell lines detected with the IIH6 antibody. Due to 
extensive glycosylation, multiple bands are detected for α-DG. (+) and (-) indicate presence or 
absence of full-length dystrophin protein expression. 
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In muscle and nerve cells the full-length dystrophin protein is always tightly 
associated with the dystroglycan complex, which is located at the cell membrane 
providing a link to the extracellular matrix. Visualization of endogenous dystrophin 
and α-DG protein in melanocytes or melanoma cell lines was not possible. This was 
due to the fact that none of the antibodies used for analysis of the proteins in 
Western blot was sensitive enough to detect them in immunofluorescence or 
immunohistochemistry. To analyze localization of dystrophin and α-DG in melanoma, 
cell lines with and without dystrophin expression were transfected with expression 
vectors for both proteins. Localization of full-length dystrophin was visualized by 
detection of eGFP fused to the N-terminus of dystrophin expressed from the attb-
pDysE vector. α-DG was expressed from the pCMV-DAG1-VSV vector, which 
contains the dystroglycan gene with a C-terminal fusion to a VSV tag. Since DAG is 
post-translationally cleaved into α- and β-DG, only β-DG can be detected with an 
anti-VSV antibody. Co-expression of both proteins was not possible due to very low 
transfection efficiencies of the melanoma cell lines. In total, 13 cell lines (8 with 
dystrophin protein expression and 5 without) were analyzed. Thereby, ectopically 
expressed dystrophin and β-DG were mainly localized at the cell membrane as 
visualized by confocal microscopy (examples are shown in Figure 19). In some cell 
lines signals from inclusion bodies or at ER/Golgi vesicles were detected. The latter 
pattern is probably due to protein overexpression. Nevertheless, the correct 
localization suggests that a functional dystrophin-dystroglycan complex is likely to be 
present in melanocytes and melanoma cell lines. 
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Figure 19 Localization of ectopically expressed dystrophin (DMD) and β-dystroglycan (β-DG) in 
melanoma cell lines. (A) Melanoma cell lines with expression of endogenous dystrophin protein. (B) 
Melanoma cell lines without expression of endogenous dystrophin protein. Dystrophin was directly 
visualized as fusion protein to eGFP, whereas β-DG was detected as VSV-fusion protein using an 
anti-VSV antibody. Scale bars, 80 µm. 
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5.3.4.2 Knockdown of DMD in melanoma cell lines 
 
In order to determine the functional consequences of DMD loss in melanoma, 
RNA interference was used to "knock down” DMD in melanoma cell lines. The 
melanoma cell lines M7 and C-32, which displayed high dystrophin expression at the 
mRNA and protein level were chosen (see chapter 5.3.3, Figure 16). Both cell lines 
were infected with a retrovirus mediating stable expression of a short hairpin RNA 
(shDMD) directed against the Dp427 isoforms or empty vector as control. Single cell 
clones were selected with puromycin and reduced dystrophin expression was 
confirmed by Western blot (Figure 20A) and qPCR analyses (Figure 20B). As the 
DGC forms a connection between the inner cytoskeleton and the extracellular matrix, 
single cell clones with knockdown of DMD expression were tested for changes in 
migration and invasion behavior. Invasion was assessed by branching morphology 
observed after placing cells into matrigel matrix. Clones with reduced DMD 
expression from both cell lines formed branching structures after 1-2 days, which 
gradually extended with time (Figure 20C). In contrast, only spheroids were observed 
in the parental cells and control clones (Figure 20C). Next, migration of cells was 
tested in a scratch assay. Cells were grown to confluence and treated with mitomycin 
C to inhibit proliferation. Afterwards the cell layer was scratched with the sealed tip of 
a Pasteur pipette. Migration of cells into the wounded area was analyzed in 
designated areas over the indicated time period. Thereby, the ability to close an 
artificial wound by migration in a monolayer was significantly enhanced in cells with 
reduced DMD expression (Figure 20D, E). In addition, cellular migration was 
analyzed in a transwell migration assay. Cells were placed in the upper compartment 
of a transwell chamber and migration through a membrane with defined pore size 
was assessed after the indicated time points. In accordance with the results from the 
scratch assay, down-regulation of DMD expression also resulted in increased 
migration of cells through the membrane (Figure 20F, G). 
As cells with knockdown of DMD showed enhanced invasion, branching 
morphology in matrigel was also analyzed in a panel of melanoma cell lines with 
(WM-98, M4) and without (M1, RPMI-7951, WM-793, M2, MM-232) dystrophin 
protein expression over a period of seven days. All cell lines tested showed the ability 
to form branching structures in matrigel. Thereby, differences were observed in onset 
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and structure of the branches formed but could not be correlated to expression of the 
dystrophin protein. 
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Figure 20 Knockdown of DMD in the melanoma cell lines C-32 and M7. (A) Detection of reduced 
dystrophin expression (shDMD) in clones of the cell lines C-32 and M7 by Western blot analysis. β-
actin was used as loading control. (B) Detection of reduced DMD expression (shDMD) in clones of the 
cell lines C-32 and M7 by qPCR analysis. cDNA was normalized against β-actin. (C) Branching 
morphology of parental cell lines, control clones, and clones with reduced dystrophin expression 
(shDMD) in matrigel matrix. Pictures were taken 3 days (C-32) and 5 days (M7) after plating. Scale 
bars; 300 µm. (D) Analysis of control clones and clones with reduced dystrophin expression (shDMD) 
from the cell line M7 in a scratch assay. **P < 0.02. (E) Analysis of control clones and clones with 
reduced dystrophin expression (shDMD) from the cell line C-32 in a scratch assay. *P < 0.005. (F) 
Migration of control clones and clones with reduced DMD expression (shDMD) through the membrane 
of a transwell chamber. The y-axis shows the percentage of migrated cells from C-32 (after 18 hours) 
and M7 (after 24 hours). (G) Pictures of representative areas of migrated cells on the membrane of the 
transwell chamber stained with crystal violet. Scale bars; 300 µm. 
 
5.3.4.3 Re-expression of dystrophin in melanoma cell lines 
 
Expression of dystrophin was restored in the melanoma cell lines RPMI-7951 
and WM-793, which showed deletion of DMD exons 17-30 and exons 42-43, 
respectively, leading to a truncated DMD mRNA. No dystrophin protein was observed 
in both cell lines in Western blot analysis (see chapter 5.3.3, Figure 16). Both cell 
lines were transfected with the attb-pDysE vector for expression of the dystrophin 
protein N-terminally tagged with eGFP and as control the attb-pEGFP vector 
expressing eGFP only. After selection with neomycin, re-expression of dystrophin 
was confirmed in the pools of both cell lines by Western blot analysis (Figure 21A, D). 
After ectopic expression of dystrophin, morphological changes could be observed in 
RPMI-7951 and WM-793. Cells adopted a flattened shape and increased in size 
(Figure 21B, F). Next, migration of WM-793 was assessed in a scratch assay. 
Thereby, decreased migration was observed in cells with restored expression of 
dystrophin compared to control cells (Figure 21C). In RPMI-7951 ectopic expression 
of dystrophin induced a senescent cell-like phenotype. As cellular senescence is 
often accompanied by expression of β-galactosidase (pH 6.0), this can be visualized 
by a chemical reaction turning the cells blue (Dimri et al., 1995). In two independent 
transfection experiments after ectopic expression of dystrophin the frequency of cells 
positive for β-galactosidase (pH 6.0) increased from 3% to 26% and 7% to 14%, 
respectively (Figure 21E, F). This was accompanied by a decrease in cell 
proliferation (Figure 22A) and an increase in the amount of apoptotic cells (Figure 
22B). 
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Figure 21 Re-expression of dystrophin in the melanoma cell lines WM-793 and RPMI-7951. (A) 
Analysis of dystrophin by Western blot after transfecting the cell line WM-793 with eGFP-tagged 
dystrophin (DMD-eGFP) or as control eGFP only. β-actin was used as control. (B) After ectopic 
expression of dystrophin, morphology of WM-793 changed. Cells adopted a flattened shape and 
increased in size compared to control cells. Scale bars, 200 µm. (C) Analysis of cellular migration in a 
scratch assay in the cell line WM-793. Migration was assessed by quantifying the size of the wounded 
area after the indicated time points. *P < 0.02. (D) Analysis of dystrophin by Western blot after 
transfecting the cell line RPMI-7951 with eGFP-tagged dystrophin (DMD-eGFP) or as control eGFP 
only. (E) Quantification of blue cells (representing SA-β-gal staining) compared to total cells. The y-
axis shows the average percentage of SA-β-gal positive cells of two independent transfection 
experiments. In total, 800 cells were counted for each condition. *P < 0.0001. (F) Representative 
areas of cells after senescence-associated β-galactosidase staining (SA-β-gal). Morphology of RPMI-
7951 changed and cells adopted a flattened shape and increased in size after ectopic expression of 
dystrophin. Scale bars, 300 µm. All experiments were performed with stable pools of cells after 
transfection and selection with neomycin for two weeks. 
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Figure 22 Proliferation and apoptosis of the melanoma cell line RPMI-7951 after re-expression of 
dystrophin. (A) Growth curve of RPMI-7951 after transfection with eGFP-tagged dystrophin (DMD-
eGFP) or as control eGFP only. Relative cell number was measured in triplicates after the indicated 
time points. (B) FACS analysis of RPMI-7951 after transfection with eGFP-tagged dystrophin (DMD-
eGFP) or as control eGFP only. Cells were fixed and stained with propidium iodide. Apoptosis was 
evaluated by comparing the percentage of cells in the sub-G1 fraction. 
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6 DISCUSSION 
 
6.1 Cytogenetic characterization of melanoma cell lines 
 
Cytogenetic techniques such as M-FISH and CGH are valuable tools to identify 
chromosomal regions important in oncogenesis and disease progression. Both 
techniques can be used to complement each other in the characterization of complex 
chromosomal changes which occur in most tumor types. M-FISH is typically applied 
to elucidate complex karyotypes involving numerical and structural aberrations, for 
example translocations, insertions or duplications. This technique also allows to 
detect genetic heterogeneity in a tumor cell population. CGH on the other hand 
allows to comprehensively analyze the average chromosomal copy number changes 
present in all cells of the tumor. 
Both methods were applied to a panel of 9 malignant melanoma cell lines to 
gain an overview of chromosomal changes and genetic heterogeneity. M-FISH 
analysis of four melanoma cell lines showed the most complex karyotypes for M1 and 
M7 with 52 and 21 chromosomes with translocations together with a high clonal 
heterogeneity. The cell lines M2 and M3 displayed a more homogeneous karyotype. 
In contrast, the cell line M1 was one of the least affected by copy number alterations 
as detected by CGH analysis. 
Analysis of chromosomal breakpoints revealed a random cluster distribution, 
indicating karyotypic progression in metastases of melanoma. However, 
chromosomes 1 and 8 were most frequently affected by rearrangements. This 
corresponds well with a series of melanoma studies that reported aberrations on 1p 
to be the most common alterations in malignant melanoma (Poetsch et al., 1998; 
Smedley et al., 2000; Thompson et al., 1995). Also, several structural aberrations for 
chromosome 8 have been detected in a case study of cutaneous metastatic 
melanoma (Wiltshire et al., 2001). 
In addition, according to M-FISH analysis amplifications were observed most 
frequently for chromosomes 3 and 7. Whereas gains of chromosome 3 appear to be 
rather uncommon, extra copies of chromosome 7 are frequently recognized in 
metastatic melanoma, and this seems to be a late event in tumor progression 
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(Pedersen and Wang, 1989; Thompson et al., 1995). Aneuploidy of chromosome 7 
has been correlated with strong EGFR gene expression, located on 7p12.3-p12.1 
(Koprowski et al., 1985; Udart et al., 2001). 
A good correlation was observed when comparing results from M-FISH with 
CGH in a given cell line, although differences occurred. This could in part be due to 
misinterpretation of aberrations caused by the complexity of the karyotypes or 
hybridization artifacts. For example, technical uncertainties of M-FISH were observed 
particularly at terminal ends and centromeric regions of chromosomes as well as at 
interfaces of breakpoint regions. 
CGH analysis of the melanoma cell lines M1-M7, M9, and CRL-1974 showed 
frequent overrepresentation of regions on chromosomes 1q, 6p, 7, 20, 22 and X with 
losses observed on 6q, 9p, and 10q. 
Gains of chromosomes 1q and 6p are frequently found in malignant melanoma 
(Bastian et al., 2003; Hoglund et al., 2004) and have been associated with a poorer 
prognosis (Namiki et al., 2005), although their prognostic significance has to be 
evaluated on a larger number of tumors. 
As mentioned above, chromosome 7 aneuploidy has been described in the 
literature in melanoma metastases using the FISH technique and correlated with 
increased expression of EGFR (Udart et al., 2001). Nevertheless, other genes 
residing on chromosome 7, which have been shown to be overexpressed in primary 
melanoma or metastases, might also be involved in tumor development; namely 
BRAF (Brose et al., 2002), PDGF-A (Barnhill et al., 1996), PAI-1 (van Muijen et al., 
1995), or MET (Natali et al., 1993). 
Amplification of chromosome 20q has been found in metastatic breast cancer 
(Tanner et al., 1994) and was also detected in malignant melanoma by FISH analysis 
(Barks et al., 1997). No potential candidate genes contributing to melanoma have 
been identified on this chromosome so far, although three uncharacterized genes 
located on 20q were isolated that are highly amplified in breast cancer (Guan et al., 
1996). 
Amplifications of chromosome 22 have been detected most frequently in acral 
melanoma (Bastian et al., 2000), whereas gains of the X chromosome have not been 
described. 
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Cytogenetic studies have shown that especially the long arm of chromosome 6 
is preferentially lost during the progression of the majority of melanoma (Morita et al., 
1998; Trent et al., 1989). The importance of chromosome 6 in melanoma has been 
confirmed by the introduction of a normal chromosome 6 into melanoma cell lines, 
leading to suppression of metastatic growth (Trent et al., 1990; Welch et al., 1994). 
Several candidate tumor-suppressor genes have been mapped to chromosome 6q, 
for example THW (now named PERP) (Hildebrandt et al., 2001), but further 
investigations refining the affected regions need to be carried out. 
At chromosome 9p the CDKN2A locus, encoding p16INK4A and p14ARF, is not 
only a melanoma susceptibility gene in familial melanoma, but also a candidate 
tumor-suppressor gene in sporadic malignant melanoma. The expression of p16 is 
significantly decreased from melanocytes over RGP and VGP to metastatic lesions 
(Keller-Melchior et al., 1998), although the frequency of p16 inactivation in uncultured 
tumors is much lower than in melanoma cell lines (Healy et al., 1996; Ohta et al., 
1994). This and the high frequency of LOH on 9p suggests the existence of other 
tumor-suppressor genes mapping to the same region (Ohta et al., 1996). 
Aberrations in the long arm of chromosome 10 have been frequently described 
in malignant melanoma of the skin (Thompson et al., 1995) and mainly associated 
with inactivation of the tumor-suppressor gene PTEN (Steck et al., 1997). 
Investigations revealed several aberrations of this gene in melanoma cell lines 
(Guldberg et al., 1997), but the analysis of a larger number of primary tumors and 
metastases limited the importance of PTEN to advanced tumor stages (Poetsch et 
al., 2001). 
Apart from aberrations involving larger chromosomal regions, high level 
amplifications found by CGH analysis were analyzed. Thereby, genomic amplification 
of hTERT, C-MYC, and AKT3 could be confirmed. hTERT together with hTERC 
compose the telomerase holoenzyme, which is essential for maintaining telomere 
length. Acquisition of telomerase activity is believed to be a decisive step in 
immortalization of human cells and thus seems to be a critical event in cancer 
development (for review see (Shay et al., 2001)). In cell lines from cutaneous 
malignant melanoma, especially from SSM primary tumors or local subcutaneous 
metastases, hTERT was found to be amplified (Pirker et al., 2003). Also, telomerase 
activity has been detected in the majority of melanoma samples (Villa et al., 2001) 
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and dysplastic nevi (Glaessl et al., 1999), which are believed to be precursor lesions 
for CMM. 
The proto-oncogene C-MYC encodes a transcription factor that is implicated in 
various cellular processes, such as cell growth, proliferation, loss of differentiation 
and apoptosis. Therefore, it is not surprising that deregulated expression of C-MYC 
has been reported in a broad range of human cancers (for review see (Pelengaris et 
al., 2002)). CGH and FISH analyses have also detected extra copies of the C-MYC 
gene in primary and metastatic melanoma (Balazs et al., 2001; Kraehn et al., 2001). 
The Akt serine/threonine protein kinases consist of three members – Akt1, Akt2, 
and Akt3, which regulate divergent cellular processes including apoptosis, 
proliferation, differentiation, and metabolism (for review see (Nicholson and 
Anderson, 2002)). Increased levels of total phosphorylated Akt were reported in 
several dysplastic nevi and metastatic melanomas (Dhawan et al., 2002). The 
predominant Akt isoform responsible for elevated pAkt levels in melanoma has been 
shown to be Akt3 (Stahl et al., 2004). Increased Akt3 activation also plays a 
significant role in progression to more advanced tumors (Stahl et al., 2004). 
Taken together, the results obtained by FISH and CGH analysis strongly 
correlate with previous findings of aberrations detected in melanoma as reported in 
the literature. 
 
6.2 Digital karyotyping of melanoma cell lines 
 
Digital karyotyping has been developed for a genome-wide analysis of DNA 
copy number alterations at high resolution (Wang et al., 2002). Since then, a small 
number of laboratories have demonstrated the remarkable power of digital 
karyotyping in detecting amplifications of several specific tumor-related genes in 
different cancer cell lines (Boon et al., 2005; Di et al., 2005; Park et al., 2006; Wang 
et al., 2004). In this work, two malignant melanoma cell lines were analyzed with the 
digital karyotyping technique in addition to CGH and M-FISH analyses. Thereby, a 
good correlation was observed between CGH and digital karyotyping concerning 
subchromosomal changes. However, as digital karyotyping allows for a much better 
resolution than CGH, additional subchromosomal changes of less than 10 Mbp were 
detected. In the cell line M2 a homozygous deletion of 1.9 Mbp containing the 
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CDKN2A locus was found, whereas in one of the two additional digital karyotyping 
experiments carried out by Alex Epanchintsev an even smaller homozygous deletion 
of 570 kbp located in the DMD gene was detected. 
With digital karyotyping it is not only possible to detect small scale genomic 
alterations, but with the completion of the sequencing of the human genome it is also 
possible to precisely map those tags that are over- or underrepresented and might 
correspond to regions containing novel oncogenes or tumor-suppressor genes. 
Currently, however, the resolution for the detection of gene dosage alterations is 
limited by the number of experimentally derived tags that can be sequenced 
economically. Wang et al. demonstrated that although the digital karyotyping shows 
exquisite sensitivity and specificity for detecting genomic amplifications and 
deletions, the positive predictive value of detection was significant only for resolutions 
of 0.1 Mbp for amplifications, 0.6 Mbp for homozygous deletions, and 4 Mbp for 
heterozygous deletions if 100,000 experimental tags were sequenced (Wang et al., 
2002). In accordance with those predictions a homozygous deletion of 250 kbp inside 
the p16INK4A gene in the cell line M3 was not detected by digital karyotyping. 
No high level amplifications could be observed in any of the malignant 
melanoma cell lines analyzed by digital karyotyping. Probable reasons could be the 
small number of libraries created or that in melanoma oncogenes are activated rather 
through point mutations than amplifications as in the case of BRAF (Davies et al., 
2002). 
 
6.3 Down-regulation of DMD in melanoma cell lines 
 
In primary melanocytes expression of the Dp427m, Dp116, and Dp71 
dystrophin isoforms was observed. The full-length Dp427m isoform normally shows 
strong expression in skeletal and cardiac muscle (Muntoni et al., 1995), and to a 
lesser extend in glial cells (Yaffe et al., 1992). So far, no full-length dystrophin 
isoform has been detected in non-muscle or non-neuronal tissues. Instead, in those 
tissues dystroglycan is linked to utrophin, a homolog of dystrophin (Haenggi and 
Fritschy, 2006) or shorter dystrophin isoforms (Jung et al., 1995; Saito et al., 1999). 
Dp116 is exclusively found in Schwann cells and seems to play an important role in 
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peripheral myelination (Comi et al., 1995). The shortest dystrophin isoform Dp71 is 
almost ubiquitously expressed except for skeletal muscle (Bar et al., 1990). In this 
work, the expression of dystrophin and dystroglycan has been described in 
melanocytes for the first time. Further experiments are needed to elucidate their 
function in this specific cell type. It can be speculated, that a dystroglycan complex 
binding the Dp427m isoform serves a similar purpose in melanocytes as in epithelial 
cells. However, no conclusions can be drawn concerning the function of the Dp116 
and Dp71 isoforms. Both isoforms lack the N-terminal actin-binding domain but retain 
the binding sites for dystroglycan, dystrobrevin, and syntrophin. Interestingly, in the 
majority of melanoma cell lines analyzed concomitant loss of the Dp427m and Dp116 
isoforms was observed, whereas Dp71 was expressed. 
The analysis of 55 melanoma cell lines by Alex Epanchintsev showed 
homozygous deletions in the DMD gene in three cases. As the DMD gene spans 
more than 2.5 Mbp it is one of the largest human genes and located close to or even 
inside the FRAXC region on Xp21.1. Almost half of the 20 largest human genes are 
located within common fragile site (CFS) regions, and because of their localization 
are uniquely susceptible to genomic instability such as occurs during the 
development of many different cancers (Smith et al., 2006). Several of the large CFS 
genes appear to function as tumor suppressors, even if they are not mutational 
targets in cancer, for example the FHIT gene in FRA3B (Druck et al., 1998; 
Vecchione et al., 2004), the WWOX gene in FRA16D (Bednarek et al., 2001; Driouch 
et al., 2002), or the Parkin gene in FRA6E (Wang et al., 2004). 
Arguing against a common genomic instability at the DMD locus is the fact, that 
although in a few publications homozygous deletions in the DMD gene have been 
described, they occurred with a much lower frequency than in the melanoma cell 
lines analyzed in this work and no conclusions can be drawn as to their effect on 
dystrophin expression. In a recent study, homozygous deletions within the DMD gene 
were detected in 2 of 636 (0.3%) cancer cell lines (Cox et al., 2005). Analysis of SNP 
genotype data obtained by the International HapMap Project identified an exon 
spanning deletion in DMD in 1 of 60 (1.7%) (Conrad et al., 2006) and a small intronic 
deletion in 1 of 269 genomes analyzed (0.4%) (McCarroll et al., 2006), but none of 
the deletions were verified by PCR. In contrast, the relatively high frequency of 3 
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homozygous deletions in 55 (5.5%) melanoma cell lines in the DMD gene suggests, 
that this might be a non-random event specific for melanoma progression. 
Furthermore, the expression of the full-length dystrophin protein is completely 
lost in 69% and significantly reduced in another 18% of melanoma cell lines. 
Sequencing of the respective cDNAs by Alex Epanchintsev did not reveal any 
nonsense mutations, which could mediate accelerated decay of the mRNA (Kerr et 
al., 2001). Also, the promoter regions of all 427 kD DMD isoforms do not contain any 
CpG islands, which may mediate silencing by hypermethylation. Therefore, further 
analyses are necessary to identify the mechanisms responsible for the loss of 
dystrophin expression in malignant melanoma cells without DMD deletions or 
nonsense mutations. In addition, it would be of interest to study expression of 
dystrophin at different stages of melanoma progression – from primary melanomas to 
RGP, VGP, and metastases. Unfortunately, until now it was not possible to visualize 
the dystrophin protein with immunohistochemical methods in primary melanocytes or 
melanoma samples probably due to its low expression level. 
The enhanced migration and invasiveness of melanoma cells observed after 
inactivation of dystrophin could be mediated through functional impairment of the 
dystroglycan complex. It has been shown, that reduction or absence of dystrophin 
protein concomitantly leads to loss of function of the dystroglycan complex (Ervasti et 
al., 1990), which plays important roles in adhesion (Ervasti and Campbell, 1993), 
basement membrane assembly (Durbeej et al., 1995), and epithelial polarization 
(Muschler et al., 2002) in a variety of cell types. Importantly, the alteration of 
dystroglycan function has been implicated not only in muscular dystrophies (Rando, 
2001) and neuronal disorders (Moore et al., 2002), but also in cancer progression 
(Henry et al., 2001). 
Reintroduction of dystrophin into melanoma cell lines in one case led to the 
opposite effect as down-regulation, namely decreased migration. In another cell line 
reintroduction of dystrophin induced a senescent phenotype, which is a phenomenon 
that has commonly been observed after introduction of tumor-suppressor genes into 
tumor cells (Schwarze et al., 2001; Xu et al., 1997). These results strongly suggest, 
that the DMD gene may play a role in the pathogenesis or progression of malignant 
melanoma. 
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Another means to link loss of dystrophin to melanoma development could be 
the analysis of epidemiological data from DMD patients or heterozygous female 
carriers. However, as male Duchenne Muscular Dystrophy patients die in their early 
twenties, it is difficult to determine whether an increased incidence of melanoma is 
linked to an inherited loss of dystrophin function. In addition, loss of dystrophin may 
be a late event during the progression of malignant melanoma and therefore its 
inherited loss may have no significant effect on the timing and frequency of 
melanoma occurrence. Analysis of the occurrence of melanoma in female carriers of 
a mutant DMD gene, which normally do not show a DMD phenotype, is complicated 
by the random inactivation of the X chromosome in the majority of cases. Also, 
analysis of the mdx mouse, which lacks full-length dystrophin, for a predisposition to 
melanoma is complicated by differences in DMD biology between mouse and human, 
as mdx mice only show a mild DMD phenotype compared to humans (Nowak and 
Davies, 2004). In addition, melanocyte biology and melanoma development 
significantly differ between humans and mice  (Yang et al., 2001). 
 
6.4 The dystrophin-glycoprotein complex in melanocytes and melanoma cell 
lines 
 
In striated muscle cells, three major functions can be assigned to the 
dystrophin-glycoprotein complex (DGC): (i) the actin binding domain of dystrophin or 
utrophin which links the complex to the cytoskeleton; (ii) the dystroglycans (DGs) with 
the transmembrane protein β-DG and the peripheral protein α-DG anchoring the 
DGC to the cell membrane and providing contact with the ECM; (iii) the binding sites 
to signaling proteins located on β-DG, syntrophin, and dystrobrevin (Ervasti and 
Campbell, 1993; Rando, 2001). 
In non-muscle tissues, the DGC typically contains fewer components 
associated with a short C-terminal isoform of dystrophin or with utrophin and is 
usually concentrated at membranes facing a basal lamina (Imamura et al., 2000). 
Although the functional role of non-muscle DGC needs to be clarified, there is 
compelling evidence for its involvement in adhesion (Ervasti and Campbell, 1993), 
basement membrane assembly (Durbeej et al., 1995), epithelial polarization 
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(Muschler et al., 2002), brain development (Nico et al., 2004), synapse formation and 
plasticity (Mehler, 2000), as well as water and ion homeostasis (Nicchia et al., 2004). 
In order to verify the existence of a dystrophin-glycoprotein complex in primary 
melanocytes and melanoma cell lines, the expression of several components of the 
DGC was analyzed. cDNA from primary melanocytes was examined by PCR and 
mRNAs encoding dystroglycan (DAG1; α- and β-dystroglycan are produced through 
post-translational cleavage from a single polypeptide), utrophin (UTRN), syntrophin 
β2 (SNTB2), β-sarcoglycan (SGCB), ε-sarcoglycan (SGCE), laminin-α2 (LAMA2), 
sarcospan (SSPN), and nitric oxide synthase 1 (neuronal) (NOS1) but not α-
dystrobrevin (DTNA) were detected. 
The expression of both dystrophin and utrophin suggests that different 
dystroglycan complexes could potentially be formed in melanocytes with either 
dystrophin or utrophin as intracellular binding partner for β-dystroglycan (James et 
al., 1996). It has been shown that binding of utrophin and dystrophin to dystroglycan 
is mutually exclusive and that both complexes are differentially localized in muscle 
and nerve cells, suggesting different functions (Bewick et al., 1992; Nguyen et al., 
1991). 
Two components of the sarcoglycan complex were found to be expressed, but 
no conclusions can be drawn as to the association of this complex with the DGC in 
melanocytes. It has been shown that in contrast to muscle cells both complexes are 
not associated in epithelial cells (Durbeej and Campbell, 1999). Likewise, sarcospan 
and NOS1 interact only indirectly with the dystroglycan complex. Sarcospan is 
associated with the DGC through its binding to the sarcoglycan complex in skeletal 
muscle (Crosbie et al., 1999) and smooth muscle (Coral-Vazquez et al., 1999), 
whereas NOS1 is associated with the DGC through interaction with syntrophin 
(Abdelmoity et al., 2000). On the other hand, all members of the syntrophin family 
interact with various members of the dystrophin family (including dystrophin, utrophin 
and dystrobrevin), with the binding being influenced by calmodulin (Newbell et al., 
1997) and phosphorylation of dystrophin (Michalak et al., 1996). Laminin-α2 is one of 
the three subunits of laminin-2, which serves as extracellular matrix substrate for α-
dystroglycan in muscle cells. But so far neither the DGC nor potential binding 
partners for α-dystroglycan have been analyzed in melanocytes. 
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In melanoma cell lines the expression of UTRN, DAG1, SGCB, SGCE, SNTB2, 
and LAMA2 was analyzed by PCR and compared to the levels in primary 
melanocytes. Thereby, significant changes in expression level were detected only for 
LAMA2, which was diminished or absent in 62% of melanoma cell lines significantly 
correlating with absence of dystrophin protein. Laminin-2 belongs to a family of at 
least 10 to 15 different laminin isoforms distinguished by their differences in subunit 
composition. Various laminins and their degradation products have been described to 
contribute to cancer progression by promoting cell adhesion or by regulating 
proteolytic cascades via matrix metalloproteases (MMPs) (Pasco et al., 2004; Tran et 
al., 2005). In a small number of melanoma cell lines expression of LAMA2 has been 
shown to promote cell adhesion and to correlate with a more metastatic phenotype 
(Jenq et al., 1994). In this work down-regulation of LAMA2 was observed. In addition, 
in melanoma cell lines with low or absent expression of dystrophin rapid attachment 
to fibronectin and to a lesser degree to laminin-1 was observed, but not to laminin-2 
(data not shown). As the functional consequences of down-regulation of LAMA2 were 
not investigated further, no final conclusions can be drawn. Also, it is not clear 
whether the DGC in melanoma cell lines preferentially binds to laminin-2 and to what 
extent other laminin receptors, for example integrins, contribute to melanocyte 
attachment. 
Localization of β-dystroglycan and dystrophin was evaluated by overexpression 
of both proteins in melanoma cell lines with and without endogenous dystrophin 
protein expression. Using confocal microscopy localization of both proteins to the cell 
membrane was observed. Due to low transfection efficiency of both plasmids into 
melanoma cell lines no co-localization studies could be performed. Nevertheless, in 
the literature interaction of dystrophin with β-dystroglycan has always been confirmed 
when both proteins were found to be expressed in the same tissue. Therefore, a 
functional dystrophin-dystroglycan complex is presumably present in melanocytes 
and melanoma cells, which could mediate interactions of melanocytes with 
extracellular matrix proteins of the basement membrane. 
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7 SUMMARY 
 
Malignant melanoma is a highly metastatic cancer whose incidence has 
increased markedly over the past decade in the white skinned population. Only a few 
genes have been shown to predispose to melanoma or to contribute to melanoma 
development and progression. To identify additional genetic alterations, several 
whole-genome analyses were applied to a panel of malignant melanoma cell lines. 
First, M-FISH and CGH analyses were carried out to gain a general overview of 
genomic, structural and numerical aberrations. Thereby, chromosomal alterations 
commonly found in melanoma were detected. Most frequently, overrepresentation of 
chromosomes 1q, 6p, 7, 20, 22, and X together with underrepresentation of 
chromosomes 6q, 9p, and 10q were observed. In addition, high-level amplifications 
of C-MYC, hTERT, and AKT3 together with frequent loss of p16INK4A were 
identified and confirmed by PCR. 
In order to detect additional single-gene genetic alterations, the digital 
karyotyping technique was employed. With this method, two digital karyotyping 
libraries were generated each comprising ~100,000 sequence tags. Thereby, a 
homozygous deletion of the CDKN2A locus was identified in the cell line M2. In 
additional digital karyotyping analyses by Alex Epanchintsev a homozygous deletion 
inside the DMD gene was observed in the melanoma cell line M1. By genomic PCR 
analysis, carried out by Alex Epanchintsev, two additional deletions, one 
homozygous and one hemizygous, were identified in the DMD gene in a total of 55 
melanoma cell lines. 
To evaluate the relevance of this finding, primary melanocytes were analyzed for 
the expression of DMD mRNA. RT-PCR analysis confirmed expression of the 
Dp427m, Dp116, and Dp71 DMD isoforms. In addition to homozygous deletion of 
DMD, the Dp427 protein was absent in 69% and present at very low levels in 18% of 
melanoma cell lines. This correlated well with DMD mRNA expression analyzed in a 
subset of melanoma cell lines. Furthermore, there was a concomitant loss of 
expression of the Dp116 and Dp427 isoforms in melanoma cell lines, whereas 
expression of Dp71 remained unchanged. 
In all tissues analyzed, dystrophin normally resides at the cell membrane in a 
complex with dystroglycans and F-actin, thereby providing a link between 
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extracellular matrix components and the intracellular cytoskeleton. Several 
components of this dystrophin-glycoprotein complex (DGC) were analyzed in primary 
melanocytes and expression of dystroglycan, utrophin, syntrophin-β2, β- and ε-
sarcoglycan, laminin-α2, sarcospan, and nitric oxide synthase 1 could be confirmed. 
As loss of dystrophin frequently leads to down-regulation of components of the DGC, 
their expression was also analyzed in melanoma cell lines. Thereby, down-regulation 
of laminin-α2 was observed which significantly correlated with loss of dystrophin 
protein. 
In order to evaluate functional consequences of loss of dystrophin, short hairpin 
RNAs directed against DMD were stably expressed in the melanoma cell lines M7 
and C-32. Upon down-regulation of DMD by RNA interference, clones of both cell 
lines showed enhanced migration and invasion compared to control clones. In 
addition, dystrophin was stably re-expressed in the cell lines WM-793 and RPMI-
7951, which were characterized by homozygous deletion of several exons of this 
gene. In both cell lines morphological changes were observed; cells became 
flattened and increased in size, displaying a senescent phenotype. This was 
accompanied with a higher rate of apoptosis and reduced proliferation in the cell line 
RPMI-7951. Also, in the cell line WM-793 migration was reduced. Taken together, 
these results suggest that the loss of dystrophin expression might be involved in the 
pathogenesis or progression of malignant melanoma. 
 
REFERENCES 
 
 
98 
8 REFERENCES 
 
Abdelmoity, A., Padre, R. C., Burzynski, K. E., Stull, J. T., and Lau, K. S. (2000). 
Neuronal nitric oxide synthase localizes through multiple structural motifs to the 
sarcolemma in mouse myotubes. FEBS Lett 482, 65-70. 
Aitken, J., Welch, J., Duffy, D., Milligan, A., Green, A., Martin, N., and Hayward, N. 
(1999). CDKN2A variants in a population-based sample of Queensland families with 
melanoma. J Natl Cancer Inst 91, 446-452. 
Albino, A. P., Nanus, D. M., Mentle, I. R., Cordon-Cardo, C., McNutt, N. S., Bressler, 
J., and Andreeff, M. (1989). Analysis of ras oncogenes in malignant melanoma and 
precursor lesions: correlation of point mutations with differentiation phenotype. 
Oncogene 4, 1363-1374. 
Anderson, J. T., Rogers, R. P., and Jarrett, H. W. (1996). Ca2+-calmodulin binds to 
the carboxyl-terminal domain of dystrophin. J Biol Chem 271, 6605-6610. 
Armstrong, B. K., and Kricker, A. (1993). How much melanoma is caused by sun 
exposure? Melanoma Res 3, 395-401. 
Armstrong, B. K., and Kricker, A. (2001). The epidemiology of UV induced skin 
cancer. J Photochem Photobiol B 63, 8-18. 
Arning, L., Jagiello, P., Schara, U., Vorgerd, M., Dahmen, N., Gencikova, A., Mortier, 
W., Epplen, J. T., and Gencik, M. (2004). Transcriptional profiles from patients with 
dystrophinopathies and limb girdle muscular dystrophies as determined by qRT-PCR. 
J Neurol 251, 72-78. 
Azofeifa, J., Fauth, C., Kraus, J., Maierhofer, C., Langer, S., Bolzer, A., Reichman, J., 
Schuffenhauer, S., and Speicher, M. R. (2000). An optimized probe set for the 
detection of small interchromosomal aberrations by use of 24-color FISH. Am J Hum 
Genet 66, 1684-1688. 
REFERENCES 
 
 
99 
Bai, C., Connolly, B., Metzker, M. L., Hilliard, C. A., Liu, X., Sandig, V., Soderman, A., 
Galloway, S. M., Liu, Q., Austin, C. P., and Caskey, C. T. (2000). Overexpression of 
M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification 
and its location in a four-gene cluster. Proc Natl Acad Sci U S A 97, 1230-1235. 
Balazs, M., Adam, Z., Treszl, A., Begany, A., Hunyadi, J., and Adany, R. (2001). 
Chromosomal imbalances in primary and metastatic melanomas revealed by 
comparative genomic hybridization. Cytometry 46, 222-232. 
Bar, S., Barnea, E., Levy, Z., Neuman, S., Yaffe, D., and Nudel, U. (1990). A novel 
product of the Duchenne muscular dystrophy gene which greatly differs from the 
known isoforms in its structure and tissue distribution. Biochem J 272, 557-560. 
Barks, J. H., Thompson, F. H., Taetle, R., Yang, J. M., Stone, J. F., Wymer, J. A., 
Khavari, R., Guan, X. Y., Trent, J. M., Pinkel, D., and Nelson, M. A. (1997). Increased 
chromosome 20 copy number detected by fluorescence in situ hybridization (FISH) in 
malignant melanoma. Genes Chromosomes Cancer 19, 278-285. 
Barnhill, R. L., Xiao, M., Graves, D., and Antoniades, H. N. (1996). Expression of 
platelet-derived growth factor (PDGF)-A, PDGF-B and the PDGF-alpha receptor, but 
not the PDGF-beta receptor, in human malignant melanoma in vivo. Br J Dermatol 
135, 898-904. 
Bastian, B. C., Kashani-Sabet, M., Hamm, H., Godfrey, T., Moore, D. H., 2nd, 
Brocker, E. B., LeBoit, P. E., and Pinkel, D. (2000). Gene amplifications characterize 
acral melanoma and permit the detection of occult tumor cells in the surrounding 
skin. Cancer Res 60, 1968-1973. 
Bastian, B. C., LeBoit, P. E., Hamm, H., Brocker, E. B., and Pinkel, D. (1998). 
Chromosomal gains and losses in primary cutaneous melanomas detected by 
comparative genomic hybridization. Cancer Res 58, 2170-2175. 
REFERENCES 
 
 
100
Bastian, B. C., Olshen, A. B., LeBoit, P. E., and Pinkel, D. (2003). Classifying 
melanocytic tumors based on DNA copy number changes. Am J Pathol 163, 1765-
1770. 
Bataille, V., Bishop, J. A., Sasieni, P., Swerdlow, A. J., Pinney, E., Griffiths, K., and 
Cuzick, J. (1996). Risk of cutaneous melanoma in relation to the numbers, types and 
sites of naevi: a case-control study. Br J Cancer 73, 1605-1611. 
Bednarek, A. K., Keck-Waggoner, C. L., Daniel, R. L., Laflin, K. J., Bergsagel, P. L., 
Kiguchi, K., Brenner, A. J., and Aldaz, C. M. (2001). WWOX, the FRA16D gene, 
behaves as a suppressor of tumor growth. Cancer Res 61, 8068-8073. 
Beggs, A. H., Koenig, M., Boyce, F. M., and Kunkel, L. M. (1990). Detection of 98% 
of DMD/BMD gene deletions by polymerase chain reaction. Hum Genet 86, 45-48. 
Bentz, M., Huck, K., du Manoir, S., Joos, S., Werner, C. A., Fischer, K., Dohner, H., 
and Lichter, P. (1995). Comparative genomic hybridization in chronic B-cell 
leukemias shows a high incidence of chromosomal gains and losses. Blood 85, 
3610-3618. 
Bentz, M., Plesch, A., Stilgenbauer, S., Dohner, H., and Lichter, P. (1998). Minimal 
sizes of deletions detected by comparative genomic hybridization. Genes 
Chromosomes Cancer 21, 172-175. 
Bewick, G. S., Nicholson, L. V., Young, C., O'Donnell, E., and Slater, C. R. (1992). 
Different distributions of dystrophin and related proteins at nerve-muscle junctions. 
Neuroreport 3, 857-860. 
Bies, R. D., Friedman, D., Roberts, R., Perryman, M. B., and Caskey, C. T. (1992). 
Expression and localization of dystrophin in human cardiac Purkinje fibers. 
Circulation 86, 147-153. 
Bies, R. D., Phelps, S. F., Cortez, M. D., Roberts, R., Caskey, C. T., and 
Chamberlain, J. S. (1992). Human and murine dystrophin mRNA transcripts are 
REFERENCES 
 
 
101
differentially expressed during skeletal muscle, heart, and brain development. Nucleic 
Acids Res 20, 1725-1731. 
Blake, D. J., Tinsley, J. M., Davies, K. E., Knight, A. E., Winder, S. J., and Kendrick-
Jones, J. (1995). Coiled-coil regions in the carboxy-terminal domains of dystrophin 
and related proteins: potentials for protein-protein interactions. Trends Biochem Sci 
20, 133-135. 
Blake, D. J., Weir, A., Newey, S. E., and Davies, K. E. (2002). Function and genetics 
of dystrophin and dystrophin-related proteins in muscle. Physiol Rev 82, 291-329. 
Boon, K., Eberhart, C. G., and Riggins, G. J. (2005). Genomic amplification of 
orthodenticle homologue 2 in medulloblastomas. Cancer Res 65, 703-707. 
Bottaro, D. P., Rubin, J. S., Faletto, D. L., Chan, A. M., Kmiecik, T. E., Vande Woude, 
G. F., and Aaronson, S. A. (1991). Identification of the hepatocyte growth factor 
receptor as the c-met proto-oncogene product. Science 251, 802-804. 
Box, N. F., Duffy, D. L., Chen, W., Stark, M., Martin, N. G., Sturm, R. A., and 
Hayward, N. K. (2001). MC1R genotype modifies risk of melanoma in families 
segregating CDKN2A mutations. Am J Hum Genet 69, 765-773. 
Brenman, J. E., Chao, D. S., Gee, S. H., McGee, A. W., Craven, S. E., Santillano, D. 
R., Wu, Z., Huang, F., Xia, H., Peters, M. F., et al. (1996). Interaction of nitric oxide 
synthase with the postsynaptic density protein PSD-95 and alpha1-syntrophin 
mediated by PDZ domains. Cell 84, 757-767. 
Brose, M. S., Volpe, P., Feldman, M., Kumar, M., Rishi, I., Gerrero, R., Einhorn, E., 
Herlyn, M., Minna, J., Nicholson, A., et al. (2002). BRAF and RAS mutations in 
human lung cancer and melanoma. Cancer Res 62, 6997-7000. 
Brummelkamp, T. R., Bernards, R., and Agami, R. (2002). A system for stable 
expression of short interfering RNAs in mammalian cells. Science 296, 550-553. 
REFERENCES 
 
 
102
Busca, R., Abbe, P., Mantoux, F., Aberdam, E., Peyssonnaux, C., Eychene, A., 
Ortonne, J. P., and Ballotti, R. (2000). Ras mediates the cAMP-dependent activation 
of extracellular signal-regulated kinases (ERKs) in melanocytes. Embo J 19, 2900-
2910. 
Busca, R., and Ballotti, R. (2000). Cyclic AMP a key messenger in the regulation of 
skin pigmentation. Pigment Cell Res 13, 60-69. 
Byers, T. J., Lidov, H. G., and Kunkel, L. M. (1993). An alternative dystrophin 
transcript specific to peripheral nerve. Nat Genet 4, 77-81. 
Campbell, K. P., and Kahl, S. D. (1989). Association of dystrophin and an integral 
membrane glycoprotein. Nature 338, 259-262. 
Carreira, S., Goodall, J., Aksan, I., La Rocca, S. A., Galibert, M. D., Denat, L., Larue, 
L., and Goding, C. R. (2005). Mitf cooperates with Rb1 and activates p21Cip1 
expression to regulate cell cycle progression. Nature 433, 764-769. 
Caspersson, T., Farber, S., Foley, G. E., Kudynowski, J., Modest, E. J., Simonsson, 
E., Wagh, U., and Zech, L. (1968). Chemical differentiation along metaphase 
chromosomes. Exp Cell Res 49, 219-222. 
Caspersson, T., Zech, L., and Johansson, C. (1970). Analysis of human metaphase 
chromosome set by aid of DNA-binding fluorescent agents. Exp Cell Res 62, 490-
492. 
Castellano, M., Pollock, P. M., Walters, M. K., Sparrow, L. E., Down, L. M., Gabrielli, 
B. G., Parsons, P. G., and Hayward, N. K. (1997). CDKN2A/p16 is inactivated in 
most melanoma cell lines. Cancer Res 57, 4868-4875. 
Chapdelaine, P., Moisset, P. A., Campeau, P., Asselin, I., Vilquin, J. T., and 
Tremblay, J. P. (2000). Functional EGFP-dystrophin fusion proteins for gene therapy 
vector development. Protein Eng 13, 611-615. 
REFERENCES 
 
 
103
Chin, L., Pomerantz, J., Polsky, D., Jacobson, M., Cohen, C., Cordon-Cardo, C., 
Horner, J. W., 2nd, and DePinho, R. A. (1997). Cooperative effects of INK4a and ras 
in melanoma susceptibility in vivo. Genes Dev 11, 2822-2834. 
Chung, W., and Campanelli, J. T. (1999). WW and EF hand domains of dystrophin-
family proteins mediate dystroglycan binding. Mol Cell Biol Res Commun 2, 162-171. 
Cohen, C., Zavala-Pompa, A., Sequeira, J. H., Shoji, M., Sexton, D. G., Cotsonis, G., 
Cerimele, F., Govindarajan, B., Macaron, N., and Arbiser, J. L. (2002). Mitogen-
actived protein kinase activation is an early event in melanoma progression. Clin 
Cancer Res 8, 3728-3733. 
Comi, G. P., Ciafaloni, E., de Silva, H. A., Prelle, A., Bardoni, A., Rigoletto, C., 
Robotti, M., Bresolin, N., Moggio, M., and Fortunato, F. (1995). A G+1-->A 
transversion at the 5' splice site of intron 69 of the dystrophin gene causing the 
absence of peripheral nerve Dp116 and severe clinical involvement in a DMD patient. 
Hum Mol Genet 4, 2171-2174. 
Comi, G. P., Prelle, A., Bresolin, N., Moggio, M., Bardoni, A., Gallanti, A., Vita, G., 
Toscano, A., Ferro, M. T., Bordoni, A., and et al. (1994). Clinical variability in Becker 
muscular dystrophy. Genetic, biochemical and immunohistochemical correlates. 
Brain 117 (Pt 1), 1-14. 
Conrad, D. F., Andrews, T. D., Carter, N. P., Hurles, M. E., and Pritchard, J. K. 
(2006). A high-resolution survey of deletion polymorphism in the human genome. Nat 
Genet 38, 75-81. 
Coral-Vazquez, R., Cohn, R. D., Moore, S. A., Hill, J. A., Weiss, R. M., Davisson, R. 
L., Straub, V., Barresi, R., Bansal, D., Hrstka, R. F., et al. (1999). Disruption of the 
sarcoglycan-sarcospan complex in vascular smooth muscle: a novel mechanism for 
cardiomyopathy and muscular dystrophy. Cell 98, 465-474. 
REFERENCES 
 
 
104
Cox, C., Bignell, G., Greenman, C., Stabenau, A., Warren, W., Stephens, P., Davies, 
H., Watt, S., Teague, J., Edkins, S., et al. (2005). A survey of homozygous deletions 
in human cancer genomes. Proc Natl Acad Sci U S A 102, 4542-4547. 
Crawford, G. E., Faulkner, J. A., Crosbie, R. H., Campbell, K. P., Froehner, S. C., 
and Chamberlain, J. S. (2000). Assembly of the dystrophin-associated protein 
complex does not require the dystrophin COOH-terminal domain. J Cell Biol 150, 
1399-1410. 
Cremer, T., Lichter, P., Borden, J., Ward, D. C., and Manuelidis, L. (1988). Detection 
of chromosome aberrations in metaphase and interphase tumor cells by in situ 
hybridization using chromosome-specific library probes. Hum Genet 80, 235-246. 
Crosbie, R. H., Lebakken, C. S., Holt, K. H., Venzke, D. P., Straub, V., Lee, J. C., 
Grady, R. M., Chamberlain, J. S., Sanes, J. R., and Campbell, K. P. (1999). 
Membrane targeting and stabilization of sarcospan is mediated by the sarcoglycan 
subcomplex. J Cell Biol 145, 153-165. 
D'Souza, V. N., Nguyen, T. M., Morris, G. E., Karges, W., Pillers, D. A., and Ray, P. 
N. (1995). A novel dystrophin isoform is required for normal retinal electrophysiology. 
Hum Mol Genet 4, 837-842. 
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., 
Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002). Mutations of the BRAF 
gene in human cancer. Nature 417, 949-954. 
Demunter, A., Stas, M., Degreef, H., De Wolf-Peeters, C., and van den Oord, J. J. 
(2001). Analysis of N- and K-ras mutations in the distinctive tumor progression 
phases of melanoma. J Invest Dermatol 117, 1483-1489. 
Dhawan, P., Singh, A. B., Ellis, D. L., and Richmond, A. (2002). Constitutive 
activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear 
factor-kappaB and tumor progression. Cancer Res 62, 7335-7342. 
REFERENCES 
 
 
105
Di, C., Liao, S., Adamson, D. C., Parrett, T. J., Broderick, D. K., Shi, Q., Lengauer, 
C., Cummins, J. M., Velculescu, V. E., Fults, D. W., et al. (2005). Identification of 
OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans 
retinoic acid. Cancer Res 65, 919-924. 
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., 
Linskens, M., Rubelj, I., Pereira-Smith, O., and et al. (1995). A biomarker that 
identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad 
Sci U S A 92, 9363-9367. 
Ding, H., Schertzer, M., Wu, X., Gertsenstein, M., Selig, S., Kammori, M., Pourvali, 
R., Poon, S., Vulto, I., Chavez, E., et al. (2004). Regulation of murine telomere length 
by Rtel: an essential gene encoding a helicase-like protein. Cell 117, 873-886. 
Driouch, K., Prydz, H., Monese, R., Johansen, H., Lidereau, R., and Frengen, E. 
(2002). Alternative transcripts of the candidate tumor suppressor gene, WWOX, are 
expressed at high levels in human breast tumors. Oncogene 21, 1832-1840. 
Druck, T., Berk, L., and Huebner, K. (1998). FHITness and cancer. Oncol Res 10, 
341-345. 
Du, J., Widlund, H. R., Horstmann, M. A., Ramaswamy, S., Ross, K., Huber, W. E., 
Nishimura, E. K., Golub, T. R., and Fisher, D. E. (2004). Critical role of CDK2 for 
melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. 
Cancer Cell 6, 565-576. 
du Manoir, S., Speicher, M. R., Joos, S., Schrock, E., Popp, S., Dohner, H., Kovacs, 
G., Robert-Nicoud, M., Lichter, P., and Cremer, T. (1993). Detection of complete and 
partial chromosome gains and losses by comparative genomic in situ hybridization. 
Hum Genet 90, 590-610. 
Durbeej, M., and Campbell, K. P. (1999). Biochemical characterization of the 
epithelial dystroglycan complex. J Biol Chem 274, 26609-26616. 
REFERENCES 
 
 
106
Durbeej, M., Jung, D., Hjalt, T., Campbell, K. P., and Ekblom, P. (1997). Transient 
expression of Dp140, a product of the Duchenne muscular dystrophy locus, during 
kidney tubulogenesis. Dev Biol 181, 156-167. 
Durbeej, M., Larsson, E., Ibraghimov-Beskrovnaya, O., Roberds, S. L., Campbell, K. 
P., and Ekblom, P. (1995). Non-muscle alpha-dystroglycan is involved in epithelial 
development. J Cell Biol 130, 79-91. 
Emery, A. E. H. (1993). Duchenne Muscular Dystrophy, 2nd edition edn (Oxford: 
Oxford University Press). 
Ervasti, J. M., and Campbell, K. P. (1991). Membrane organization of the dystrophin-
glycoprotein complex. Cell 66, 1121-1131. 
Ervasti, J. M., and Campbell, K. P. (1993). A role for the dystrophin-glycoprotein 
complex as a transmembrane linker between laminin and actin. J Cell Biol 122, 809-
823. 
Ervasti, J. M., Ohlendieck, K., Kahl, S. D., Gaver, M. G., and Campbell, K. P. (1990). 
Deficiency of a glycoprotein component of the dystrophin complex in dystrophic 
muscle. Nature 345, 315-319. 
Fauth, C., Zhang, H., Harabacz, S., Brown, J., Saracoglu, K., Lederer, G., Rittinger, 
O., Rost, I., Eils, R., Kearney, L., and Speicher, M. R. (2001). A new strategy for the 
detection of subtelomeric rearrangements. Hum Genet 109, 576-583. 
Feener, C. A., Koenig, M., and Kunkel, L. M. (1989). Alternative splicing of human 
dystrophin mRNA generates isoforms at the carboxy terminus. Nature 338, 509-511. 
Fountain, J. W., Bale, S. J., Housman, D. E., and Dracopoli, N. C. (1990). Genetics of 
melanoma. Cancer Surv 9, 645-671. 
Friedberg, E. C. (2003). DNA damage and repair. Nature 421, 436-440. 
REFERENCES 
 
 
107
Gardner, R. J., Bobrow, M., and Roberts, R. G. (1995). The identification of point 
mutations in Duchenne muscular dystrophy patients by using reverse-transcription 
PCR and the protein truncation test. Am J Hum Genet 57, 311-320. 
Gavet, O., Ozon, S., Manceau, V., Lawler, S., Curmi, P., and Sobel, A. (1998). The 
stathmin phosphoprotein family: intracellular localization and effects on the 
microtubule network. J Cell Sci 111 (Pt 22), 3333-3346. 
Gee, S. H., Montanaro, F., Lindenbaum, M. H., and Carbonetto, S. (1994). 
Dystroglycan-alpha, a dystrophin-associated glycoprotein, is a functional agrin 
receptor. Cell 77, 675-686. 
Glaessl, A., Bosserhoff, A. K., Buettner, R., Hohenleutner, U., Landthaler, M., and 
Stolz, W. (1999). Increase in telomerase activity during progression of melanocytic 
cells from melanocytic naevi to malignant melanomas. Arch Dermatol Res 291, 81-
87. 
Goldstein, A. M., Struewing, J. P., Chidambaram, A., Fraser, M. C., and Tucker, M. 
A. (2000). Genotype-phenotype relationships in U.S. melanoma-prone families with 
CDKN2A and CDK4 mutations. J Natl Cancer Inst 92, 1006-1010. 
Gorecki, D. C., Monaco, A. P., Derry, J. M., Walker, A. P., Barnard, E. A., and 
Barnard, P. J. (1992). Expression of four alternative dystrophin transcripts in brain 
regions regulated by different promoters. Hum Mol Genet 1, 505-510. 
Grange, F., Chompret, A., Guilloud-Bataille, M., Guillaume, J. C., Margulis, A., Prade, 
M., Demenais, F., and Avril, M. F. (1995). Comparison between familial and 
nonfamilial melanoma in France. Arch Dermatol 131, 1154-1159. 
Guan, X. Y., Xu, J., Anzick, S. L., Zhang, H., Trent, J. M., and Meltzer, P. S. (1996). 
Hybrid selection of transcribed sequences from microdissected DNA: isolation of 
genes within amplified region at 20q11-q13.2 in breast cancer. Cancer Res 56, 3446-
3450. 
REFERENCES 
 
 
108
Guldberg, P., thor Straten, P., Birck, A., Ahrenkiel, V., Kirkin, A. F., and Zeuthen, J. 
(1997). Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent 
event in malignant melanoma. Cancer Res 57, 3660-3663. 
Haenggi, T., and Fritschy, J. M. (2006). Role of dystrophin and utrophin for assembly 
and function of the dystrophin glycoprotein complex in non-muscle tissue. Cell Mol 
Life Sci. 
Halaban, R., Rubin, J. S., Funasaka, Y., Cobb, M., Boulton, T., Faletto, D., Rosen, 
E., Chan, A., Yoko, K., White, W., and et al. (1992). Met and hepatocyte growth 
factor/scatter factor signal transduction in normal melanocytes and melanoma cells. 
Oncogene 7, 2195-2206. 
Hanahan, D., and Weinberg, R. A. (2000). The hallmarks of cancer. Cell 100, 57-70. 
Healy, E., Flannagan, N., Ray, A., Todd, C., Jackson, I. J., Matthews, J. N., Birch-
Machin, M. A., and Rees, J. L. (2000). Melanocortin-1-receptor gene and sun 
sensitivity in individuals without red hair. Lancet 355, 1072-1073. 
Healy, E., Sikkink, S., and Rees, J. L. (1996). Infrequent mutation of p16INK4 in 
sporadic melanoma. J Invest Dermatol 107, 318-321. 
Henry, M. D., and Campbell, K. P. (1998). A role for dystroglycan in basement 
membrane assembly. Cell 95, 859-870. 
Henry, M. D., Cohen, M. B., and Campbell, K. P. (2001). Reduced expression of 
dystroglycan in breast and prostate cancer. Hum Pathol 32, 791-795. 
Herzog, C., Has, C., Franzke, C. W., Echtermeyer, F. G., Schlotzer-Schrehardt, U., 
Kroger, S., Gustafsson, E., Fassler, R., and Bruckner-Tuderman, L. (2004). 
Dystroglycan in skin and cutaneous cells: beta-subunit is shed from the cell surface. 
J Invest Dermatol 122, 1372-1380. 
REFERENCES 
 
 
109
Hildebrandt, T., van Dijk, M. C., van Muijen, G. N., and Weidle, U. H. (2001). Loss of 
heterozygosity of gene THW is frequently found in melanoma metastases. Anticancer 
Res 21, 1071-1080. 
Hoeijmakers, J. H. (2001). Genome maintenance mechanisms for preventing cancer. 
Nature 411, 366-374. 
Hoglund, M., Gisselsson, D., Hansen, G. B., White, V. A., Sall, T., Mitelman, F., and 
Horsman, D. (2004). Dissecting karyotypic patterns in malignant melanomas: 
temporal clustering of losses and gains in melanoma karyotypic evolution. Int J 
Cancer 108, 57-65. 
Hsu, M. Y., Meier, F., and Herlyn, M. (2002). Melanoma development and 
progression: a conspiracy between tumor and host. Differentiation 70, 522-536. 
Hsu, M. Y., Wheelock, M. J., Johnson, K. R., and Herlyn, M. (1996). Shifts in 
cadherin profiles between human normal melanocytes and melanomas. J Investig 
Dermatol Symp Proc 1, 188-194. 
Hugnot, J. P., Gilgenkrantz, H., Vincent, N., Chafey, P., Morris, G. E., Monaco, A. P., 
Berwald-Netter, Y., Koulakoff, A., Kaplan, J. C., Kahn, A., and et al. (1992). Distal 
transcript of the dystrophin gene initiated from an alternative first exon and encoding 
a 75-kDa protein widely distributed in nonmuscle tissues. Proc Natl Acad Sci U S A 
89, 7506-7510. 
Hussussian, C. J., Struewing, J. P., Goldstein, A. M., Higgins, P. A., Ally, D. S., 
Sheahan, M. D., Clark, W. H., Jr., Tucker, M. A., and Dracopoli, N. C. (1994). 
Germline p16 mutations in familial melanoma. Nat Genet 8, 15-21. 
Hwang, P. H., Yi, H. K., Kim, D. S., Nam, S. Y., Kim, J. S., and Lee, D. Y. (2001). 
Suppression of tumorigenicity and metastasis in B16F10 cells by 
PTEN/MMAC1/TEP1 gene. Cancer Lett 172, 83-91. 
REFERENCES 
 
 
110
Ibraghimov-Beskrovnaya, O., Ervasti, J. M., Leveille, C. J., Slaughter, C. A., Sernett, 
S. W., and Campbell, K. P. (1992). Primary structure of dystrophin-associated 
glycoproteins linking dystrophin to the extracellular matrix. Nature 355, 696-702. 
Ibraghimov-Beskrovnaya, O., Milatovich, A., Ozcelik, T., Yang, B., Koepnick, K., 
Francke, U., and Campbell, K. P. (1993). Human dystroglycan: skeletal muscle 
cDNA, genomic structure, origin of tissue specific isoforms and chromosomal 
localization. Hum Mol Genet 2, 1651-1657. 
Imamura, M., Araishi, K., Noguchi, S., and Ozawa, E. (2000). A sarcoglycan-
dystroglycan complex anchors Dp116 and utrophin in the peripheral nervous system. 
Hum Mol Genet 9, 3091-3100. 
Isola, J. J., Kallioniemi, O. P., Chu, L. W., Fuqua, S. A., Hilsenbeck, S. G., Osborne, 
C. K., and Waldman, F. M. (1995). Genetic aberrations detected by comparative 
genomic hybridization predict outcome in node-negative breast cancer. Am J Pathol 
147, 905-911. 
Jafari, M., Papp, T., Kirchner, S., Diener, U., Henschler, D., Burg, G., and 
Schiffmann, D. (1995). Analysis of ras mutations in human melanocytic lesions: 
activation of the ras gene seems to be associated with the nodular type of human 
malignant melanoma. J Cancer Res Clin Oncol 121, 23-30. 
James, M., Nguyen, T. M., Wise, C. J., Jones, G. E., and Morris, G. E. (1996). 
Utrophin-dystroglycan complex in membranes of adherent cultured cells. Cell Motil 
Cytoskeleton 33, 163-174. 
Jennekens, F. G., ten Kate, L. P., de Visser, M., and Wintzen, A. R. (1991). 
Diagnostic criteria for Duchenne and Becker muscular dystrophy and myotonic 
dystrophy. Neuromuscul Disord 1, 389-391. 
Jenq, W., Wu, S. J., and Kefalides, N. A. (1994). Expression of the alpha 2-subunit of 
laminin correlates with increased cell adhesion and metastatic propensity. 
Differentiation 58, 29-36. 
REFERENCES 
 
 
111
Johnson, G. L., and Lapadat, R. (2002). Mitogen-activated protein kinase pathways 
mediated by ERK, JNK, and p38 protein kinases. Science 298, 1911-1912. 
Jones, P. A., and Baylin, S. B. (2002). The fundamental role of epigenetic events in 
cancer. Nat Rev Genet 3, 415-428. 
Jung, D., Yang, B., Meyer, J., Chamberlain, J. S., and Campbell, K. P. (1995). 
Identification and characterization of the dystrophin anchoring site on beta-
dystroglycan. J Biol Chem 270, 27305-27310. 
Kallioniemi, A., Kallioniemi, O. P., Sudar, D., Rutovitz, D., Gray, J. W., Waldman, F., 
and Pinkel, D. (1992). Comparative genomic hybridization for molecular cytogenetic 
analysis of solid tumors. Science 258, 818-821. 
Keller-Melchior, R., Schmidt, R., and Piepkorn, M. (1998). Expression of the tumor 
suppressor gene product p16INK4 in benign and malignant melanocytic lesions. J 
Invest Dermatol 110, 932-938. 
Kerr, T. P., Sewry, C. A., Robb, S. A., and Roberts, R. G. (2001). Long mutant 
dystrophins and variable phenotypes: evasion of nonsense-mediated decay? Hum 
Genet 109, 402-407. 
Koenig, M., Beggs, A. H., Moyer, M., Scherpf, S., Heindrich, K., Bettecken, T., Meng, 
G., Muller, C. R., Lindlof, M., Kaariainen, H., and et al. (1989). The molecular basis 
for Duchenne versus Becker muscular dystrophy: correlation of severity with type of 
deletion. Am J Hum Genet 45, 498-506. 
Koenig, M., and Kunkel, L. M. (1990). Detailed analysis of the repeat domain of 
dystrophin reveals four potential hinge segments that may confer flexibility. J Biol 
Chem 265, 4560-4566. 
Koenig, M., Monaco, A. P., and Kunkel, L. M. (1988). The complete sequence of 
dystrophin predicts a rod-shaped cytoskeletal protein. Cell 53, 219-226. 
REFERENCES 
 
 
112
Koprowski, H., Herlyn, M., Balaban, G., Parmiter, A., Ross, A., and Nowell, P. (1985). 
Expression of the receptor for epidermal growth factor correlates with increased 
dosage of chromosome 7 in malignant melanoma. Somat Cell Mol Genet 11, 297-
302. 
Kraehn, G. M., Utikal, J., Udart, M., Greulich, K. M., Bezold, G., Kaskel, P., Leiter, U., 
and Peter, R. U. (2001). Extra c-myc oncogene copies in high risk cutaneous 
malignant melanoma and melanoma metastases. Br J Cancer 84, 72-79. 
Kraemer, K. H., and Greene, M. H. (1985). Dysplastic nevus syndrome. Familial and 
sporadic precursors of cutaneous melanoma. Dermatol Clin 3, 225-237. 
Krimpenfort, P., Quon, K. C., Mooi, W. J., Loonstra, A., and Berns, A. (2001). Loss of 
p16Ink4a confers susceptibility to metastatic melanoma in mice. Nature 413, 83-86. 
Kumar, R., Sauroja, I., Punnonen, K., Jansen, C., and Hemminki, K. (1998). Selective 
deletion of exon 1 beta of the p19ARF gene in metastatic melanoma cell lines. Genes 
Chromosomes Cancer 23, 273-277. 
Kumar, R., Smeds, J., Berggren, P., Straume, O., Rozell, B. L., Akslen, L. A., and 
Hemminki, K. (2001). A single nucleotide polymorphism in the 3'untranslated region 
of the CDKN2A gene is common in sporadic primary melanomas but mutations in the 
CDKN2B, CDKN2C, CDK4 and p53 genes are rare. Int J Cancer 95, 388-393. 
Lederfein, D., Levy, Z., Augier, N., Mornet, D., Morris, G., Fuchs, O., Yaffe, D., and 
Nudel, U. (1992). A 71-kilodalton protein is a major product of the Duchenne 
muscular dystrophy gene in brain and other nonmuscle tissues. Proc Natl Acad Sci U 
S A 89, 5346-5350. 
Lengauer, C., Kinzler, K. W., and Vogelstein, B. (1998). Genetic instabilities in human 
cancers. Nature 396, 643-649. 
Lengauer, C., Speicher, M. R., Popp, S., Jauch, A., Taniwaki, M., Nagaraja, R., 
Riethman, H. C., Donis-Keller, H., D'Urso, M., Schlessinger, D., and et al. (1993). 
REFERENCES 
 
 
113
Chromosomal bar codes produced by multicolor fluorescence in situ hybridization 
with multiple YAC clones and whole chromosome painting probes. Hum Mol Genet 2, 
505-512. 
Li, G., and Herlyn, M. (2000). Dynamics of intercellular communication during 
melanoma development. Mol Med Today 6, 163-169. 
Li, G., Schaider, H., Satyamoorthy, K., Hanakawa, Y., Hashimoto, K., and Herlyn, M. 
(2001). Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte 
growth factor during melanoma development. Oncogene 20, 8125-8135. 
Lichter, P., Cremer, T., Borden, J., Manuelidis, L., and Ward, D. C. (1988). 
Delineation of individual human chromosomes in metaphase and interphase cells by 
in situ suppression hybridization using recombinant DNA libraries. Hum Genet 80, 
224-234. 
Lidov, H. G., Selig, S., and Kunkel, L. M. (1995). Dp140: a novel 140 kDa CNS 
transcript from the dystrophin locus. Hum Mol Genet 4, 329-335. 
Liechti-Gallati, S., Koenig, M., Kunkel, L. M., Frey, D., Boltshauser, E., Schneider, V., 
Braga, S., and Moser, H. (1989). Molecular deletion patterns in Duchenne and 
Becker type muscular dystrophy. Hum Genet 81, 343-348. 
Liu, L., Dilworth, D., Gao, L., Monzon, J., Summers, A., Lassam, N., and Hogg, D. 
(1999). Mutation of the CDKN2A 5' UTR creates an aberrant initiation codon and 
predisposes to melanoma. Nat Genet 21, 128-132. 
Love, D. R., Flint, T. J., Marsden, R. F., Bloomfield, J. F., Daniels, R. J., Forrest, S. 
M., Gabrielli, O., Giorgi, P., Novelli, G., and Davies, K. E. (1990). Characterization of 
deletions in the dystrophin gene giving mild phenotypes. Am J Med Genet 37, 136-
142. 
REFERENCES 
 
 
114
Madhavan, R., Massom, L. R., and Jarrett, H. W. (1992). Calmodulin specifically 
binds three proteins of the dystrophin-glycoprotein complex. Biochem Biophys Res 
Commun 185, 753-759. 
Markowitz, S. (2000). DNA repair defects inactivate tumor suppressor genes and 
induce hereditary and sporadic colon cancers. J Clin Oncol 18, 75S-80S. 
McCarroll, S. A., Hadnott, T. N., Perry, G. H., Sabeti, P. C., Zody, M. C., Barrett, J. 
C., Dallaire, S., Gabriel, S. B., Lee, C., Daly, M. J., et al. (2006). Common deletion 
polymorphisms in the human genome. Nat Genet 38, 86-92. 
Mehler, M. F. (2000). Brain dystrophin, neurogenetics and mental retardation. Brain 
Res Brain Res Rev 32, 277-307. 
Michalak, M., Fu, S. Y., Milner, R. E., Busaan, J. L., and Hance, J. E. (1996). 
Phosphorylation of the carboxyl-terminal region of dystrophin. Biochem Cell Biol 74, 
431-437. 
Michaloglou, C., Vredeveld, L. C., Soengas, M. S., Denoyelle, C., Kuilman, T., van 
der Horst, C. M., Majoor, D. M., Shay, J. W., Mooi, W. J., and Peeper, D. S. (2005). 
BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436, 
720-724. 
Micheli, A., Mugno, E., Krogh, V., Quinn, M. J., Coleman, M., Hakulinen, T., Gatta, 
G., Berrino, F., and Capocaccia, R. (2002). Cancer prevalence in European registry 
areas. Ann Oncol 13, 840-865. 
Monaco, A. P., Bertelson, C. J., Liechti-Gallati, S., Moser, H., and Kunkel, L. M. 
(1988). An explanation for the phenotypic differences between patients bearing 
partial deletions of the DMD locus. Genomics 2, 90-95. 
Monaco, A. P., Bertelson, C. J., Middlesworth, W., Colletti, C. A., Aldridge, J., 
Fischbeck, K. H., Bartlett, R., Pericak-Vance, M. A., Roses, A. D., and Kunkel, L. M. 
REFERENCES 
 
 
115
(1985). Detection of deletions spanning the Duchenne muscular dystrophy locus 
using a tightly linked DNA segment. Nature 316, 842-845. 
Monni, O., Oinonen, R., Elonen, E., Franssila, K., Teerenhovi, L., Joensuu, H., and 
Knuutila, S. (1998). Gain of 3q and deletion of 11q22 are frequent aberrations in 
mantle cell lymphoma. Genes Chromosomes Cancer 21, 298-307. 
Montanaro, F., Gee, S. H., Jacobson, C., Lindenbaum, M. H., Froehner, S. C., and 
Carbonetto, S. (1998). Laminin and alpha-dystroglycan mediate acetylcholine 
receptor aggregation via a MuSK-independent pathway. J Neurosci 18, 1250-1260. 
Moore, S. A., Saito, F., Chen, J., Michele, D. E., Henry, M. D., Messing, A., Cohn, R. 
D., Ross-Barta, S. E., Westra, S., Williamson, R. A., et al. (2002). Deletion of brain 
dystroglycan recapitulates aspects of congenital muscular dystrophy. Nature 418, 
422-425. 
Morita, R., Fujimoto, A., Hatta, N., Takehara, K., and Takata, M. (1998). Comparison 
of genetic profiles between primary melanomas and their metastases reveals genetic 
alterations and clonal evolution during progression. J Invest Dermatol 111, 919-924. 
Morrison, C., Radmacher, M., Mohammed, N., Suster, D., Auer, H., Jones, S., 
Riggenbach, J., Kelbick, N., Bos, G., and Mayerson, J. (2005). MYC amplification 
and polysomy 8 in chondrosarcoma: array comparative genomic hybridization, 
fluorescent in situ hybridization, and association with outcome. J Clin Oncol 23, 9369-
9376. 
Muntoni, F., Melis, M. A., Ganau, A., and Dubowitz, V. (1995). Transcription of the 
dystrophin gene in normal tissues and in skeletal muscle of a family with X-linked 
dilated cardiomyopathy. Am J Hum Genet 56, 151-157. 
Muntoni, F., Torelli, S., and Ferlini, A. (2003). Dystrophin and mutations: one gene, 
several proteins, multiple phenotypes. Lancet Neurol 2, 731-740. 
REFERENCES 
 
 
116
Muschler, J., Levy, D., Boudreau, R., Henry, M., Campbell, K., and Bissell, M. J. 
(2002). A role for dystroglycan in epithelial polarization: loss of function in breast 
tumor cells. Cancer Res 62, 7102-7109. 
Namiki, T., Yanagawa, S., Izumo, T., Ishikawa, M., Tachibana, M., Kawakami, Y., 
Yokozeki, H., Nishioka, K., and Kaneko, Y. (2005). Genomic alterations in primary 
cutaneous melanomas detected by metaphase comparative genomic hybridization 
with laser capture or manual microdissection: 6p gains may predict poor outcome. 
Cancer Genet Cytogenet 157, 1-11. 
Natali, P. G., Nicotra, M. R., Di Renzo, M. F., Prat, M., Bigotti, A., Cavaliere, R., and 
Comoglio, P. M. (1993). Expression of the c-Met/HGF receptor in human melanocytic 
neoplasms: demonstration of the relationship to malignant melanoma tumour 
progression. Br J Cancer 68, 746-750. 
Nevo, Y., Muntoni, F., Sewry, C., Legum, C., Kutai, M., Harel, S., and Dubowitz, V. 
(2003). Large in-frame deletions of the rod-shaped domain of the dystrophin gene 
resulting in severe phenotype. Isr Med Assoc J 5, 94-97. 
Newbell, B. J., Anderson, J. T., and Jarrett, H. W. (1997). Ca2+-calmodulin binding to 
mouse alpha1 syntrophin: syntrophin is also a Ca2+-binding protein. Biochemistry 36, 
1295-1305. 
Nguyen, T. M., Ellis, J. M., Love, D. R., Davies, K. E., Gatter, K. C., Dickson, G., and 
Morris, G. E. (1991). Localization of the DMDL gene-encoded dystrophin-related 
protein using a panel of nineteen monoclonal antibodies: presence at neuromuscular 
junctions, in the sarcolemma of dystrophic skeletal muscle, in vascular and other 
smooth muscles, and in proliferating brain cell lines. J Cell Biol 115, 1695-1700. 
Nicchia, G. P., Nico, B., Camassa, L. M., Mola, M. G., Loh, N., Dermietzel, R., Spray, 
D. C., Svelto, M., and Frigeri, A. (2004). The role of aquaporin-4 in the blood-brain 
barrier development and integrity: studies in animal and cell culture models. 
Neuroscience 129, 935-945. 
REFERENCES 
 
 
117
Nicholson, K. M., and Anderson, N. G. (2002). The protein kinase B/Akt signalling 
pathway in human malignancy. Cell Signal 14, 381-395. 
Nico, B., Paola Nicchia, G., Frigeri, A., Corsi, P., Mangieri, D., Ribatti, D., Svelto, M., 
and Roncali, L. (2004). Altered blood-brain barrier development in dystrophic MDX 
mice. Neuroscience 125, 921-935. 
Nishio, H., Takeshima, Y., Narita, N., Yanagawa, H., Suzuki, Y., Ishikawa, Y., 
Minami, R., Nakamura, H., and Matsuo, M. (1994). Identification of a novel first exon 
in the human dystrophin gene and of a new promoter located more than 500 kb 
upstream of the nearest known promoter. J Clin Invest 94, 1037-1042. 
Nowak, K. J., and Davies, K. E. (2004). Duchenne muscular dystrophy and 
dystrophin: pathogenesis and opportunities for treatment. EMBO Rep 5, 872-876. 
Nudel, U., Zuk, D., Einat, P., Zeelon, E., Levy, Z., Neuman, S., and Yaffe, D. (1989). 
Duchenne muscular dystrophy gene product is not identical in muscle and brain. 
Nature 337, 76-78. 
Ohlendieck, K., and Campbell, K. P. (1991). Dystrophin-associated proteins are 
greatly reduced in skeletal muscle from mdx mice. J Cell Biol 115, 1685-1694. 
Ohta, M., Berd, D., Shimizu, M., Nagai, H., Cotticelli, M. G., Mastrangelo, M., Shields, 
J. A., Shields, C. L., Croce, C. M., and Huebner, K. (1996). Deletion mapping of 
chromosome region 9p21-p22 surrounding the CDKN2 locus in melanoma. Int J 
Cancer 65, 762-767. 
Ohta, M., Nagai, H., Shimizu, M., Rasio, D., Berd, D., Mastrangelo, M., Singh, A. D., 
Shields, J. A., Shields, C. L., Croce, C. M., and et al. (1994). Rarity of somatic and 
germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in 
melanoma. Cancer Res 54, 5269-5272. 
Palmer, J. S., Duffy, D. L., Box, N. F., Aitken, J. F., O'Gorman, L. E., Green, A. C., 
Hayward, N. K., Martin, N. G., and Sturm, R. A. (2000). Melanocortin-1 receptor 
REFERENCES 
 
 
118
polymorphisms and risk of melanoma: is the association explained solely by 
pigmentation phenotype? Am J Hum Genet 66, 176-186. 
Papp, T., Pemsel, H., Rollwitz, I., Schipper, H., Weiss, D. G., Schiffmann, D., and 
Zimmermann, R. (2003). Mutational analysis of N-ras, p53, CDKN2A (p16(INK4a)), 
p14(ARF), CDK4, and MC1R genes in human dysplastic melanocytic naevi. J Med 
Genet 40, E14. 
Park, J. T., Li, M., Nakayama, K., Mao, T. L., Davidson, B., Zhang, Z., Kurman, R. J., 
Eberhart, C. G., Shih Ie, M., and Wang, T. L. (2006). Notch3 gene amplification in 
ovarian cancer. Cancer Res 66, 6312-6318. 
Parrett, T. J., and Yan, H. (2005). Digital karyotyping technology: exploring the 
cancer genome. Expert Rev Mol Diagn 5, 917-925. 
Pasco, S., Ramont, L., Maquart, F. X., and Monboisse, J. C. (2004). Control of 
melanoma progression by various matrikines from basement membrane 
macromolecules. Crit Rev Oncol Hematol 49, 221-233. 
Pedersen, M. I., and Wang, N. (1989). Chromosomal evolution in the progression 
and metastasis of human malignant melanoma. A multiple lesion study. Cancer 
Genet Cytogenet 41, 185-201. 
Pelengaris, S., Khan, M., and Evan, G. (2002). c-MYC: more than just a matter of life 
and death. Nat Rev Cancer 2, 764-776. 
Petrof, B. J., Shrager, J. B., Stedman, H. H., Kelly, A. M., and Sweeney, H. L. (1993). 
Dystrophin protects the sarcolemma from stresses developed during muscle 
contraction. Proc Natl Acad Sci U S A 90, 3710-3714. 
Pfaffl, M. W. (2001). A new mathematical model for relative quantification in real-time 
RT-PCR. Nucleic Acids Res 29, e45. 
REFERENCES 
 
 
119
Piccinin, S., Doglioni, C., Maestro, R., Vukosavljevic, T., Gasparotto, D., D'Orazi, C., 
and Boiocchi, M. (1997). p16/CDKN2 and CDK4 gene mutations in sporadic 
melanoma development and progression. Int J Cancer 74, 26-30. 
Pickl, W. F., Majdic, O., Fischer, G. F., Petzelbauer, P., Fae, I., Waclavicek, M., 
Stockl, J., Scheinecker, C., Vidicki, T., Aschauer, H., et al. (1997). MUC18/MCAM 
(CD146), an activation antigen of human T lymphocytes. J Immunol 158, 2107-2115. 
Pillers, D. A., Bulman, D. E., Weleber, R. G., Sigesmund, D. A., Musarella, M. A., 
Powell, B. R., Murphey, W. H., Westall, C., Panton, C., Becker, L. E., and et al. 
(1993). Dystrophin expression in the human retina is required for normal function as 
defined by electroretinography. Nat Genet 4, 82-86. 
Pinkel, D., Landegent, J., Collins, C., Fuscoe, J., Segraves, R., Lucas, J., and Gray, 
J. (1988). Fluorescence in situ hybridization with human chromosome-specific 
libraries: detection of trisomy 21 and translocations of chromosome 4. Proc Natl Acad 
Sci U S A 85, 9138-9142. 
Pinkel, D., Segraves, R., Sudar, D., Clark, S., Poole, I., Kowbel, D., Collins, C., Kuo, 
W. L., Chen, C., Zhai, Y., et al. (1998). High resolution analysis of DNA copy number 
variation using comparative genomic hybridization to microarrays. Nat Genet 20, 207-
211. 
Pirker, C., Holzmann, K., Spiegl-Kreinecker, S., Elbling, L., Thallinger, C., 
Pehamberger, H., Micksche, M., and Berger, W. (2003). Chromosomal imbalances in 
primary and metastatic melanomas: over-representation of essential telomerase 
genes. Melanoma Res 13, 483-492. 
Poetsch, M., Dittberner, T., and Woenckhaus, C. (2001). PTEN/MMAC1 in malignant 
melanoma and its importance for tumor progression. Cancer Genet Cytogenet 125, 
21-26. 
Poetsch, M., Woenckhaus, C., Dittberner, T., Pambor, M., Lorenz, G., and Herrmann, 
F. H. (1998). An increased frequency of numerical chromosomal abnormalities and 
REFERENCES 
 
 
120
1p36 deletions in isolated cells from paraffin sections of malignant melanomas by 
means of interphase cytogenetics. Cancer Genet Cytogenet 104, 146-152. 
Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., 
Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., et al. (2003). High frequency 
of BRAF mutations in nevi. Nat Genet 33, 19-20. 
Prior, T. W., Bartolo, C., Pearl, D. K., Papp, A. C., Snyder, P. J., Sedra, M. S., 
Burghes, A. H., and Mendell, J. R. (1995). Spectrum of small mutations in the 
dystrophin coding region. Am J Hum Genet 57, 22-33. 
Rando, T. A. (2001). The dystrophin-glycoprotein complex, cellular signaling, and the 
regulation of cell survival in the muscular dystrophies. Muscle Nerve 24, 1575-1594. 
Riopel, M. A., Spellerberg, A., Griffin, C. A., and Perlman, E. J. (1998). Genetic 
analysis of ovarian germ cell tumors by comparative genomic hybridization. Cancer 
Res 58, 3105-3110. 
Roberts, R. G., Barby, T. F., Manners, E., Bobrow, M., and Bentley, D. R. (1991). 
Direct detection of dystrophin gene rearrangements by analysis of dystrophin mRNA 
in peripheral blood lymphocytes. Am J Hum Genet 49, 298-310. 
Roberts, R. G., Gardner, R. J., and Bobrow, M. (1994). Searching for the 1 in 
2,400,000: a review of dystrophin gene point mutations. Hum Mutat 4, 1-11. 
Robertson, G. P. (2005). Functional and therapeutic significance of Akt deregulation 
in malignant melanoma. Cancer Metastasis Rev 24, 273-285. 
Robertson, G. P., Furnari, F. B., Miele, M. E., Glendening, M. J., Welch, D. R., 
Fountain, J. W., Lugo, T. G., Huang, H. J., and Cavenee, W. K. (1998). In vitro loss of 
heterozygosity targets the PTEN/MMAC1 gene in melanoma. Proc Natl Acad Sci U S 
A 95, 9418-9423. 
REFERENCES 
 
 
121
Rosa, G., Ceccarini, M., Cavaldesi, M., Zini, M., and Petrucci, T. C. (1996). 
Localization of the dystrophin binding site at the carboxyl terminus of beta-
dystroglycan. Biochem Biophys Res Commun 223, 272-277. 
Ruas, M., and Peters, G. (1998). The p16INK4a/CDKN2A tumor suppressor and its 
relatives. Biochim Biophys Acta 1378, F115-177. 
Rybakova, I. N., Amann, K. J., and Ervasti, J. M. (1996). A new model for the 
interaction of dystrophin with F-actin. J Cell Biol 135, 661-672. 
Sadoulet-Puccio, H. M., and Kunkel, L. M. (1996). Dystrophin and its isoforms. Brain 
Pathol 6, 25-35. 
Saito, F., Masaki, T., Kamakura, K., Anderson, L. V., Fujita, S., Fukuta-Ohi, H., 
Sunada, Y., Shimizu, T., and Matsumura, K. (1999). Characterization of the 
transmembrane molecular architecture of the dystroglycan complex in schwann cells. 
J Biol Chem 274, 8240-8246. 
Schofield, J. N., Blake, D. J., Simmons, C., Morris, G. E., Tinsley, J. M., Davies, K. 
E., and Edwards, Y. H. (1994). Apo-dystrophin-1 and apo-dystrophin-2, products of 
the Duchenne muscular dystrophy locus: expression during mouse embryogenesis 
and in cultured cell lines. Hum Mol Genet 3, 1309-1316. 
Schreiber-Agus, N., Meng, Y., Hoang, T., Hou, H., Jr., Chen, K., Greenberg, R., 
Cordon-Cardo, C., Lee, H. W., and DePinho, R. A. (1998). Role of Mxi1 in ageing 
organ systems and the regulation of normal and neoplastic growth. Nature 393, 483-
487. 
Schrock, E., du Manoir, S., Veldman, T., Schoell, B., Wienberg, J., Ferguson-Smith, 
M. A., Ning, Y., Ledbetter, D. H., Bar-Am, I., Soenksen, D., et al. (1996). Multicolor 
spectral karyotyping of human chromosomes. Science 273, 494-497. 
Schulten, H. J., Gunawan, B., Otto, F., Hassmann, R., Hallermann, C., Noebel, A., 
and Fuzesi, L. (2002). Cytogenetic characterization of complex karyotypes in seven 
REFERENCES 
 
 
122
established melanoma cell lines by multiplex fluorescence in situ hybridization and 
DAPI banding. Cancer Genet Cytogenet 133, 134-141. 
Schulze, A., Zerfass, K., Spitkovsky, D., Henglein, B., and Jansen-Durr, P. (1994). 
Activation of the E2F transcription factor by cyclin D1 is blocked by p16INK4, the 
product of the putative tumor suppressor gene MTS1. Oncogene 9, 3475-3482. 
Schwarze, S. R., Shi, Y., Fu, V. X., Watson, P. A., and Jarrard, D. F. (2001). Role of 
cyclin-dependent kinase inhibitors in the growth arrest at senescence in human 
prostate epithelial and uroepithelial cells. Oncogene 20, 8184-8192. 
Serrano, M., Lee, H., Chin, L., Cordon-Cardo, C., Beach, D., and DePinho, R. A. 
(1996). Role of the INK4a locus in tumor suppression and cell mortality. Cell 85, 27-
37. 
Sgambato, A., Migaldi, M., Montanari, M., Camerini, A., Brancaccio, A., Rossi, G., 
Cangiano, R., Losasso, C., Capelli, G., Trentini, G. P., and Cittadini, A. (2003). 
Dystroglycan expression is frequently reduced in human breast and colon cancers 
and is associated with tumor progression. Am J Pathol 162, 849-860. 
Sharpless, N. E., Alson, S., Chan, S., Silver, D. P., Castrillon, D. H., and DePinho, R. 
A. (2002). p16(INK4a) and p53 deficiency cooperate in tumorigenesis. Cancer Res 
62, 2761-2765. 
Sharpless, N. E., Kannan, K., Xu, J., Bosenberg, M. W., and Chin, L. (2003). Both 
products of the mouse Ink4a/Arf locus suppress melanoma formation in vivo. 
Oncogene 22, 5055-5059. 
Shay, J. W., Zou, Y., Hiyama, E., and Wright, W. E. (2001). Telomerase and cancer. 
Hum Mol Genet 10, 677-685. 
Shih Ie, M., and Wang, T. L. (2005). Apply innovative technologies to explore cancer 
genome. Curr Opin Oncol 17, 33-38. 
REFERENCES 
 
 
123
Shih, I. M., Elder, D. E., Hsu, M. Y., and Herlyn, M. (1994). Regulation of Mel-
CAM/MUC18 expression on melanocytes of different stages of tumor progression by 
normal keratinocytes. Am J Pathol 145, 837-845. 
Simon, R., Burger, H., Brinkschmidt, C., Bocker, W., Hertle, L., and Terpe, H. J. 
(1998). Chromosomal aberrations associated with invasion in papillary superficial 
bladder cancer. J Pathol 185, 345-351. 
Simpson, L., and Parsons, R. (2001). PTEN: life as a tumor suppressor. Exp Cell Res 
264, 29-41. 
Smedley, D., Sidhar, S., Birdsall, S., Bennett, D., Herlyn, M., Cooper, C., and 
Shipley, J. (2000). Characterization of chromosome 1 abnormalities in malignant 
melanomas. Genes Chromosomes Cancer 28, 121-125. 
Smith, D. I., Zhu, Y., McAvoy, S., and Kuhn, R. (2006). Common fragile sites, 
extremely large genes, neural development and cancer. Cancer Lett 232, 48-57. 
Solinas-Toldo, S., Lampel, S., Stilgenbauer, S., Nickolenko, J., Benner, A., Dohner, 
H., Cremer, T., and Lichter, P. (1997). Matrix-based comparative genomic 
hybridization: biochips to screen for genomic imbalances. Genes Chromosomes 
Cancer 20, 399-407. 
Soufir, N., Avril, M. F., Chompret, A., Demenais, F., Bombled, J., Spatz, A., Stoppa-
Lyonnet, D., Benard, J., and Bressac-de Paillerets, B. (1998). Prevalence of p16 and 
CDK4 germline mutations in 48 melanoma-prone families in France. The French 
Familial Melanoma Study Group. Hum Mol Genet 7, 209-216. 
Speicher, M. R., Gwyn Ballard, S., and Ward, D. C. (1996). Karyotyping human 
chromosomes by combinatorial multi-fluor FISH. Nat Genet 12, 368-375. 
St Croix, B., Rago, C., Velculescu, V., Traverso, G., Romans, K. E., Montgomery, E., 
Lal, A., Riggins, G. J., Lengauer, C., Vogelstein, B., and Kinzler, K. W. (2000). Genes 
expressed in human tumor endothelium. Science 289, 1197-1202. 
REFERENCES 
 
 
124
Stahl, J. M., Sharma, A., Cheung, M., Zimmerman, M., Cheng, J. Q., Bosenberg, M. 
W., Kester, M., Sandirasegarane, L., and Robertson, G. P. (2004). Deregulated Akt3 
activity promotes development of malignant melanoma. Cancer Res 64, 7002-7010. 
Stambolic, V., Suzuki, A., de la Pompa, J. L., Brothers, G. M., Mirtsos, C., Sasaki, T., 
Ruland, J., Penninger, J. M., Siderovski, D. P., and Mak, T. W. (1998). Negative 
regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 
95, 29-39. 
Steck, P. A., Pershouse, M. A., Jasser, S. A., Yung, W. K., Lin, H., Ligon, A. H., 
Langford, L. A., Baumgard, M. L., Hattier, T., Davis, T., et al. (1997). Identification of 
a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is 
mutated in multiple advanced cancers. Nat Genet 15, 356-362. 
Sugita, S., Saito, F., Tang, J., Satz, J., Campbell, K., and Sudhof, T. C. (2001). A 
stoichiometric complex of neurexins and dystroglycan in brain. J Cell Biol 154, 435-
445. 
Surono, A., Takeshima, Y., Wibawa, T., Ikezawa, M., Nonaka, I., and Matsuo, M. 
(1999). Circular dystrophin RNAs consisting of exons that were skipped by alternative 
splicing. Hum Mol Genet 8, 493-500. 
Tanner, M. M., Tirkkonen, M., Kallioniemi, A., Collins, C., Stokke, T., Karhu, R., 
Kowbel, D., Shadravan, F., Hintz, M., Kuo, W. L., and et al. (1994). Increased copy 
number at 20q13 in breast cancer: defining the critical region and exclusion of 
candidate genes. Cancer Res 54, 4257-4260. 
Teng, D. H., Hu, R., Lin, H., Davis, T., Iliev, D., Frye, C., Swedlund, B., Hansen, K. L., 
Vinson, V. L., Gumpper, K. L., et al. (1997). MMAC1/PTEN mutations in primary 
tumor specimens and tumor cell lines. Cancer Res 57, 5221-5225. 
Thompson, F. H., Emerson, J., Olson, S., Weinstein, R., Leavitt, S. A., Leong, S. P., 
Emerson, S., Trent, J. M., Nelson, M. A., Salmon, S. E., and et al. (1995). 
REFERENCES 
 
 
125
Cytogenetics of 158 patients with regional or disseminated melanoma. Subset 
analysis of near-diploid and simple karyotypes. Cancer Genet Cytogenet 83, 93-104. 
Thompson, J. F., Scolyer, R. A., and Kefford, R. F. (2005). Cutaneous melanoma. 
Lancet 365, 687-701. 
Tienari, J., Reima, I., Larramendy, M. L., Knuutila, S., von Boguslawsky, K., 
Kaartinen, M., Virtanen, I., and Lehtonen, E. (1998). A cloned human germ cell 
tumor-derived cell line differentiating in culture. Int J Cancer 77, 710-719. 
Tran, K. T., Lamb, P., and Deng, J. S. (2005). Matrikines and matricryptins: 
Implications for cutaneous cancers and skin repair. J Dermatol Sci 40, 11-20. 
Trent, J. M., Stanbridge, E. J., McBride, H. L., Meese, E. U., Casey, G., Araujo, D. E., 
Witkowski, C. M., and Nagle, R. B. (1990). Tumorigenicity in human melanoma cell 
lines controlled by introduction of human chromosome 6. Science 247, 568-571. 
Trent, J. M., Thompson, F. H., and Meyskens, F. L., Jr. (1989). Identification of a 
recurring translocation site involving chromosome 6 in human malignant melanoma. 
Cancer Res 49, 420-423. 
Trevor, K. T., Cover, C., Ruiz, Y. W., Akporiaye, E. T., Hersh, E. M., Landais, D., 
Taylor, R. R., King, A. D., and Walters, R. E. (2004). Generation of dendritic cell-
tumor cell hybrids by electrofusion for clinical vaccine application. Cancer Immunol 
Immunother 53, 705-714. 
Tsao, H., Zhang, X., Kwitkiwski, K., Finkelstein, D. M., Sober, A. J., and Haluska, F. 
G. (2000). Low prevalence of germline CDKN2A and CDK4 mutations in patients with 
early-onset melanoma. Arch Dermatol 136, 1118-1122. 
Udart, M., Utikal, J., Krahn, G. M., and Peter, R. U. (2001). Chromosome 7 
aneusomy. A marker for metastatic melanoma? Expression of the epidermal growth 
factor receptor gene and chromosome 7 aneusomy in nevi, primary malignant 
melanomas and metastases. Neoplasia 3, 245-254. 
REFERENCES 
 
 
126
Uhrig, S., Schuffenhauer, S., Fauth, C., Wirtz, A., Daumer-Haas, C., Apacik, C., 
Cohen, M., Muller-Navia, J., Cremer, T., Murken, J., and Speicher, M. R. (1999). 
Multiplex-FISH for pre- and postnatal diagnostic applications. Am J Hum Genet 65, 
448-462. 
Valverde, P., Healy, E., Jackson, I., Rees, J. L., and Thody, A. J. (1995). Variants of 
the melanocyte-stimulating hormone receptor gene are associated with red hair and 
fair skin in humans. Nat Genet 11, 328-330. 
van der Velden, P. A., Sandkuijl, L. A., Bergman, W., Pavel, S., van Mourik, L., 
Frants, R. R., and Gruis, N. A. (2001). Melanocortin-1 receptor variant R151C 
modifies melanoma risk in Dutch families with melanoma. Am J Hum Genet 69, 774-
779. 
van Elsas, A., Zerp, S. F., van der Flier, S., Kruse, K. M., Aarnoudse, C., Hayward, N. 
K., Ruiter, D. J., and Schrier, P. I. (1996). Relevance of ultraviolet-induced N-ras 
oncogene point mutations in development of primary human cutaneous melanoma. 
Am J Pathol 149, 883-893. 
van Muijen, G. N., Danen, E. H., de Vries, T. J., Quax, P. H., Verheijen, J. H., and 
Ruiter, D. J. (1995). Properties of metastasizing and nonmetastasizing human 
melanoma cells. Recent Results Cancer Res 139, 105-122. 
Vecchione, A., Sevignani, C., Giarnieri, E., Zanesi, N., Ishii, H., Cesari, R., Fong, L. 
Y., Gomella, L. G., Croce, C. M., and Baffa, R. (2004). Inactivation of the FHIT gene 
favors bladder cancer development. Clin Cancer Res 10, 7607-7612. 
Veldman, T., Vignon, C., Schrock, E., Rowley, J. D., and Ried, T. (1997). Hidden 
chromosome abnormalities in haematological malignancies detected by multicolour 
spectral karyotyping. Nat Genet 15, 406-410. 
Villa, R., Porta, C. D., Folini, M., Daidone, M. G., and Zaffaroni, N. (2001). Possible 
regulation of telomerase activity by transcription and alternative splicing of 
REFERENCES 
 
 
127
telomerase reverse transcriptase in human melanoma. J Invest Dermatol 116, 867-
873. 
Wang, F., Denison, S., Lai, J. P., Philips, L. A., Montoya, D., Kock, N., Schule, B., 
Klein, C., Shridhar, V., Roberts, L. R., and Smith, D. I. (2004). Parkin gene alterations 
in hepatocellular carcinoma. Genes Chromosomes Cancer 40, 85-96. 
Wang, T. L., Diaz, L. A., Jr., Romans, K., Bardelli, A., Saha, S., Galizia, G., Choti, M., 
Donehower, R., Parmigiani, G., Shih Ie, M., et al. (2004). Digital karyotyping identifies 
thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in 
metastatic colorectal cancer patients. Proc Natl Acad Sci U S A 101, 3089-3094. 
Wang, T. L., Maierhofer, C., Speicher, M. R., Lengauer, C., Vogelstein, B., Kinzler, K. 
W., and Velculescu, V. E. (2002). Digital karyotyping. Proc Natl Acad Sci U S A 99, 
16156-16161. 
Welch, D. R., Chen, P., Miele, M. E., McGary, C. T., Bower, J. M., Stanbridge, E. J., 
and Weissman, B. E. (1994). Microcell-mediated transfer of chromosome 6 into 
metastatic human C8161 melanoma cells suppresses metastasis but does not inhibit 
tumorigenicity. Oncogene 9, 255-262. 
Wellbrock, C., Ogilvie, L., Hedley, D., Karasarides, M., Martin, J., Niculescu-Duvaz, 
D., Springer, C. J., and Marais, R. (2004). V599EB-RAF is an oncogene in 
melanocytes. Cancer Res 64, 2338-2342. 
Wheway, J. M., and Roberts, R. G. (2003). The dystrophin lymphocyte promoter 
revisited: 4.5-megabase intron, or artifact? Neuromuscul Disord 13, 17-20. 
Widlund, H. R., and Fisher, D. E. (2003). Microphthalamia-associated transcription 
factor: a critical regulator of pigment cell development and survival. Oncogene 22, 
3035-3041. 
Williamson, R. A., Henry, M. D., Daniels, K. J., Hrstka, R. F., Lee, J. C., Sunada, Y., 
Ibraghimov-Beskrovnaya, O., and Campbell, K. P. (1997). Dystroglycan is essential 
REFERENCES 
 
 
128
for early embryonic development: disruption of Reichert's membrane in Dag1-null 
mice. Hum Mol Genet 6, 831-841. 
Wiltshire, R. N., Dennis, T. R., Sondak, V. K., Meltzer, P. S., and Trent, J. M. (2001). 
Application of molecular cytogenetic techniques in a case study of human cutaneous 
metastatic melanoma. Cancer Genet Cytogenet 131, 97-103. 
Wolfel, T., Hauer, M., Schneider, J., Serrano, M., Wolfel, C., Klehmann-Hieb, E., De 
Plaen, E., Hankeln, T., Meyer zum Buschenfelde, K. H., and Beach, D. (1995). A 
p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human 
melanoma. Science 269, 1281-1284. 
Wu, H., Goel, V., and Haluska, F. G. (2003). PTEN signaling pathways in melanoma. 
Oncogene 22, 3113-3122. 
Xu, H. J., Zhou, Y., Ji, W., Perng, G. S., Kruzelock, R., Kong, C. T., Bast, R. C., Mills, 
G. B., Li, J., and Hu, S. X. (1997). Reexpression of the retinoblastoma protein in 
tumor cells induces senescence and telomerase inhibition. Oncogene 15, 2589-2596. 
Yaffe, D., Makover, A., Lederfein, D., Rapaport, D., Bar, S., Barnea, E., and Nudel, 
U. (1992). Multiple products of the Duchenne muscular dystrophy gene. Symp Soc 
Exp Biol 46, 179-188. 
Yang, B., Jung, D., Motto, D., Meyer, J., Koretzky, G., and Campbell, K. P. (1995). 
SH3 domain-mediated interaction of dystroglycan and Grb2. J Biol Chem 270, 
11711-11714. 
Yang, F. C., Merlino, G., and Chin, L. (2001). Genetic dissection of melanoma 
pathways in the mouse. Semin Cancer Biol 11, 261-268. 
Yoshida, M., and Ozawa, E. (1990). Glycoprotein complex anchoring dystrophin to 
sarcolemma. J Biochem (Tokyo) 108, 748-752. 
REFERENCES 
 
 
129
Zhang, Y., Xiong, Y., and Yarbrough, W. G. (1998). ARF promotes MDM2 
degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and 
p53 tumor suppression pathways. Cell 92, 725-734. 
Zuo, L., Weger, J., Yang, Q., Goldstein, A. M., Tucker, M. A., Walker, G. J., Hayward, 
N., and Dracopoli, N. C. (1996). Germline mutations in the p16INK4a binding domain 
of CDK4 in familial melanoma. Nat Genet 12, 97-99. 
 
 
ABBREVIATIONS 
 
 
130
9 ABBREVIATIONS 
 
ATCC American type culture collection 
bp base pair 
cAMP cyclic adenosine monophosphate 
CC domain coiled coil domain 
cDNA complementary deoxyribonucleic acid 
CFS common fragile site 
CGH comparative genomic hybridization 
CMM cutaneous malignant melanoma 
CMV cytomegalovirus (promoter) 
COOH- or C-terminal carboxy-terminal 
DGC dystrophin-glycoprotein complex 
DK digital karyotyping 
DMD/BMD Duchenne/Becker muscular dystrophy 
DNA deoxyribonucleic acid 
dNTP deoxynucleotide triphosphate 
ECM extracellular matrix 
EF-hand motif calcium-binding motif 
FRA fragile site 
HDF human dermal fibroblast 
ISCN International System for Human Cytogenetic Nomenclature 
kbp kilo base pair 
kD kilodalton 
LOH loss of heterozygosity 
MAA melanoma-associated antigen 
Mbp mega base pair 
M-FISH multiplex fluorescence in situ hybridization 
MMP matrix metalloprotease 
mRNA messenger RNA 
NH2- or N-terminal amino-terminal 
NM nodular melanoma 
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PCR polymerase chain reaction 
qPCR quantitative PCR 
RGP radial growth phase 
RHC red hair color (phenotype) 
RNA ribonucleic acid 
RT-PCR reverse transcriptase PCR 
shDMD short hairpin RNA directed against DMD 
SKY spectral karyotyping 
SSM superficial spreading melanoma 
Tris (Hydroxymethyl)aminomethane 
U units 
UV ultraviolet 
VGP vertical growth phase 
VSV vesicular stomatitis virus (tag) 
WW domain domain with two signature tryptophan residues 
ZZ domain zinc finger domain 
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10 APPENDIX 
Supplementary Table 1 Description of melanoma cell lines, their origin and culture conditions. Abbreviations: n. a., not available 
Cell line Description Origin Medium 
A375P low invasive malignant melanoma Dr. A. Ullrich 1) DMEM high glucose, 5 % FBS 
Bow-G melanosarcoma Dr. A. Ullrich 1) DMEM low glucose, 10 % FBS 
C-32 amelanotic melanoma Dr. A. Ullrich 1) MEM, non-essential amino acids, sodium pyruvate, L-glutamine, 10 % FBS 
C-8161 metastatic melanoma Dr. A. Ullrich 1) DMEM high glucose, 5 % FBS 
CRL-1974 malignant melanoma ATCC RPMI 1640, 10 % FBS, sodium pyruvate, L-glutamine, sodium bicarbonate 
F-01 metastatic melanoblastoma Dr. A. Ullrich 1) RPMI 1640, 10 % FBS, L-glutamine 
G-361 malignant melanoma Dr. A. Ullrich 1) McCoy´s 5A, 10 % FBS 
Hs-294T metastatic malignant melanoma Dr. A. Ullrich 1) DMEM high glucose, 10 % FBS 
Hs-695T metastatic malignant melanoma Dr. A. Ullrich 1) MEM, 10 % FBS, L-glutamine 
HT-144 metastatic malignant melanoma Dr. A. Ullrich 1) McCoy´s 5A, 10 % FBS 
IGR-39 n. a. Dr. A. Ullrich 1) RPMI 1640, 10 % FBS, L-glutamine 
Malme3M metastatic malignant melanoma Dr. A. Ullrich 1) Leibovitz L15, 10 % FBS 
Mel Gerlach n. a. Dr. A. Ullrich 1) RPMI 1640, 10 % FBS, L-glutamine 
Mel Juso primary melanoma Dr. A. Ullrich 1) RPMI 1640, 10 % FBS, L-glutamine 
MeWO3 metastatic malignant melanoma Dr. A. Ullrich 1) DMEM low glucose, 10 % FBS 
MRI-H 221 metastatic malignant melanoma Dr. A. Ullrich 1) RPMI 1640, 10 % FBS, L-glutamine 
RPMI-7951 metastatic malignant melanoma Dr. A. Ullrich 1) MEM, non-essential amino acids, sodium pyruvate, L-glutamine, 10 % FBS 
SBCL2 metastatic malignant melanoma Dr. A. Ullrich 1) MCDB 153/L15 (4:1), 2 % FBS, 5 µg/ml insulin 
Sk-Mel 1 metastatic malignant melanoma Dr. A. Ullrich 1) MEM, non-essential amino acids, sodium pyruvate, L-glutamine , 10 % FBS 
Sk-Mel 2 metastatic malignant melanoma Dr. A. Ullrich 1) MEM, non-essential amino acids, sodium pyruvate, L-glutamine, 10 % FBS 
Sk-Mel 24 metastatic malignant melanoma Dr. A. Ullrich 1) MEM, non-essential amino acids, sodium pyruvate, L-glutamine , 10 % FBS 
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Supplementary Table 1 continued. 
Cell line Description Origin Medium 
Sk-Mel 28 malignant melanoma Dr. A. Ullrich 1) MEM, non-essential amino acids, sodium pyruvate, L-glutamine , 10 % FBS 
Sk-Mel 3 metastatic malignant melanoma Dr. A. Ullrich 1) McCoy´s 5A, 10 % FBS 
Sk-Mel 31 malignant melanoma Dr. A. Ullrich 1) MEM, non-essential amino acids, sodium pyruvate, L-glutamine , 15 % FBS 
Sk-Mel 5 metastatic malignant melanoma Dr. A. Ullrich 1) MEM, non-essential amino acids, sodium pyruvate, L-glutamine , 10 % FBS 
WM-115 primary melanoma Dr. A. Ullrich 1) MEM, non-essential amino acids, sodium pyruvate, L-glutamine , 10 % FBS 
WM-1205LU n. a. Dr. A. Ullrich 1) MCDB 153/L15 (4:1), 2 % FBS, 5 µg/ml insulin 
WM-1341D RGP/VGP melanoma Dr. A. Ullrich 1) RPMI 1640, 10 % FBS, 0.04 i.U./ml h-insulin, L-glutamine 
WM-239A metastatic melanoma from WM-115 Dr. A. Ullrich 1) RPMI 1640, 10 % FBS, 0.04 i.U./ml h-insulin, L-glutamine 
WM-266-4 metastatic melanoma from WM-115 Dr. A. Ullrich 1) RPMI 1640, 10 % FBS, L-glutamine 
WM-35 RGP/VGP melanoma Dr. A. Ullrich 1) MCDB 153/L15 (4:1), 2 % FBS, 5 µg/ml insulin 
WM-793 RGP/VGP melanoma Dr. A. Ullrich 1) MCDB 153/L15 (4:1), 2 % FBS, 5 µg/ml insulin 
WM-852 metastatic melanoma Dr. A. Ullrich 1) MCDB 153/L15 (4:1), 2 % FBS, 5 µg/ml insulin 
WM-902B VGP melanoma Dr. A. Ullrich 1) RPMI 1640, 10 % FBS, 0.04 IU/ml h-insulin, L-glutamine 
WM-98 n. a. Dr. D. Herlyn 2) MCDB 153/L15 (4:1), 2 % FBS, 5 µg/ml insulin 
WM-3450 n. a. Dr. D. Herlyn 2) RPMI 1640, 10 % FBS, L-glutamine 
WM-3451 n. a. Dr. D. Herlyn 2) RPMI 1640, 10 % FBS, L-glutamine 
WM-3453 n. a. Dr. D. Herlyn 2) RPMI 1640, 10 % FBS, L-glutamine 
WM-3456 n. a. Dr. D. Herlyn 2) RPMI 1640, 10 % FBS, L-glutamine 
MM-031 metastatic malignant melanoma Dr. L. Füzesi 3) RPMI 1640, 10 % FBS, L-glutamine 
MM-194 metastatic malignant melanoma Dr. L. Füzesi 3) RPMI 1640, 10 % FBS, L-glutamine 
MM-195 metastatic malignant melanoma Dr. L. Füzesi 3) RPMI 1640, 10 % FBS, L-glutamine 
MM-201 metastatic malignant melanoma Dr. L. Füzesi 3) RPMI 1640, 10 % FBS, L-glutamine 
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Supplementary Table 1 continued. 
Cell line Description Origin Medium 
MM-232 metastatic malignant melanoma Dr. L. Füzesi 3) RPMI 1640, 10 % FBS, L-glutamine 
MM-254 metastatic malignant melanoma Dr. L. Füzesi 3) RPMI 1640, 10 % FBS, L-glutamine 
MM-358 metastatic malignant melanoma Dr. L. Füzesi 3) RPMI 1640, 10 % FBS, L-glutamine 
KAII metastatic malignant melanoma Dr. L. Füzesi 3) RPMI 1640, 10 % FBS, L-glutamine 
M1 metastatic malignant melanoma Dr. B. Schuler-Thurner 4) RPMI 1640, 10 % FBS, L-glutamine 
M2 metastatic malignant melanoma Dr. B. Schuler-Thurner 4) RPMI 1640, 10 % FBS, L-glutamine 
M3 metastatic malignant melanoma Dr. B. Schuler-Thurner 4) RPMI 1640, 10 % FBS, L-glutamine 
M4 metastatic malignant melanoma Dr. B. Schuler-Thurner 4) MCDB 153/L15 (4:1), 2 % FBS, 5 µg/ml insulin 
M5 metastatic malignant melanoma Dr. B. Schuler-Thurner 4) RPMI 1640, 10 % FBS, L-glutamine 
M6 metastatic malignant melanoma Dr. B. Schuler-Thurner 4) RPMI 1640, 10 % FBS, L-glutamine 
M7 metastatic malignant melanoma Dr. B. Schuler-Thurner 4) MCDB 153/L15 (4:1), 2 % FBS, 5 µg/ml insulin 
M8 metastatic malignant melanoma Dr. B. Schuler-Thurner 4) RPMI 1640, 10 % FBS, L-glutamine 
M9 metastatic malignant melanoma Dr. B. Schuler-Thurner 4) RPMI 1640, 10 % FBS, L-glutamine 
1)Department of Molecular Biology, MPI of Biochemistry, Martinsried, Germany 
2)Wistar Insitute, Philadelphia, USA 
3)Department of Pathology, Georg August University, Goettingen, Germany (Schulten et al., 2002) 
4)Department of Dermatology, University Hospital of Erlangen, Erlangen, Germany 
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Supplementary Table 2 Description of gender and expression levels of DMD mRNA and protein in 
melanoma cell lines. Also listed is the deletion status of DMD on genomic DNA as analyzed by Alex 
Epanchintsev. The DMD mRNA expression was calculated relative to expression in primary 
melanocytes. If unspecific PCR products together with a PCR product specific for DMD were observed, 
no exact calculation was possible and expression was denoted with <. Dystrophin protein was 
classified as expressed (+) or not expressed (-). n. a., not available; n. d., not determined. 
 
Melanoma cell line 
 
Sex 
 
% DMD mRNA 
expression 
Dystrophin 
protein 
expression 
 
DMD deletion on 
genomic DNA 
primary melanocytes HM40p7 male 100 +  
primary melanocytes HM9p6 male 100 +  
A375P female n. d. -  
BOW-G n. a. 33 -  
C-32 male 68 +  
C-8161 female n. d. -  
CRL-1974 male 32 -  
F-01 male <1 -  
G-361 male n. d. -  
Hs-294T male 100 +  
Hs-695T male 0 -  
HT-144 male n. d. -  
IGR-39 n. a. n. d. -  
KAII n. a. 10 -  
M1 female 0 - exons 3-29 
M2 female 0 -  
M3 male 1 -  
M4 male 12 +  
M5 female 4 -  
M6 female <8 -  
M7 female 100 +  
M9 female n. d. -  
Malme3M male <4 -  
Mel-Gerlach n. a. n.d. -  
Mel-Juso female <1 -  
MM-031 male n. d. -  
MM-194 male 1 -  
MM-195 male <17 +  
MM-201 female n. d. -  
MM-232 female n. d. -  
MM-254 female n. d. -  
APPENDIX 
 
136 
Supplementary Table 2 continued. 
 
Melanoma cell line 
 
Sex 
 
% DMD RNA 
expression 
Dystrophin 
protein 
expression 
 
DMD deletion on 
genomic DNA 
MM-358 female n. d. -  
MeWO3 male 3 -  
MRI-H 221 female 100 +  
RPMI-7951 female 0 - exons 17-30 
SBCL2 n. a. n. d. -  
Sk-Mel 1 male n. d. +  
Sk-Mel 2 male 7 -  
Sk-Mel 24 male 5 +  
Sk-Mel 28 male n. d. -  
Sk-Mel 3 female n. d. -  
Sk-Mel 31 female 100 +  
Sk-Mel 5 female <1 -  
WM-115 female 37 +  
WM-1205LU male <5 -  
WM-1341D male 3 +  
WM-239A female 1 -  
WM-266-4 female 1 +  
WM-3450 n. a. n. d. -  
WM-3451 n. a. n. d. +  
WM-3453 n. a. 48 -  
WM-3456 n. a. 58 +  
WM-35 female 4 +  
WM-793 male 21 - exons 42-43 
WM-852 male 26 +  
WM-902B n. a. <1 -  
WM-98 n. a. 100 +  
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